Document:

EX-4.19

 Exhibit 4.19 

CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT WAS OMITTED BY MEANS OF MARKING SUCH INFORMATION WITH BRACKETS (“[***]”) BECAUSE
THE IDENTIFIED CONFIDENTIAL INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

LICENSE AGREEMENT 
 This
LICENSE AGREEMENT (the “Agreement”) is entered into on March 29, 2021 (the “Effective Date”) between: 

SIMCERE PHARMACEUTICAL CO., LTD., a company organized under the laws of the People’s
Republic of China and having a place of business at No.99, Huakang Road, Nanjing Jiangbei New Area, Nanjing, Jiangsu, China (“Simcere”); and 

KAZIA THERAPEUTICS, LTD. (ACN 063 259 754), a company organized under the laws of
New South Wales, Australia and having a place of business at Three International Towers, L24, 300 Barangaroo Avenue, Sydney, NSW 2000, Australia (“Kazia”). 

Kazia and Simcere are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” 

Recitals 

WHEREAS, Kazia is developing paxalisib (also known as GDC-0084),
a proprietary PI3K/AKT/mTOR pathway inhibitor, for the treatment of glioblastoma and certain other cancers, and owns or controls certain patent, know-how and other intellectual property rights relating to such
product candidate; and 
 WHEREAS, Simcere wishes to obtain from Kazia, and Kazia is willing to grant
to Simcere licenses to research, develop, manufacture and commercialize such product in the greater China region, all on the terms and conditions set forth herein. 

NOW THEREFORE, in consideration of the foregoing premises and the mutual covenants
contained herein, the receipt and sufficiency of which are hereby acknowledged, Simcere and Kazia hereby agree as follows: 
 ARTICLE 1

 DEFINITIONS 

Unless the context otherwise requires, the terms in this Agreement with initial letters capitalized, shall have the meanings set forth below,
or the meaning as designated in the indicated places throughout this Agreement. 

1.1    “Affiliate” means, with respect to a Party, any Person that controls, is controlled by, or
is under common control with that Party. For the purpose of this definition, “control” (including, with correlative meaning, the terms “controlled by” and “under the common control”) means the actual power, either
directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such Person, whether by the ownership of more than fifty percent (50%) of the voting stock of such Person, by contract or
otherwise. 

 1.2    “Claims” means all Third Party demands,
claims, actions, proceedings and liability (whether criminal or civil, in contract, tort or otherwise) for losses, damages, reasonable legal costs and other reasonable expenses of any nature. 

1.3    “Commercialize” or “Commercialization” means all activities directed to
marketing, distributing, detailing or selling the Product (as well as importing and exporting activities in connection therewith), including all activities directed to obtaining pricing and reimbursement approvals for the Product. 

1.4    “Commercially Reasonable Efforts” means, with respect to the Development and
Commercialization of the Product under this Agreement, those efforts consistent with the exercise of prudent scientific and business judgment as applied by a Party to the development and commercialization of its own product that is at a similar
stage of development or commercialization and has similar market potential, taking into account efficacy, safety, patent and regulatory exclusivity, anticipated or approved labeling, present and future market potential, competitive market
conditions, the profitability of the product in light of pricing and reimbursement issues, and all other relevant factors. Commercially Reasonable Efforts shall be determined on a
market-by-market and indication-by-indication basis, and it is anticipated that the level
of effort required may be different for different markets and indications and may change over time, reflecting changes in the status of the Product and markets involved. 

1.5    “Compound” means paxalisib (also known as GDC-0084)
or any salt, polymorph, hydrate, solvate or metabolite, as set forth in Exhibit A. 

1.6    “Confidential Information” of a Party means all
Know-How, unpublished patent applications and all other information and data, including information and data of a financial, commercial, business, operational or technical nature belonging or relating to a
Party or any of its Affiliates, whether made available orally, in writing, graphically, or in electronic or any other form. For the avoidance of doubt, the terms and conditions of this Agreement are the Confidential Information of both Parties. 

1.7    “Control” or “Controlled” means, with respect to any Know-How, Patents or other intellectual property rights, that a Party has the legal authority or right (whether by ownership, license or otherwise) to grant a license, sublicense, access or other right (as
applicable) under such Know-How, Patents, or other intellectual property rights to the other Party on the terms and conditions set forth herein, in each case without breaching the terms of any agreement with a
Third Party. 
 1.8    “Develop” or “Development” means all development
activities necessary or useful to obtain or maintain Regulatory Approval for the Product, including all non-clinical studies and clinical trials of the Product, manufacture process development, distribution of
the Product for use in clinical trials (including placebos and comparators), statistical analyses, and the preparation and submission of Regulatory Materials for, and all regulatory affairs related to, the Product. 

1.9    “Dollar” means U.S. dollars, and “$” shall be interpreted accordingly. 

1.10    “Expert” has the meaning given to that term in Exhibit H. 

  
 2 

 1.11    “E.U.” means the European Union and its
member states, territories and possessions. 
 1.12    “Field” means all therapeutic uses in
humans. 
 1.13    “First Commercial Sale” means, with respect to a Product in a region in the
Territory, the first sale of such Product by Simcere, its Affiliates or sublicensees to a Third Party for distribution, use or consumption in such region after Regulatory Approval of the Product has been granted in such region. 

1.14    “Genentech Agreement” means that certain Exclusive License Agreement between Kazia and
Genentech, Inc. (“Genentech”), dated October 25, 2016. 
 1.15    “Global Clinical
Trial” means a clinical trial of the Product, other than GBM AGILE: 
 (a)    that is conducted (in
whole or in part) by or on behalf of Kazia in collaboration with an academic or non-profit collaborator (but not by Kazia itself or commercial partners of Kazia); 

(b)    that is conducted in sites in multiple jurisdictions, including in the Territory and at least one of the
U.S., United Kingdom, France, Germany, Italy or Spain; and 
 (c)    where the planned number of patients to be
enrolled in the Territory does not exceed twenty percent (20%) of the planned global enrollment in such clinical trial. 
 For clarity, Kazia may not
conduct a clinical trial of the Product in the Territory by itself or through its Affiliate or any commercial partners. 

1.16    “Government Authority” means any federal, state, national, provincial or local government,
or political subdivision thereof, or any organization established under statute or any authority, agency or commission entitled to exercise any administrative, executive, legislative, regulatory or taxing authority or power (or any department,
bureau or division thereof, or any governmental body). 
 1.17    “IND” means any
investigational new drug application, clinical trial application, clinical trial exemption or similar or equivalent application filed with the applicable Regulatory Authority for approval to conduct clinical testing of a pharmaceutical product in
humans. 
 1.18    “Indication” means a separate and distinct disease, disorder or medical
condition for which a Product can be used to diagnose, treat or prevent, which use is the subject of a separate MA or separate approval within the same MA. For clarity, subpopulations or patients with a primary disease or condition, however
stratified, shall not be deemed to be separate “Indications” for the purposes of this Agreement, including stratification by stages or progression (including precursor condition), particular combinations of symptoms associated with the
primary disease or condition, prior treatment courses, response to prior treatment, different lines of treatment, family history, clinical history, phenotype, age (e.g. adult and pediatric) or other stratification. In addition, combination
treatments with the Product and another product shall not be deemed to be separate “Indication” for the purpose of this Agreement unless the Product’s purpose is to diagnose, treat or prevent a separate and distinct disease, disorder
or medical condition. 

  
 3 

 1.19    “Invention” means any data, results,
discovery, finding, process, improvement, enhancement, modification, development, method, composition of matter, article of manufacture, patentable or otherwise, that is invented, reduced to practice, or otherwise generated by either Party
exercising its rights or carrying out its obligations under this Agreement, whether directly or via its Affiliates, agents, contractors or sublicensees, including all rights, title and interest in and to the intellectual property rights therein.

 1.20    “Know-How” means any technical, commercial,
scientific, regulatory or practical information, including discoveries, improvements, modifications, processes, methods, protocols, formulas, data, inventions, know-how and trade secrets, patentable or
otherwise, but excluding any Patents. 
 1.21    “Law” means any federal, state, local, foreign
or multinational law, statute, standard, ordinance, code, rule, regulation, resolution or promulgation, the rules of the security exchange on which a Party’s or its Affiliate’s stock is publicly traded, or any order by any Government
Authority, or any license, franchise, permit or similar right granted under any of the foregoing, or any similar provision having the force or effect of law. 

1.22 “Licensed IP” means the Licensed Know-How and Licensed Patents. 

1.23    “Licensed Know-How” means all Know-How that (a) is Controlled by Kazia or its Affiliates as of the Effective Date or at any time during the Term, and (b) is necessary or reasonably useful, but not otherwise readily available, for the
Development, Manufacture or Commercialization of the Compound and Product. 
 1.24    “Licensed
Patents” means all Patents that are Controlled by Kazia or its Affiliates as of the Effective Date or at any time during the Term, and which claim or cover the Compound or Product (including composition of matter, methods of making and
using). Licensed Patents existing as of the Effective Date are set forth in Exhibit B. 

1.25    “MA” or “Marketing Authorization” means a Regulatory Approval issued by
an appropriate Regulatory Authority for the importation, promotion, marketing, sale and supply of a pharmaceutical product in a particular jurisdiction and all amendments and supplements thereto, including an approved New Drug Application
(“NDA”) and an approved Biologic License Application (“BLA”) following filing with the Food and Drug Administration in the U.S., and equivalent foreign approvals, but excluding pricing and reimbursement approval.

 1.26    “Manufacture” or “Manufacturing” means activities directed to the
manufacture of the Product, including the planning, purchasing, producing, manufacturing, processing, transportation, quality assurance testing, quality control, regulatory compliance, storage, waste disposal, sample retention, formulation,
stability testing, filling, packaging, labelling, leafleting, release and dispatch and such other related matters in each case as applicable to the Product. 

  
 4 

 1.27    “Manufacturing Cost” means, with respect
to the Compound and Product supplied by Kazia to Simcere hereunder: 
 (a)    if the Compound or Product is
Manufactured by Kazia’s Third Party contract manufacturer, Kazia’s actual Third Party cost of the Manufacture and supply of such Compound or Product; and 

(b)    if the Compound or Product is Manufactured by Kazia itself or its Affiliate, the actual, fully-burdened cost
for the Manufacture and supply of such Compound or Product, including raw materials, direct labor and benefits, and the proportionate share of indirect Manufacturing costs. Such fully-burdened cost shall be calculated (i) if applicable, on a
theoretical full-capacity basis, with the percentage allocable to Manufacturing Cost representing the number of units or runs of the Compound or Product produced or performed as a percentage of the total number of units or runs, including those of
other products, that could be manufactured in such facility during a calendar year; and (ii) in accordance with applicable accounting standards consistently applied. 

1.28    “Net Sales” means the gross amount received by Simcere, its Affiliates or sublicensees for
sale of the Product to Third Parties (other than Simcere’s sublicensees) less the following amounts incurred or paid by the selling party in connection with the sale of the Product: (a) normal and customary trade, cash and quantity
discounts or rebates; (b) credits or allowances actually granted to the customer for damaged goods, returns, recalls, rebates or rejections of the Product; (c) reasonable charges for insurance, freight, and other transportation costs
directly related to the delivery of the Product to the extent such charges were included on the invoice provided to the customer; (d) taxes (including sales tax and VAT, but not income taxes), tariff, duty or governmental charges levied on the
sales, transfer, transportation or delivery of the Product included on the invoice for the Product and not reimbursed directly or indirectly; (e) customary rebates and chargeback payments with respect to such Product granted to managed health
care organizations, pharmacy benefit managers (or equivalents thereof), national, state, provincial, local, and other governments, their agencies and purchasers and reimbursers, or to trade customers; and (f) any other similar and customary
deductions that are consistent with applicable accounting standards. 
 If a Product is sold in a region in the Territory as a combination
of the Compound with another active pharmaceutical ingredient or component that is not a Compound (“Combination”), then the gross amount invoiced, for the purposes of determining royalty payments on the Combination, shall be
calculated using one of the following alternative methods: 
 (i)    by multiplying the gross amount invoiced for
the Combination by the fraction A/(A+B), where A is the gross amount invoiced, during the relevant reporting period, for the Product that contains the Compound as its only active ingredient (the “Mono Product”) when sold separately
in such region, and B is the gross amount invoiced, during the relevant reporting period, of the other active ingredients or components in the Combination (the “Other Products”) when sold separately in such region; or 

  
 5 

 (ii)    if no such separate sales in such region are made of any
or all of the Other Products during the relevant reporting period, then the gross amount invoiced, for the purposes of determining royalty payments on the Combination, shall be calculated by multiplying the gross amount invoiced for the Combination
by the fraction A/C where A is the gross amount invoiced, during the relevant reporting period, for the Mono Product when sold separately in such region (provided that if there is no separate sale of the Mono Product in such region, then A shall be
estimated in good faith by Simcere), and C is the gross amount invoiced, during the relevant reporting period, for the Combination sold in such region. 

Where Simcere is considering or intends to supply or sell Product in a region in the Territory as a bundle with any other product or products
for the one (combined) price (“Bundle”), then Simcere must provide prior notice to Kazia, and Simcere and Kazia must agree how the price (including gross amount and Net Sales) of the Product in the Bundle should be allocated for the
purposes of this Agreement prior to the first such sale or supply. 
 1.29    “NMPA” means
National Medical Products Administration of China (formerly known as the China Food and Drug Administration), or its successor. 

1.30    “Patents” means all patents and patent applications (which for the purpose of this
Agreement shall be deemed to include certificates of invention and applications for certificates of invention), including all divisionals, continuations, substitutions,
continuations-in-part, re- examinations, reissues, additions, renewals, revalidations, extensions, registrations, pediatric exclusivity periods and supplemental
protection certificates and the like of any such patents and patent applications, and any and all foreign equivalents of the foregoing. 

1.31    “Person” means any individual, partnership, limited liability company, firm, corporation,
association, trust, unincorporated organization or other entity. 
 1.32    “Product” means any
pharmaceutical product that contains a Compound as an active pharmaceutical ingredient, in any formulation or dosage form and for any mode of administration. 

1.33    “Regulatory Approval” means with respect to a Product, all registrations, approvals,
permits, authorizations or licenses issued by an applicable Regulatory Authority in a jurisdiction that are necessary for the Manufacture, importation, storage, promotion, marketing, sale, distribution or other Commercialization of that Product in
the relevant jurisdiction (including applicable approvals of labelling for that product in that jurisdiction and any customs and tax approvals, but excluding any price and reimbursement approval) and including any amendment or supplement thereto.

 1.34    “Regulatory Authority” means any applicable Government Authority responsible for
granting Regulatory Approvals for the Product. 
 1.35    “Regulatory Material” means any
regulatory application, submission, notification, communication, correspondence, registration and other filings made to, received from or otherwise conducted with a Regulatory Authority in order to Develop, Manufacture, market, sell or otherwise
Commercialize the Product in a particular country or jurisdiction. For clarity, Regulatory Materials include IND, MAs (including applications for the same) and Regulatory Approvals. 

  
 6 

 1.36    “Territory” means China, including
mainland China, Hong Kong, Macao and Taiwan, [***]. 
 1.37    “Third Party” means any Person
other than a Party or an Affiliate of a Party. 
 1.38    “Valid Claim” means a claim of
(a) an issued and unexpired Patent that has not been revoked, held invalid or unenforceable by a patent office, court or other Government Authority of competent jurisdiction in a final and non-appealable
judgment (or judgment from which no appeal was taken within the allowable time period) and has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination or
disclaimer, or (b) a pending patent application to the extent the claim continues to be prosecuted in good faith, has not been irretrievably cancelled, withdrawn or abandoned, and that has been pending for less than [***] years from its
earliest priority date; provided that if the claim ever issues, it shall become a Valid Claim again after issuance. 

1.39    “United States” or “U.S.” means the United States of America and its
territories and possessions. 
 1.40    Interpretation. In this Agreement, unless otherwise specified: 

(a)    The words “include”, “includes” and “including” shall be deemed to be followed
by the phrase “without limitation”; 
 (b)    words denoting the singular shall include the plural and
vice versa and words denoting any gender shall include all genders; 
 (c)    the word “or” is used in
the inclusive sense typically associated with the phrase “and/or”; 
 (d)    words such as
“herein”, “hereof”, and “hereunder” refer to this Agreement as a whole and not merely to the particular provision in which such words appear; and 

(e)    the Exhibits and other attachments form part of the operative provision of this Agreement and references to
this Agreement shall include references to the Exhibits and attachments. 
 1.41    Additional Definitions.
The following table identifies the location of definitions set forth in various Sections of the Agreement: 
  

			
	 Defined Terms
	  	Section
	 ADS
	  	5.2
	 Alliance Manager
	  	3.5
	 Audit
	  	5.11(b)
	 Auditor
	  	5.11(b)

  
 7 

			
	 Defined Terms
	  	Section
	 Bankruptcy Code
	  	6.6
	 Executive Officers
	  	3.4
	 GCAR
	  	4.4(a)
	 GBM AGILE
	  	4.4(a)
	 IDL
	  	4.5(d)
	 Indemnified Party
	  	10.3
	 Indemnifying Party
	  	10.3
	 Joint Steering Committee or JSC
	  	3.1
	 Kazia Indemnitees
	  	10.2
	 Licensed Trademarks
	  	6.7(a)
	 Prior CDA
	  	7.7
	 Product Marks
	  	6.7(b)
	 Recipient
	  	7.3
	 Remedial Action
	  	4.12
	 Review Period
	  	5.5(f)
	 Royalty Query
	  	5.5(f)
	 Royalty Report
	  	5.5(e)
	 Royalty Term
	  	5.5(b)
	 Securities Regulators
	  	7.6(b)
	 Share Subscription Agreement
	  	5.2
	 Simcere Indemnitees
	  	10.1
	 Territory Infringement
	  	6.3

 ARTICLE 2 

LICENSE 

2.1    License to Simcere. As between the parties, Kazia hereby grants Simcere and its Affiliates an
exclusive (even as to Kazia and its Affiliates) and royalty bearing license for the Term (but subject to Section 8.1(a)) under the Licensed IP solely to research, Develop, make, have made, use, sell, offer for sale, have sold, import and
Commercialize the Compound and Product in the Field in the Territory. Simcere acknowledges and agrees that Kazia obtained Control of certain Licensed Know-How through a
non-exclusive license from Genentech under the Genentech Agreement, and therefore: 

(a)    the foregoing license granted by Kazia to Simcere under such Licensed
Know-How shall be exclusive with respect to Kazia and its Affiliates only; and 
 (b) such
Licensed Know-How may be otherwise used or licensed by Genentech. 

  
 8 

 2.2    Subcontractors and Sublicenses. 

(a)    Subject to Sections 2.2(c) and 2.2(d), Simcere shall have the right to engage Third Party subcontractors in
connection with the Development, Manufacture and Commercialization of the Compound and Product in the Field in the Territory, and shall have the right to grant sublicenses to its subcontractors solely in order to enable the subcontractors to perform
such work for Simcere, provided that such sublicenses shall not include the right for the subcontractors to market, promote or sell the Product, unless the subcontractor serves as Simcere’s distributor or contract sales force for the Product.

 (b)    Sublicenses to any Third Party whom shall serve as Simcere’s distributor or contract sales force
for the Product shall require Kazia’s prior written consent, which shall not be unreasonably withheld, delayed or conditioned. 

(c)    Simcere must ensure that any subcontractor or sublicensee agrees in writing to be subject to, and bound by,
to the extent applicable, terms and conditions substantially similar to the terms and conditions of this Agreement. Simcere will remain responsible to Kazia for all acts performed by, and omissions of, any subcontractor or sublicensee pursuant to
any subcontract or sublicense agreements as if such act or omission was undertaken by Simcere, and Simcere must ensure compliance by all subcontractors and sublicensees with the obligations of Simcere under this Agreement. 

(d)    Irrespective of any subcontract or sublicense arrangement, Simcere will be responsible for the payment of
all amounts due under this Agreement, regardless of whether the terms of the subcontract or sublicense arrangement provide for such amount to be paid by the subcontractor or sublicensee directly to Kazia. 

2.3    License Back. Notwithstanding the exclusive (as between the parties) license granted to Simcere under
Section 2.1, Simcere grants back to Kazia a royalty-free, sub- licensable, irrevocable for the Term, non-exclusive license under the Licensed IP to (a) conduct
non-clinical research, GBM AGILE and other Global Clinical Trials, in each case, of the Compound and the Product in the Field in the Territory, and (b) Manufacture the Compound and Product in the
Territory for export out of the Territory. For the avoidance of doubt, the Parties acknowledge that Kazia retains the exclusive right to practice, license and otherwise exploit the Licensed IP outside the scope of the license granted to Simcere
under Section 2.1. 
 2.4    No Implied License. Except as expressly set forth herein, neither Party
shall acquire any license, right or other interest, by implication or otherwise, under any intellectual property rights of the other Party. 

2.5    Termination of Genentech Agreement. To the extent possible, upon the early termination of the
Genentech Agreement for any reason, this Agreement will continue in full force and effect, provided that: 

(a)    all rights and licenses granted by Kazia under Section 2.1 under any Licensed IP which Kazia obtained
Control of through a license from Genentech under the Genentech Agreement shall terminate; and 

  
 9 

 (b)    all necessary consequential amendments to this Agreement
will be taken to have been made (including with respect to applicable representations and warranties) with effect on and from the date upon which the Genentech Agreement terminates. 

ARTICLE 3 
 GOVERNANCE

 3.1    Joint Steering Committee. Subject to Section 8.1(b), within thirty (30) days after
the Effective Date, the Parties shall establish a joint steering committee (the “Joint Steering Committee” or the “JSC”), composed of two (2) senior executives of each Party (or such number of representatives
as agreed by the Parties, provided that the Parties shall have equal number of representatives at the JSC), to oversee and coordinate the Parties’ activities under this Agreement. The JSC shall in particular: 

(a)    provide a forum for the discussion of the Parties’ activities under this Agreement and facilitate
communications between the Parties with respect thereto; 
 (b)    oversee the technology transfer and assistance
to be provided by Kazia to Simcere hereunder and related activities; 
 (c)    discuss and coordinate the
Development of the Compound and Product by each Party (including their respective Affiliates, licensees and sublicensees); 

(d)    review and discuss Simcere’s reports of its Development and Commercialization of the Product in the
Territory; 
 (e)    establish joint subcommittees as it deems necessary or advisable for the Development,
Manufacture and Commercialization of the Compound and Product; 
 (f)    discuss the status of GBM AGILE within
and outside the Territory and the status of any current or planned clinical trials of the Product in the Field in the Territory; and 

(g)    perform such other functions as appropriate to further the purposes of this Agreement, as expressly set
forth in this Agreement or allocated to it by the Parties in writing. 
 3.2    Limitations of JSC
Authority. The JSC shall only have the powers expressly assigned to it in this Article 3 and elsewhere in this Agreement and shall not have the authority to: (a) modify or amend the terms and conditions of this Agreement; (b) waive or
determine either Party’s compliance with the terms and conditions of under this Agreement; or (c) decide any issue in a manner that would conflict with the express terms and conditions of this Agreement. 

3.3     JSC Membership and Meetings. 

(a)    Subject to Section 8.1(b), within thirty (30) days following the Effective Date, each Party shall
designate its initial members to serve on the JSC. Each Party may replace its representatives on the JSC on written notice to the other Party. Each Party shall appoint one (1) of its representatives on the JSC to act as a co-chairperson of the JSC. The co-chairpersons shall jointly prepare and circulate agendas and reasonably detailed minutes for each JSC meeting. 

  
 10 

 (b)    The JSC shall hold meetings at such times as it elects to
do so, but in no event shall such meetings be held less frequently than once every six (6) months.    Meetings of the JSC must be conducted in English and may be held in person, by audio or video teleconference; provided
that the Parties shall endeavor to hold one JSC meeting in person each year.    In person JSC meetings shall be held at locations selected alternatively by the Parties. Each Party shall be responsible for all of its own expenses
of participating in the JSC. No action taken at any meeting of the JSC shall be effective unless at least one (1) representative from each Party is participating. 

(c)    Each Party may from time to time invite a reasonable number of participants, in addition to its
representatives, to attend the JSC meetings in a non-voting capacity; provided that such participants shall be bound by confidentiality and non-use obligations
consistent with the terms of this Agreement and that each Party shall provide prior written notice to the other Party if it has invited any third party (including any consultant) to attend such a meeting. 

3.4    Decision-Making. All decisions of the JSC shall be made by unanimous vote, with each Party’s
representatives collectively having one (1) vote, which may be exercised by a Party’s sole attendee at a meeting if both of its representatives do not attend. If after reasonable discussion and good faith consideration of each Party’s
view on a matter before the JSC that is within its authority, the representatives of the Parties cannot reach unanimous agreement as to such matter within thirty (30) days after such matter was brought to the JSC for resolution, such
disagreement shall be referred to the Chief Executive Officer of Kazia and a Senior Vice President or Vice President level executive of Simcere (the “Executive Officers”) for resolution. If the Executive Officers do not resolve such
matter within ten (10) business days after such matter has been referred to them, then: Kazia shall have the final decision making authority with respect to the Development, Manufacture and Commercialization of the Compound and Product outside
the Territory, and Simcere shall have the final decision making authority with respect to the Development, Manufacture and Commercialization of the Compound and Product in the Territory; provided however that (a) Kazia may not make a decision
that is inconsistent with its obligations to use Commercially Reasonable Efforts to Develop the Product outside the Territory and to complete GBM AGILE (including sites in the Territory), (b) Simcere may not make a decision that is inconsistent with
its obligations to use Commercially Reasonable Efforts to Develop and Commercialize the Product in the Territory, (c) each Party shall use Commercially Reasonable Efforts not to make any decision that is reasonably expected to materially and
adversely affect the Compound and Product in the Territory; and (d) Simcere may not make any decision regarding a clinical trial of the Product in the Territory that will create material risk to the safety and wellbeing of the patients enrolled
in such clinical trial. For the avoidance of doubt, the Parties agree that Kazia will not breach any of its obligations under this Section 3.4 if it ceases to pursue Commercialization of a Product in a jurisdiction outside the Territory. 

3.5    Alliance Manager. In addition to the JSC, subject to Section 8.1(b), within thirty (30) days after the
Effective Date, each Party shall appoint (and notify the other Party of the identity of) a representative who is fluent in English and has appropriate qualifications (including a general understanding of pharmaceutical development, manufacture and
commercialization issues) to act as its alliance manager under this Agreement (the “Alliance Manager”). The Alliance Managers shall serve as the primary contact points between the Parties regarding the activities contemplated by
this Agreement. The Alliance Managers shall facilitate the flow of information and otherwise promote communication, coordination and collaboration between the Parties, providing single point communication for seeking consensus both internally within
each Party’s respective organization, including facilitating review of external corporate communications, and raising cross-Party and/or cross-functional issues in a timely manner. Each Party may replace its Alliance Manager by written notice
to the other Party. 

  
 11 

 ARTICLE 4 

DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION 

4.1    General. Subject to the terms and conditions of this Agreement and except for GBM AGILE, Simcere
shall be solely responsible for the Development and Commercialization of the Product in the Field in the Territory, at Simcere’s own cost and expense. 

4.2    Diligence. Subject to Kazia complying with its obligations hereunder with respect to technology
transfer and supply of Compound and Product to Simcere, Simcere (either by itself or through its Affiliates and sublicensees) shall use Commercially Reasonable Efforts to Develop and Commercialize at least one Product in the Field in the Territory.
Kazia shall use Commercially Reasonable Efforts to Develop the Product outside the Territory and to complete GBM AGILE (including sites in the Territory). Notwithstanding the foregoing, Kazia acknowledges that certain Development activities planned
by Simcere overlap with activities otherwise being conducted as part of GBM AGILE, and agrees that, subject to Section 4.4(c)(ii), Simcere shall not be required to conduct such Development activities to the extent such activities overlap with
any relevant activities conducted as part of GBM AGILE. 
 4.3    Technology Transfer. Within thirty
(30) days after receiving a notice from Simcere to initiate technology transfer, Kazia shall provide Simcere with all Licensed Know- How that exists on the Effective Date and not previously provided to Simcere, including those items, and on the
terms, set forth in Exhibit C. If any additional Licensed Know-How comes into Kazia’s Control during the Term of this Agreement (including any data resulting from GBM AGILE and other Development
work of the Compound and Product conducted by Kazia, its Affiliates, licensees and sublicensees), Kazia shall notify Simcere and provide copies thereof to Simcere at the next scheduled JSC meeting (except that data and reports from GBM AGILE shall
be provided to Simcere promptly (within five (5) days in any event)). Upon Simcere’s request, Kazia shall also provide Simcere with reasonable technical assistance in connection with the practice of the Licensed IP in the Development of
the Compound and Product, including reasonable access to Kazia’s available technical personnel involved in the research and Development of the Compound and Product, at no additional cost to Simcere (but subject to reimbursement of reasonable out-of-pocket cost). 

4.4    Development. 

(a)    As of the Effective Date, Kazia is conducting a global phase 2 / 3 clinical trial of the Product in
glioblastoma as part of the Glioblastoma Adaptive Global Innovative Learning Environment sponsored by the Global Coalition for Adaptive Research (“GCAR”) (such trial of the Product, the “GBM AGILE”). After the
Effective Date, Kazia (either by itself or through GCAR or Third Party contractors) shall use Commercially Reasonable Efforts to complete GBM AGILE (including sites in the Territory) at Kazia’s own cost and expense. Kazia shall keep Simcere
informed on the progress and results of the GBM AGILE and shall consider in good faith suggestions and comments provided by Simcere regarding the conduct of GBM AGILE in the Territory, including the selection of sites and contractors in the
Territory for GBM AGILE. Without limiting the foregoing, where appropriate and when it is able, Kazia shall invite Simcere to participate in any meetings and discussions with GCAR regarding the conduct of GBM AGILE in the Territory. Kazia shall
provide Simcere with copies of all GBM AGILE data and reports within five (5) days after receipt from GCAR or clinical sites. 

  
 12 

 (b)    Kazia shall notify Simcere if Kazia wishes to conduct a
Global Clinical Trial . Kazia shall keep Simcere informed on the planning, progress and results of any Global Clinical Trial and shall consider in good faith any suggestions and comments provided by Simcere regarding the conduct of any Global
Clinical Trial in the Territory, including with respect to Simcere’s potential direct involvement, and the selection of sites and contractors, in the Territory for the Global Clinical Trial. Kazia shall also include in contractual arrangements
with collaborators with respect to Global Clinical Trials obligations consistent with those in Section 7.5(b) with respect to the publication or disclosure of the results of a Global Clinical Trial. 

(c)    Except for GBM AGILE and any Global Clinical Trial, Simcere (either by itself or through its Affiliates and
sublicensees), at its own cost and expense, shall be responsible for the Development of the Product in the Field in the Territory, including all pre-clinical studies and all clinical trials of the Product in
the Field in the Territory. As of the Effective Date, the Parties expect the efficacy data from GBM AGILE may be used to assist in obtaining the MA of the Product in glioblastoma in the Territory. However, the Parties acknowledge that neither Kazia,
nor GCAR, the respective Regulatory Authorities or any other party can provide binding assurances that GBM AGILE will be sufficient to obtain any such MA. If the data from GBM AGILE is not sufficient to support the granting of a MA, Simcere may
conduct additional clinical trials of the Product in glioblastoma in order to obtain a MA in the Territory and, subject to Simcere obtaining any necessary approvals or authorizations from all parties involved in a Global Clinical Trial, Simcere may
also participate in the Global Clinical Trial through clinical sites in the Territory. For clarity: 

(i)    where Simcere does not obtain any necessary approvals or authorizations from all parties involved in a
Global Clinical Trial, it will not participate in that Global Clinical Trial; and 
 (ii)    Simcere shall be
responsible for any pharmacokinetic study that is required by a Regulatory Authority in the Territory. 

4.5    Regulatory. 

(a)    Subject to the remainder of this Section 4.5, Simcere (either by itself or through its Affiliates and
sublicensees) shall apply for and maintain, at its own cost and expense, all Regulatory Approvals of the Product in the Field in the Territory. Subject to Section 4.5(b), Simcere shall be responsible for the preparation of all Regulatory
Materials and all communications and interactions with Regulatory Authorities with respect to the Product in the Field in the Territory, both prior to and subsequent to Regulatory Approval. Simcere (or its Affiliate or sublicensee) shall file all
required regulatory dossiers to obtain (and maintain) Regulatory Approval of the Product in the Field in the Territory and shall be the holder of such Regulatory Approvals in the Territory. 

  
 13 

 (b)    Unless otherwise agreed by the Parties in writing and
except in exigent circumstance, prior to responding to, or submitting, any material communication to any Regulatory Authority with respect to the Product in the Territory, Simcere shall submit such response or communication to Kazia for review and
shall consider in good faith any comments provided by Kazia. 
 (c)    Notwithstanding Section 4.5(a), Kazia
(and its collaborators and contractors, such as GCAR) shall have the right to submit Regulatory Materials, communicate with Regulatory Authorities, and hold Regulatory Approvals with respect to the Product in the Territory solely to the extent
required to continue and complete GBM AGILE or any other Global Clinical Trial, including the IND for GBM AGILE or such other Global Clinical Trial. 

(d)    For Product that is first approved outside the Territory, Manufactured and supplied by Kazia to Simcere
pursuant to Section 4.9(a), and approved in mainland China as an imported drug under an Imported Drug License (“IDL”), if applicable Laws do not allow Simcere to be the holder of the IDL or other Regulatory Materials related to
such imported Product, then Kazia shall initially be the holder of the IDL and such Regulatory Materials for the sole benefit of Simcere, until Simcere is permitted by applicable Law to be the holder of the IDL and such Regulatory Materials, at
which time Kazia shall use its best endeavors to promptly transfer the IDL and such Regulatory Materials to Simcere. While Kazia is the holder of the IDL and such Regulatory Materials, Kazia shall (i) subject to Section 4.5(b), appoint
Simcere as its exclusive regulatory agent to communicate and handle regulatory activities relating to the IDL and such Regulatory Materials with the NMPA and other Regulatory Authorities in mainland China, (ii) appoint Simcere under the IDL as
the exclusive distributor of the Product in mainland China, and (iii) not take any action that adversely affects the IDL and such Regulatory Materials in mainland China (without limiting the foregoing, Kazia shall not transfer the ownership of
the corresponding Regulatory Approval of the Product outside the Territory to a Third Party, which transfer results in a change to the holder of the IDL in mainland China, unless the Third Party transferee expressly agrees to assume Kazia’s
obligations to hold the IDL and such Regulatory Materials in mainland China for the benefit of Simcere as set forth above in this Section 4.5(d). 

4.6    Data Sharing. At each JSC meeting, each Party shall keep the other Party reasonably informed on the
Development activities conducted by or on behalf of such Party (including its Affiliates, licensees and sublicensees) for the Compound and Product, and, subject to applicable Laws, shall provide the other Party with copies of all data and results,
including pre-clinical data, clinical reports and reasonable supporting documentation (such as protocols and data analysis plans) directly relevant to the Development of the Compound or Product, or
Commercialization of the Product, in the Field, generated by or on behalf of such Party through the Development of the Compound and Product. Each Party shall have the right to use and reference such data and results provided by the other Party,
without additional consideration, for the purpose of obtaining and maintaining Regulatory Approval of the Product in the Field in its territory. 

  
 14 

 4.7    Cross Reference. Each Party shall also keep the
other Party reasonably informed on the regulatory activities conducted by or on behalf of such Party (including its Affiliates, licensees and sublicensees) for the Product, and shall promptly provide the other Party with copies of all Regulatory
Materials directly relevant to the Development of the Compound or Product, or Commercialization of the Product, in the Field submitted to or received from Regulatory Authorities in the Territory. Kazia will also promptly provide Simcere with copies
of any Regulatory Materials directly relevant to the Development of the Compound or Product, or Commercialization of the Product, in the Field in the Territory submitted by Kazia to or received from the US FDA, European Medicines Agency (EMA) and
Pharmaceuticals and Medical Devices Agency of Japan. Each Party hereby grants to the other Party a right of reference to all Regulatory Materials filed by or on behalf of such Party for the Product, which right of reference the other Party may use
for the purpose of seeking, obtaining and maintaining Regulatory Approvals of the Product in the Field in such other Party’s territory. 

4.8    Pharmacovigilance. Each Party hereby agrees to comply with its respective obligations under the
Exhibit E with respect to the safety and pharmacovigilance procedures for the Parties with respect to the Product, such as safety data sharing and exchange, adverse events reporting and prescription events monitoring and to cause its
Affiliates, licensees and sublicensees to comply with such obligations. Promptly following the Effective Date, but in no event later than the date of the first IND approval for any clinical trial of the Product received by Simcere, Kazia and Simcere
shall enter into a written pharmacovigilance agreement which will be consistent with the above terms. 

4.9    Manufacture and Supply. 

(a)    Kazia shall (either by itself or through its Affiliate or Third Party contract manufacturer) Manufacture and
supply the Compound and Product requested by Simcere in accordance with Exhibit F for Development and Commercialization use at a price equal to: (i) Manufacturing Cost plus a [***] markup, for Compound and Product supplied for Development
use; and (ii) Manufacturing Cost plus a [***] markup, for Compound and Product supplied for Commercialization use. Kazia shall deliver the Compound and Product to Simcere CIF (Incoterms 2020) to Simcere designated port of import in the
Territory, provided that Simcere shall reimburse Kazia for the reasonable shipping cost incurred for the delivery of the Product. The Parties must comply with the obligations in Exhibit F with respect to the supply of Compound and Product.
The Parties may also negotiate in good faith and seek to agree to a detailed contract manufacturing agreement. 

(b)    In addition to purchasing the Compound and Product from Kazia for Development and Commercialization use in
the Territory pursuant to Section 4.9(a) above, Simcere shall have the right to Manufacture and have Manufactured the Compound and Product in the Territory, either by itself or through its own contract manufacturer, provided such contract
manufacturer is located in the Territory. Upon Simcere’s reasonable request, Kazia shall make available to Simcere all Licensed Know-How directly related to the Manufacture of the Compound and Product in
the Territory, and provide Simcere (or its designee) with any reasonable technical assistance to the extent necessary to enable Simcere (or its designee) to Manufacture the Compound and Product in the Territory, at no additional cost to Simcere (but
subject to reimbursement of reasonable out-of-pocket cost). In addition, upon Simcere’s reasonable request, Kazia shall introduce Simcere to Kazia’s contract
manufacturer for the Compound and Product and shall reasonably assist Simcere to negotiate a technology transfer agreement and, if such contract manufacturer Manufactures the Product in the Territory, a supply agreement directly with such contract
manufacturer. 

  
 15 

 4.10    Commercialization. 

(a)    Subject to Section 4.10(b), Simcere (either by itself or through its Affiliates and sublicensees) shall
be responsible for all aspects of the Commercialization of the Product in the Field in the Territory, at Simcere’s own cost and expense, including: (a) developing and executing a commercial launch and
pre-launch plan, (b) negotiating with applicable Government Authorities regarding the price and reimbursement status of the Product; (c) marketing and promotion; (d) booking sales and distribution
and performance of related services; (e) handling all aspects of order processing, invoicing and collection, inventory and receivables; (f) providing customer support, including handling medical queries, and performing other related
functions; and (g) conforming its practices and procedures to applicable Laws relating to the marketing, detailing and promotion of the Product in the Territory. 

(b)    Simcere must only market, distribute and sell the Product in the Territory. Simcere (either by itself or
through its Affiliates or sublicensees) must not sell any Product to parties where it knows or should know, or where it reasonably suspects, that the party may seek to sell the Product outside of the Territory. 

(c)    Kazia must only market, distribute and sell the Product outside the Territory. Kazia (either by itself or
through its Affiliates, licensees or sublicensees, other than Simcere and Simcere’s sublicensees) must not sell any Product to parties where it knows or should know, or where it reasonably suspects, that the party may seek to sell the Product
in the Territory. 
 4.11    Reporting. Within sixty (60) days after the end of each calendar year,
Simcere shall provide to Kazia a report summarizing its Development and Commercialization of the Product in the Field in the Territory. Together with each report, Simcere shall also provide to Kazia a summary of its plans for the Development and
Commercialization of the Product in the next year. The Parties shall review and discuss such report and plan at the JSC meetings. 

4.12    Remedial Actions. Each Party will notify the other Party immediately, and promptly confirm such
notice in writing, if it obtains information indicating that any Product may be subject to any recall, corrective action or other regulatory action with respect to such product taken by virtue of applicable Law (a “Remedial
Action”). The Parties will assist each other in gathering and evaluating such information as is necessary to determine the necessity of conducting a Remedial Action. Simcere shall have sole discretion with respect to any matters relating to
any Remedial Action for the Product in the Field in the Territory. In the event that Simcere determines that any Remedial Action with respect to the Product should be commenced in the Field in the Territory, or if Remedial Action is required by any
Regulatory Authority having jurisdiction over the matter in the Territory, Simcere will control and coordinate all efforts necessary to conduct such Remedial Action in the Field in the Territory and shall be responsible for all cost and expense of
such Remedial Action (unless the Remedial Action is due to Manufacturing defect in the Compound or Product supplied by Kazia, in which case Kazia shall reimburse Simcere for the cost and expense of such Remedial Action). Notwithstanding the
foregoing, to the extent possible, Simcere will consult with Kazia regarding any such Remedial Action plan and provide to Kazia a copy of any communication from, or which Simcere proposes to provide to, a Regulatory Authority relating to a Remedial
Action. Kazia may review and provide comments on any proposed communications to a Regulatory Authority by Simcere, in which case Simcere must consider such comments in good faith and acting reasonably. 

  
 16 

 4.13    Regulatory/Quality Audit. Upon reasonable advance
notice, Kazia shall have the right to audit the regulatory, safety, quality and compliance systems, procedures and practices of Simcere relating to the Development and Manufacture of the Compound and the Product in the Field in the Territory. Kazia
may not conduct such audit more than once each calendar year unless (a) a prior audit in that calendar year discovers material non-compliance by Simcere with its obligations under this Agreement, or
(b) a Regulatory Authority conducts an audit of Kazia or its Affiliates for the purpose of verifying any matter related to the Compound or Product. Such audit shall take place during Simcere’s normal business hours and shall not interfere
with Simcere’s normal operations, and Simcere shall have the right to limit access to and/or redact information relating to other products. After the completion of the audit, Kazia shall promptly provide Simcere with a written audit report. If
the audit reveals any potential or actual non-compliance by Simcere or its Affiliates or areas of improvement, the Parties shall discuss such findings and Simcere shall take corrective or improvement actions as mutually agreed by the Parties. 

ARTICLE 5 
 Payments

 5.1    Upfront Payment. Simcere shall pay to Kazia a
one-time, non-refundable upfront payment of seven million Dollars ($7,000,000) within forty five (45) days after receipt of the invoice issued by Kazia after the
Effective Date. 
 5.2    Equity Investment. Prior to or concurrently with the execution of this
Agreement, the Parties (or their designated Affiliates) shall enter into a share subscription agreement, pursuant to which Kazia shall issue to Simcere, and Simcere shall subscribe from Kazia, four million Dollars ($4,000,000) of newly issued
American Depository Shares of Kazia, each representing 10 ordinary shares of Kazia (the “ADSs”), at a purchase price per ADS equal to one hundred twenty percent (120%) [***]. 

  
 17 

	 	5.3	 Development Milestone Payments. 

(a)    Milestone Events. Subject to the remainder of this Section 5.3, Simcere shall pay to Kazia the
following one-time, non-refundable development milestone payments set forth in the table below upon the first achievement of the corresponding milestone event: 

 

			
	 Development Milestone Event
	  	
Milestone Payment in
Dollars

	[***]	  	[***]
	[***]	  	[***]
	[***]	  	
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]

 (b)    Milestone Conditions. 

(i)    Each development milestone payment set forth above shall be due and payable only once, regardless of how
many times such milestone event is achieved and/or the number of Products that achieve such milestone event. For milestone #3 (Obtainment of a MA for glioblastoma from NMPA), the milestone payments in either clause (a) or clause (b), but not
both, may be due and payable. For clarity, the aggregate milestone payments under this Section 5.3 shall not exceed [***] 

(ii)    “Initiation” of a human clinical trial means the first dosing of the first human subject enrolled
in such clinical trial. 

  
 18 

 (iii)    “Successful completion of GBM AGILE” means
that the results of such clinical trial meet all study endpoints specified in Exhibit D attached hereto. 

(iv)    “additional major Indication” means (A) brain metastases from a primary tumour of the
breast, lung, skin, colon, or kidney, or combination thereof, or (B) newly-diagnosed unmethylated glioblastoma, newly-diagnosed methylated glioblastoma, or recurrent glioblastoma; provided that in both (A) and (B) that at least fifty per
cent (50%) of the patients covered by such new approval were not previously approved to receive treatment with the Product, and that the approval was the subject of a distinct MA filing to the applicable regulatory agency. 

(v)    “additional non-major Indication” means primary brain
tumours other than glioblastoma, and brain metastases from primary tumours other than those listed in Section 5.3(b)(iv). 

(vi)    approvals in Indications which do not meet the definition of “additional major Indication” or
“additional non-major Indication” will be discussed between the Parties in good faith to determine whether such approvals should be considered major or non-major Indications for the purposes of this
Agreement. 
 For clarity, an additional major Indication or an additional non-major Indication shall require a
separate MA to any other MA involving the Compound already in existence. 
 (c)    Notice and Payment. For
milestone #2 ([***]), Kazia shall notify Simcere in writing within thirty (30) days after the first achievement of such milestone and shall provide Simcere with reasonable supporting documents for the achievement of such milestone [***]. For
all other milestones set forth above, Simcere shall notify Kazia in writing within thirty (30) days after the first achievement of such milestone. Simcere shall pay to Kazia the corresponding milestone payment within forty five (45) days
after the receipt of the invoice issued by Kazia after the achievement of such milestone. For the avoidance of doubt, payment in accordance with these terms must be made even where notice of milestone satisfaction is not provided in accordance with
this clause 5.3(c). 
  

	 	5.4	 Sales Milestone Payments. 

(a)    Milestone Events. Subject to the remainder of this Section 5.4, Simcere shall pay to Kazia the
following one-time, non-refundable sales milestone payments set forth in the table below when the aggregated annual Net Sales of the Product sold in the Territory in a
calendar year first reach the corresponding threshold value indicated below. 
  

			
	 First time aggregate annual Net Sales (in Dollars) of the
Product
in the Territory exceed:
	  	
Milestone Payment in
Dollars

	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]

  
 19 

			
	 First time aggregate annual Net Sales (in Dollars) of the
Product
in the Territory exceed:
	  	
Milestone Payment in
Dollars

	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]

 (b)    Milestone Conditions.    Each sales
milestone payment set forth above shall be due and payable only once, regardless of how many times such milestone event is achieved. The Net Sales of Product sold in a region in the Territory after the expiration of the Royalty Term in such region
shall not be included in the calculation of annual Net Sales to determine whether any Net Sales threshold has been achieved. The aggregate milestone payments under this Section 5.4 shall not exceed [***]. 

(c)    Notice and Payment. As part of the Royalty Report in Section 5.5(e), Simcere shall provide
written notice to Kazia if the aggregated annual Net Sales of the Product in the Territory first reach any threshold value set forth in Section 5.4(a) above during the time period to which such report pertains. Simcere shall pay to Kazia the
corresponding milestone payments within forty five (45) days after the receipt of the invoice issued by Kazia after the achievement of such milestone. For the avoidance of doubt, payment in accordance with these terms must be made even where
notice of milestone satisfaction is not provided in accordance with this clause 5.4(c). 
  

	 	5.5	 Royalty Payments. 

(a)    Royalty Rate. Subject to the remainder of this Section 5.5, Simcere shall make quarterly non-refundable royalty payments to Kazia on the Net Sales of the Product sold in the Territory, as calculated by multiplying the applicable royalty rate set forth in the table below by the corresponding amount of
incremental, aggregated annual Net Sales of the Product sold in the Territory during the applicable calendar year. 
  

			
	 For that portion of annual Net Sales (in Dollars) of the Product in
the Territory
	  	 Royalty Rate

	[***]	  	[***]
	 [***]
	  	[***]
	[***]	  	[***]

 (b)    Royalty Term. Simcere’s obligation to pay royalties pursuant to
this Section 5.5 shall expire, on a Product-by-Product and region-by-region basis,
[***] after the First Commercial Sale of such Product in such region (the “Royalty Term”). 

  
 20 

 (c)    Royalty Conditions. The royalties under this
Section 5.5 shall be subject to the following conditions: 
 (i)    only one (1) royalty shall be due
with respect to each unit of Product, without regard to whether there is more than one Valid Claim or Licensed Patent claiming such Product; 

(ii)    no royalties shall be due upon the sale or other transfer of the Product among Simcere, its Affiliates and
sublicensees, but in such cases the royalty shall be due and calculated upon Simcere’s, its Affiliate’s or sublicensee’s Net Sales of Product to the first Third Party (other than sublicensee); 

(iii)    no royalties shall accrue on the disposition of Product in reasonable quantities by Simcere, its
Affiliates or sublicensees for use in clinical trials and other development work, as part of an expanded access program, as free samples, or as donations to non-profit institutions or government agencies for non-commercial purposes, provided that in each case no revenue is generated by Simcere, its Affiliates or sublicensees; and 

(iv)    the Net Sales of Product sold in a region after the expiration of the Royalty Term in such region shall
not be included in the calculation of annual Net Sales to determine the applicable royalty tiers. 
 (d)    Royalty
Reductions. 
 (i)    If a Product is sold in a region in the Territory during the applicable Royalty Term
at a time when there is no Valid Claim in the Licensed Patents that claims the composition of matter of the Compound contained in such Product in such region, then the royalty rate applicable to the Net Sales of such Product in such region during
such time shall be reduced by [***] of the royalty rate otherwise applicable to all Net Sales for such Product in the Territory under Section 5.5(a). 

(ii)    If Simcere, its Affiliate or sublicensee, upon the advice of competent counsel properly qualified to
provide the advice, requires and obtains a license under a Third Party patent where such composition of matter patent covers the Compound included in a Product, then Simcere shall have the right to deduct, from the royalty payment that would
otherwise have been due pursuant to Section 5.5(a), an amount equal to [***] of the amount paid by Simcere or its Affiliate or sublicensee to such Third Party pursuant to such license during the same period; provided, however, that in no event
shall the amount otherwise payable under Section 5.5(a) to Kazia with respect to such Product be reduced more than [***] of what would otherwise be due on the sale of such Product. 

(e)    Report. Within forty five (45) days after the end of each calendar quarter, commencing with the
First Commercial Sale of the Product in the Territory, Simcere shall provide Kazia with a royalty report that contains the following information for the applicable calendar quarter and calendar year (to date if not yet a full calendar year), on a Product-by-Product and region-by-region basis: (i) the number of units of each Product sold; (ii) the amount of gross sales
of the Product, (iii) a calculation of Net Sales of the Product, (iv) a calculation of the royalty payment due on such Net Sales, including the application of any reduction made in accordance with Section 5.5(d), (v) the exchange rate
for such region, and (vi) the aggregate annual Net Sales and whether any sales milestone has been achieved (“Royalty Report”). 

  
 21 

 (f)    Payment. Within ten (10) business days after
the date on which the Royalty Report is given to Kazia (“Review Period”), Kazia may, acting reasonably and in good faith, make an enquiry to Simcere about any aspect of the Royalty Report (“Royalty Query”). 

(i)    If at the end of the Review Period, Kazia has not made any Royalty Query, all amounts set out in the
Royalty Report will be taken to be final and binding on the Parties and Simcere must, within forty five (45) days after the issue of a valid invoice by Kazia, pay to Kazia an amount equal to the royalty amount set out in Section 5.5(a),
being the amount included in the Royalty Report in accordance with Section 5.5(e)(iv), in respect of Net Sales made during the period of the relevant Royalty Report. 

(ii)    If a Royalty Query is made within the Review Period, then Simcere must properly respond to such Royalty
Query, including (if applicable) providing evidence to support the amounts set out in the Royalty Report. If the Royalty Query has not been resolved within forty-five (45) business days after the Royalty Query is made, Kazia may exercise its
audit right in accordance with Section 5.11. 
 (iii)    Where a Royalty Query is: (a) resolved or
otherwise agreed by the Parties; or (b) determined by an Auditor in accordance with Section 5.11, Kazia must issue an invoice to Simcere for the agreed or determined royalty amount and Simcere must pay that amount within forty-five
(45) days after issue of the invoice. 
 5.6    Kazia’s Third Parties Payment Obligations. Kazia shall
be solely responsible for the payment of royalty, milestone and other payments due to Third Parties under any agreements between Kazia (or its Affiliates) and Third Parties (including the Genentech Agreement) on account of Simcere’s, its
Affiliates’ and sublicensees’ Development, Manufacture and Commercialization of the Product in the Field in the Territory. 

5.7    Currency; Exchange Rate. All payments due from Simcere to Kazia under this Agreement shall be made by
Simcere in Dollars by bank wire transfer in immediately available funds to a bank account designated by Kazia in writing. The rate of exchange to be used in computing the amount of currency equivalent in Dollars shall be made at the average of the
closing exchange rates reported by Bank of China for the first, middle and last business days of the applicable reporting period for the payment due. 

5.8    Blocked Currency. If the conversion of a local currency in the Territory into Dollars or transfer of
funds out of a region in the Territory becomes materially restricted, forbidden or substantially delayed due to applicable Laws, then Simcere must immediately notify Kazia and amounts accrued in such region may be paid by Simcere in local currency
into an account in a local bank designated by Kazia, or such legal payment method as otherwise directed by Kazia. If the conversion of local currency into Dollars or transfer of funds out of a region in the Territory is materially restricted,
forbidden or substantially delayed due to applicable Laws for more than eight (8) months and while it continues, Kazia may, at its sole discretion, terminate this Agreement with immediate effect by giving written notice to Simcere. 

  
 22 

 5.9    Late Payments. If Kazia does not receive payment of
any sum due to it on or before the due date, interest shall thereafter accrue on the sum due from the due date until the date of payment at a per-annum rate of prime (as reported Bank of China) plus two
(2) percentage points or the maximum rate allowable by applicable Law, whichever is less. Notwithstanding the foregoing, the interest set forth in this Section 5.9 shall not apply if the payment is delayed due to government restriction on
currency conversion or transfer of funds out of a region in the Territory. 
 5.10    Taxes. 

(a)    Taxes on Income. Each Party shall be solely responsible for the payment of all taxes imposed on its
share of income arising directly or indirectly from the activities of the Parties under this Agreement. For clarity, all payment amounts in this Article 5 are on a pre-tax basis. 

(b)    Tax Cooperation. The Parties agree to cooperate with one another and use reasonable efforts to avoid
or reduce tax withholding or similar obligations in respect of royalties, milestone payments, and other payments made under this Agreement. To the extent Simcere is required to deduct and withhold taxes on any payment to Kazia, Simcere shall deduct
those taxes from the remittable payment, pay the taxes to the proper tax authority in a timely manner, and promptly send proof of payment to Kazia. Kazia shall provide Simcere any tax forms that may be reasonably necessary in order for Simcere to
not withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty. Kazia shall use reasonable efforts to provide any such tax forms to Simcere in advance of the due date. At the request and expense of Kazia,
Simcere shall provide reasonable assistance to enable the recovery, to the extent permitted by Law, of withholding taxes or similar obligations resulting from payments made under this Agreement. 

5.11    Records and Audit. 

(a)    Simcere shall maintain complete and accurate records of its, and its Affiliates’ and sublicensees’
sales, transfers and other dispositions of the Product necessary for the calculation of payment due to Kazia under this Agreement. Simcere shall maintain such records for the longer of (i) the period of time required under any applicable Law,
and (ii) three (3) years following the end of the calendar year to which of such records pertain. 

(b)    Kazia may, at any time during the Term and for a period of three (3) years following the expiration or
termination of this Agreement, through an independent certified public accountant nominated by Kazia and acceptable to Simcere (the “Auditor”), undertake an audit of Simcere’s records related to the sale and disposition of the
Product, for the three (3) year period before such notice for the purpose of verifying all payments made under this Agreement (“Audit”). Simcere shall, no later than thirty (30) days of Kazia’s notice of an Audit,
permit the Auditor to have access to Simcere’s records related to the sale and disposition of the Product, for the three (3) year period before such notice and during Simcere’s normal business hours for the purpose of undertaking the
Audit. The Auditor shall be required to enter into a confidentiality agreement reasonably acceptable to Simcere to protect the confidentiality of Simcere’s records before the Audit starts. Kazia may not conduct an Audit more than once each
calendar year unless: (i) a prior Audit in that calendar year determined an error by Simcere resulting in underpayment to Kazia of greater than five percent (5%) for the audited period; or (ii) Kazia is required to verify payments made
under this Agreement as a result of Genentech seeking to conduct an audit in accordance with the terms of the Genentech Agreement. 

  
 23 

 (c)    Kazia shall bear the cost of an Audit under this
Section 5.11, unless the Auditor’s audit report reveals an uncontested underpayment by Simcere of more than five percent (5%) of the amount actually due for the time period being audited or a material breach by Simcere of its obligations
under this Agreement, in which case Simcere shall reimburse Kazia for the costs of the relevant Audit. 

(d)    Upon completion of the Audit, the Auditor shall deliver its audit report to both Parties. Where the
Auditor’s audit report shows that payments made by Simcere are deficient, Simcere shall pay to Kazia the uncontested underpayment within sixty (60) days after the date of the Auditor’s audit report, plus interest (as set forth in
Section 5.9) from the original due date. If the Auditor’s audit report reveals an uncontested overpayment by Simcere, then Simcere may take a credit for such uncontested overpayment against any future payments due to Kazia (if there will
be no future payment due, then Kazia shall promptly refund such amount to Simcere). Contested amounts are subject to dispute resolution by an Expert under Exhibit H. The full amount of any underpayment by Simcere determined to be payable to
Kazia pursuant to this Section 5.11(d) shall accrue interest in accordance with Section 5.9. 

(e)    Where the Auditor’s audit report shows that Simcere is in breach of its obligations under this
Agreement, the Parties will promptly meet to agree a remediation plan such that any breach by Simcere may be remedied. In such case, Kazia must provide to Simcere reasonable evidence of the relevant findings set out in the Auditor’s audit
report. 
 ARTICLE 6 

INTELLECTUAL PROPERTY RIGHTS 

6.1    Inventions. 

(a)    Each Party shall solely own all Inventions invented or developed solely by or on behalf of such Party,
including its and its Affiliate’s employees, contractors and/or agents. The Parties shall jointly own all Inventions invented or developed jointly by both Parties. Except to the extent restricted by the licenses and other rights granted to the
other Party under this Agreement or any other agreement between the Parties, with respect to jointly developed Inventions each Party, as joint owners, shall be entitled to practice, license, assign and otherwise exploit its interest in the jointly
owned Inventions without the duty of accounting or seeking consent from the other Party. 
 (b)    Each Party
shall promptly disclose to the other Party all Inventions invented or developed by or on behalf of such Party under this Agreement, including any invention disclosures, or other similar documents, submitted to it by its employees, agents or
independent contractors describing such Inventions, and shall promptly respond to reasonable request from the other Party for additional information relating to such Inventions. 

  
 24 

 (c)    Simcere hereby grants to Kazia a non-exclusive and royalty free license under any Inventions invented or developed solely by Simcere to (i) research, Develop, make, have made, use, sell, offer for sale, have sold, import and otherwise
Commercialize the Compound and Product in the Field outside the Territory, (ii) conduct non-clinical research, GBM AGILE and other Global Clinical Trials in each case for the Compound and the Product in
the Field in the Territory, and (iii) Manufacture the Compound and Product in the Territory for export out of the Territory, which license shall be sublicenseable by Kazia provided that the sublicensee grants to Kazia a sublicensable license
under any invention invented or developed by the sublicensee through the Development, Manufacture or Commercialization of the Product so that Kazia can include such invention in the Licensed IP and the license granted to Simcere hereunder. 

6.2    Patent Prosecution. 

(a)    As between the Parties, Kazia shall have the first right to file, prosecute and maintain all Licensed
Patents throughout the world, at Kazia’s own cost and expense. 
 (b)    Kazia shall consult with Simcere
and keep Simcere reasonably informed of the status of the Licensed Patents in the Territory and also in the US and EU, and shall promptly provide Simcere with all material correspondence received from any patent authority in the Territory in
connection therewith. In addition, Kazia shall promptly provide Simcere with drafts of all proposed material filings and correspondence to any patent authority in the Territory with respect to the Licensed Patents for Simcere’s review and
comment prior to the submission of such proposed filings and correspondences. Kazia shall consider in good faith Simcere’s comments prior to submitting such filing and correspondences. 

(c)    Kazia shall notify Simcere of any decision to cease prosecution or maintenance of any Licensed Patents in
the Territory. Kazia shall provide such notice at least thirty (30) days prior to any filing or payment due date, or any other due date that requires action, in connection with such Licensed Patent. In such event, upon Simcere’s request,
Kazia shall transfer the prosecution and maintenance of such Patents in the Territory to Simcere, and Simcere shall have the right to continue prosecution or maintenance of such Patents in the Territory at Simcere’s own expense. 

(d)    Each Party shall provide the other Party all reasonable assistance and cooperation in the patent prosecution
efforts under this Section 6.2, including providing any necessary powers of attorney and executing any other required documents or instruments for such prosecution. 

6.3    Patent Enforcement. 

(a)    [***]. 

(b)    [***] 

(c)    [***] 

(d)    [***] 

(e)    [***] 

  
 25 

 (f)    [***][***] 

(g)    [***] 
  

	 	6.4    [***]	 

(a)    [***] 

(b)    [***] 

  
 26 

	 	6.5    [***]	 

6.6    Bankruptcy Protection. All licenses granted by a Party to the other Party under this Agreement are
and shall otherwise be deemed to be, for purposes of Section 365(n) of Title 11, United States Code or foreign equivalent Laws (the “Bankruptcy Code”), licenses of rights to “intellectual property” as defined in
Section 101 of the Bankruptcy Code. To the extent permitted by Law, as the licensee, the non-bankruptcy Party shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code.
Upon the bankruptcy of a Party, the non-bankruptcy Party, as the licensee, shall, to the extent permitted by Law, further be entitled to a complete duplicate of, or complete access to, any such intellectual
property, and such, if not already in its possession, shall be promptly delivered to the non-bankruptcy Party, unless the bankruptcy Party elects to continue, and continues, to perform all of its obligations
under this Agreement. 

  
 27 

 6.7    Trademarks. 

(a)    Kazia hereby grants to Simcere a non-exclusive license (with the
right to sublicense) for the Term to the trademarks and trade names Controlled by Kazia and used by Kazia in connection with the Product (“Licensed Trademarks”) solely in order for Simcere to Commercialize the Product in the Field
in the Territory. During the Term, Kazia shall not grant any licence under the Licensed Trademarks to any Third Party in order for the Third Party to Commercialize the Product in the Territory. Kazia shall own all rights in the Licensed Trademarks,
and all goodwill in the Licensed Trademarks shall accrue to Kazia. Kazia shall register, maintain and enforce, at its own cost, expense and discretion, the Licensed Trademarks in the Territory as Kazia determines reasonably necessary. 

(b)    In addition to (or in lieu of ) the Licensed Trademarks, Simcere shall have the right to brand the Product
for use in connection with its Commercialization in the Territory using Simcere related trademarks and any other trademarks and trade names (including Chinese character trademarks and trade names) Simcere determines appropriate for the Products,
which may vary by region or within a region in the Territory (“Product Marks”). Simcere shall own all rights in the Product Marks, and all goodwill in the Product Marks shall accrue to Simcere. Simcere shall register, maintain and
enforce, at its own cost and expense, the Product Marks in the Territory as Simcere determines reasonably necessary. 

6.8    License Registration. If required or permitted by applicable Laws, Simcere may register the license
granted by Kazia to Simcere hereunder with Government Authorities in the Territory, including the China National Intellectual Property Administration, by submitting this Agreement (or a simplified and/or Chinese language version of this Agreement)
and other required documents to the applicable Government Authorities. Upon Simcere’s reasonable request, Kazia shall execute such documents and take such further action reasonably required by Simcere in connection with such registration. 

ARTICLE 7 

CONFIDENTIALITY 

7.1    Confidentiality Obligations. Except to the extent expressly authorized by this Agreement or otherwise
agreed in writing by the Parties, each Party agrees that, during the Term of this Agreement and ten (10) years thereafter, it shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as
provided for in this Agreement (which includes the exercise of any rights or the performance of any obligations hereunder) any Confidential Information of the other Party. 

7.2    Exceptions. The obligations set forth in Section 7.1 shall not apply to any information that the
receiving Party can demonstrate that such information: 

  
 28 

 (a)    is known by the receiving Party at the time of its receipt
without an obligation of confidentiality, and not through a prior disclosure by the disclosing Party, as documented by the receiving Party’s business records; 

(b)    is in the public domain before its receipt from the disclosing Party, or thereafter enters the public domain
other than through the receiving Party’s breach of the confidentiality obligations set forth herein; 

(c)    is subsequently disclosed to the receiving Party by a Third Party who may lawfully do so and is not under an
obligation of confidentiality to the disclosing Party; or 
 (d)    is developed by the receiving Party
independently and without use of, or reference to, any Confidential Information of the disclosing Party, as documented by the Receiving Party’s business records. 

Any combination of features or disclosures shall not be deemed to fall within the foregoing exclusions merely because individual features are published or
available to the general public or in the rightful possession of the receiving Party unless the combination itself and principle of operation are published or available to the general public or in the rightful possession of the receiving Party. 

7.3    Authorized Disclosures. Notwithstanding the obligations set forth in Sections 7.1 and 7.6, a Party may
disclose the other Party’s Confidential Information to any Affiliate, actual or bona fide potential sublicensee, subcontractor, agent, officer, investor, professional adviser, banker, auditor, clinician or other consultant (each a
“Recipient”) only if the disclosure is made strictly on a “need to know basis” and, prior to the disclosure, the Party (i) notifies the Recipient of the confidential nature of the Confidential Information to be
disclosed, and (ii) the Recipient enters into a written agreement of confidentiality with the Party, or the Recipient is bound by professional or ethics obligation regarding confidentiality, which in either case is at least as restrictive as
the obligations in this Article 7 (provided that the duration of such confidentiality obligation can be shorter (but no less than five (5) years) for a Recipient that is a banker, investor, or other financial partners). Without limiting the
foregoing, a Party may disclose Confidential Information to the extent: 
 (a)    such disclosure is necessary:
(i) for the filing, prosecution and enforcement of Patents as contemplated by this Agreement; (ii) in connection with regulatory filings for Product; (iii) for the prosecuting or defending litigation as contemplated by this Agreement;
or (iv) in connection with the exercise of a Party’s rights or the performance of its obligations hereunder; 

(b)    such disclosure is required by applicable Laws, judicial or administrative process, provided that in such
event, to the extent possible, such Party shall promptly inform the other Party of such required disclosure and provide the other Party an opportunity to challenge or limit the disclosure obligations. Confidential Information that is disclosed
pursuant to this Section 7.3(b) shall remain otherwise subject to the confidentiality and non-use provisions of this Article 7, and the Party disclosing Confidential Information pursuant to Law or court
order shall take all steps reasonably necessary, including seeking of confidential treatment or a protective order to ensure the continued confidential treatment of such Confidential Information. 

  
 29 

 7.4    Breach by Recipient. A Party which discloses the
other Party’s Confidential Information to a Recipient, is liable for breach of this Article 7 by a Recipient as if the Recipient was a Receiving Party in relation to the Confidential Information disclosed to the Recipient. 

7.5    Scientific Publication. 

(a)    Except to the extent required by applicable Laws, Simcere shall not publish any peer-reviewed manuscripts,
or give other forms of public disclosure such as abstracts and presentations, relating to the Compound or Product other than in the Territory and with Kazia’s approval. Simcere shall provide Kazia with a draft of any proposed publication
relating to the Compound or Product at least thirty (30) days prior to its intended submission for publication. Upon Kazia’s request, Simcere shall remove any and all of Kazia’s Confidential Information from the proposed publication,
and shall delay the submission for a period up to ninety (90) days to allow time for the preparation and filing of a patent application directed to any Inventions disclosed in such publication. Simcere shall also provide Kazia a copy of the
manuscript at the time of the submission. 
 (b)    Kazia shall keep Simcere informed on any scientific
publication relating to the Compound and Product and shall provide Simcere with a draft of any such proposed publication for review at least thirty (30) days prior to its intended submission for publication. Kazia shall consider Simcere’s
comments in good faith and shall not include any Confidential Information of Simcere in its publication, but Simcere shall not have the right to approve Kazia’s publication. 

7.6    Publicity. 

(a)    The Parties have agreed on language of press release for each Party announcing this Agreement, which is
attached hereto as Exhibit G, to be issued by the Parties promptly after the Effective Date. Subject to the rest of this Section 7.6 and Section 7.3, no disclosure of the terms of this Agreement may be made by either Party, and
neither Party shall use the name, trademark, trade name or logo of the other Party, its Affiliates or their respective employee(s) in any publicity, promotion, news release or disclosure relating to this Agreement or its subject matter, without the
prior express written permission of the other Party, except as may be required by Law. Following the initial joint press release announcing this Agreement, either Party shall be free to disclose or publicize, without the other Party’s prior
written consent, the existence of this Agreement, the identity of the other Party, and those terms of the Agreement which have already been publicly disclosed in accordance herewith. 

(b)    A Party may disclose this Agreement and its terms in securities filings with the Securities Exchange
Commission (or equivalent agency) or the stock exchange on which such Party’s or its Affiliate’s stock is publicly traded (the “Securities Regulators”) to the extent required by Law or the rules of the Securities Regulator
after complying with the procedure set forth in this Section 7.6. In such event, the Party seeking such disclosure will, where possible, prepare a draft confidential treatment request and proposed redacted version of this Agreement to request
confidential treatment for this Agreement, and the other Party agrees to promptly (and in any event, no less than seven (7) days after receipt of such confidential treatment request and proposed redactions) give its input in a reasonable manner
in order to allow the Party seeking disclosure to file its request within the time lines proscribed by applicable Laws. The Party seeking such disclosure shall exercise Commercially Reasonable Efforts to obtain confidential treatment of this
Agreement as represented by the redacted version reviewed by the other Party or to the extent otherwise reasonably possible. 

  
 30 

 (c)    Each Party acknowledges that the other Party may be
legally required to make public disclosures (including in filings with Securities Regulators) of certain material developments or material information generated under this Agreement and agrees that each Party may make such disclosures as required by
Law or the rules of the Securities Regulator, provided that the Party seeking such disclosure, where possible, first provides the other Party a copy of the proposed disclosure, and provided further that (except to the extent that the Party seeking
disclosure is required to disclose such information to comply with Law or the rules of the Securities Regulator and where possible) if the other Party demonstrates to the reasonable satisfaction of the Party seeking disclosure, within three
(3) business days of such Party’s providing the copy, that the public disclosure of previously undisclosed information may adversely affect the Development and/or Commercialization of the Product, the Party seeking disclosure will remove
from the disclosure such specific previously undisclosed information as the other Party shall reasonably request to be removed. 

7.7    Prior CDA. This Agreement supersedes the Confidentiality Agreement between the Parties dated 21 April 2020
(the “Prior CDA”) with respect to information disclosed thereunder. All information exchanged between the Parties under the Prior CDA shall be deemed Confidential Information of the disclosing Party and shall be subject to the terms
of this Article 7. 
 7.8    Equitable Relief. Each Party acknowledges that a breach of this Article 7
cannot reasonably or adequately be compensated in damages in an action at law and that such a breach shall cause the other Party irreparable injury and damage. By reason thereof, each Party agrees that the other Party shall be entitled, in addition
to any other remedies it may have under this Agreement or otherwise, to preliminary and permanent injunctive and other equitable relief to prevent or curtail any breach of the obligations relating to Confidential Information set forth herein. 

ARTICLE 8 
 TERM AND
TERMINATION 
 8.1    Term. 

(a)    Subject to clause 8.1(b), the term of this Agreement (“Term”) shall commence upon the
Effective Date and, unless terminated by either Party pursuant to Section 8.2, shall continue in full force and effect, on Product-by-Product and region-by-region basis, until the expiration of the Royalty Term for such Product in such region. After the expiration (but not early termination) of the Term for a particular
Product in a particular region, the licenses granted by Kazia to Simcere hereunder shall continue and shall become fully paid, royalty free, perpetual and irrevocable with respect to such Product in such region. 

  
 31 

 (b)    The formation of a binding contract by this Agreement,
other than this Section 8.1 and Article 1 (Definitions), Section 5.2 (Equity Investment), Article 7 (Confidentiality) and Article 11 (General Provisions) is subject to the fulfilment of the obligation in Section 5.2 to enter into the
Share Subscription Agreement. Where that obligation is not fulfilled within forty five (45) days of the Effective Date, Kazia will be entitled to terminate this Agreement (to the limited extent it applies) upon written notice to Simcere with
immediate effect. 
 8.2    Termination. 

(a)    Termination where Development or Commercialization deemed unviable. At any time during the Term, if
Simcere considers that the Development of the Compound or Product, or Commercialization of the Product, in the Field in the Territory is unviable, Simcere may request to terminate this Agreement (either in whole or on a Product-by-Product and region-by-region basis) by providing written notice to Kazia. The Parties must discuss any such notice in good
faith and following reasonable efforts to remediate, either Party may terminate this Agreement (either in whole or on a Product-by-Product and region-by-region basis as requested by Simcere in its notice) on the basis of such notice by providing written notice of termination to the other Party, which notice includes
an effective date of termination at least thirty (30) days after the date of the notice. 

(b)    Termination for Material Breach. If either Party believes that the other is in breach of its material
obligations hereunder, then the non-breaching Party may deliver notice of such breach to the other Party. The allegedly breaching Party shall have sixty (60) days from such notice to dispute or cure such
breach. If the Party receiving notice of breach fails to cure, or fails to dispute, that breach within the cure period set forth above, then the Party originally delivering the notice of breach may terminate this Agreement effective on written
notice of termination to the other Party. If the allegedly breaching Party disputes the existence, materiality or cure of the alleged breach, the other Party shall not have the right to terminate this Agreement until it has been determined pursuant
to Section 11.6 that the alleged breaching Party is in material breach of this Agreement, and such breaching Party further fails to cure such breach within thirty (30) days after the conclusion of that dispute resolution procedure. 

(c)    Termination by Kazia. Kazia may immediately terminate this Agreement by providing written notice of
termination to Simcere if Simcere (i) materially breaches any of its representations or warranties under Article 9, (ii) materially breaches any of its obligations under Article 5, or (iii) fails to use Commercially Reasonable Efforts to
satisfy each milestone event under Article 5 or to Develop and Commercialize the Licensed IP; and, in each case, fails to remedy the breach in (i), (ii) or (iii) within sixty (60) days of being given notice to do so by Kazia. 

  
 32 

 8.3    Effect of Termination. 

(a)    Termination of Simcere’s License. Upon the early termination of this Agreement for any reason,
all rights and licenses granted by Kazia to Simcere under this Agreement shall terminate. 
 (b)    Specific
Consequences. 
 (i)    Reversion License. Upon early termination of this Agreement for any reason, Simcere
shall grant to Kazia an exclusive license under the data, results and other Inventions generated by Simcere through the Development, Manufacture and Commercialization of the Compound and Product to research, Develop, make, have made, use, sell,
offer for sale, have sold, import and otherwise Commercialize the Compound and Product in the Field, which license shall not be subject to a royalty payment unless the Agreement is terminated by Simcere for Kazia’s uncured material breach, in
which case any such royalty payment to Simcere will be negotiated and agreed by the Parties and shall become effective only upon such termination and the Parties’ agreement on such royalty payment. Upon expiration of this Agreement, Simcere
shall grant to Kazia a non-exclusive license under the data, results and other Inventions generated by Simcere through the Development, Manufacture and Commercialization of the Compound and Product to
research, Develop, make, have made, use, sell, offer for sale, have sold, import and otherwise Commercialize the Compound and Product in the Field, which license shall not be subject to a royalty payment. 

(ii)    Payment. Upon expiration or early termination of this Agreement for any reason, Simcere must pay to
Kazia in accordance with the terms of this Agreement any unpaid invoices submitted before termination or any invoices submitted by Kazia after termination in relation to royalties or other payments accrued before termination and due in accordance
with Article 5. 
 (iii)    Cessation of activities. Upon early termination of this Agreement for any
reason, Simcere must cease conducting any activities with respect to Development or Manufacture of any Compound or Products and Commercialization of Products. Simcere must also discontinue making any representations regarding its status as a
licensee of Kazia for any Products. 
 (iv)    Reversion of prosecution and maintenance of Patents. Upon
expiration or early termination of this Agreement for any reason, Simcere must transfer the prosecution and maintenance of such Licensed Patents in the Territory to Kazia it, at any time during the Term, became responsible for in accordance with
Section 6.2(c). 
 (v)    Regulatory Materials. Upon early termination of this Agreement for any
reason, Simcere shall, to the extent permitted by applicable Laws, transfer and assign to Kazia all of Simcere’s and its Affiliates’ right, title and interest in and to any and all Regulatory Approvals and other Regulatory Materials for
the Product. 
 (vi)    Data. Upon expiration or early termination of this Agreement for any reason,
subject to applicable Laws, Simcere shall provide Kazia with copies of any data and results generated from clinical trials and other studies of the Product which were not previously provided to Kazia by Simcere. 

  
 33 

 (vii)    Product Inventory. Upon early termination of this
Agreement for any reason, Kazia shall have the right to purchase from Simcere all or part of the inventory of the Product held by Simcere as of the effective date of termination at a price equal to the cost paid by Simcere for such inventory (or
Simcere’s fully burdened manufacturing cost if such inventory is manufactured by Simcere itself). Kazia shall notify Simcere whether Kazia elects to exercise such right within thirty (30) days after the effective date of termination. If
Kazia does not exercise such right, then Simcere shall have the right to continue to sell any remaining inventory of the Product, for a period of no more than one (1) year after the date of termination, provided that Simcere continues to pay
Kazia royalties on the Net Sales of the Product sold after termination in accordance with Section 5.5. 

(viii)    Product Marks. Upon early termination of this Agreement for any reason, Simcere shall assign to
Kazia all Product Marks that relate exclusively to the Product (which, for clarity, exclude the corporate names and logos of Simcere, its Affiliates and sublicensees). Simcere must also provide to Kazia all records, information and documents related
to the registration and maintenance of any Product Marks which will be transferred to Kazia in accordance with this Section 8.3(b)(viii). 

(ix)    Transition Assistance. Upon early termination of this Agreement for any reason, at Kazia’s reasonable
request and expense, Simcere shall provide assistance to Kazia as may be reasonably necessary or useful for Kazia to commence or continue the Development, Manufacture or Commercialization of the Product in the Field in the Territory, for a period of
no more than six (6) months after the effective date of such termination, and to the extent Simcere is then performing or having performed such activities, including transferring or amending as appropriate, upon Kazia’s request, any
contracts with Third Parties for services related to the Development, Manufacture or Commercialization of the Product in the Field in the Territory. If any such contract is not assignable to Kazia, then Simcere shall reasonably cooperate with Kazia
in its efforts to obtain such services from such Third Party. 
 (c)    Return of Confidential Information.
Upon early termination of this Agreement for any reason, each Party must (i) immediately cease using all Confidential Information of or relating to the other Party (or the other Party’s Affiliate), (ii) deliver to the other Party all
documents and other materials in its possession or control containing, recording or constituting that Confidential Information or destroy, and certify to the other Party that it has destroyed, those documents and materials, and (iii) for
Confidential Information stored electronically, permanently delete that Confidential Information from all electronic media on which it is stored, so that it cannot be restored. Notwithstanding the foregoing, a Party shall be permitted to retain a
copy (or copies, as necessary) of Confidential Information of or relating to the other Party which it has the right to retain under this Agreement, or otherwise for archival purposes or as required by any applicable Law, and neither Party shall be
required to delete or destroy any electronic back-up tapes or other electronic back-up files that have been created by automatic or routine archiving and back-up procedures, to the extent created and retained in a manner consistent with standard archiving and back-up procedures. For the avoidance of doubt, the confidentiality
obligations under Article 7 will continue to apply to any retained Confidential Information. 

  
 34 

 (d)    Clinical Trial Transition Assistance. The Parties
agree to provide reasonable run off and transitional assistance if a clinical trial is ongoing as at the date of expiration or termination of this Agreement, to ensure trial participants affected by termination receive adequate medical care,
provided that if Kazia wishes to continue such clinical trial, then Kazia shall be bear the cost of such transition. 

8.4    Survival. Expiration or termination of this Agreement shall not relieve the Parties of any obligation
accruing prior to such expiration or termination. Without limiting the foregoing, the following provisions shall survive the expiration or termination of this Agreement: Sections 5.11, 6.1, 6.7(a), Article 7, Sections 8.3, 8.4, and 8.5, Article 10
and Article 11. 
 8.5    Termination Not Sole Remedy. Termination is not the sole remedy under this
Agreement and, whether or not termination is effected and notwithstanding anything contained in this Agreement to the contrary, all other remedies shall remain available except as agreed to otherwise herein. 

ARTICLE 9 

REPRESENTATIONS AND WARRANTIES 

9.1    Mutual Representations and Warranties. Each Party hereby represents, warrants, and covenants (as applicable)
to the other Party as follows: 
 (a)    it is a company or corporation duly organized, validly existing, and in
good standing under the laws of the jurisdiction in which it is incorporated, and has full corporate power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being conducted and as
contemplated in this Agreement, including, without limitation, the right to grant the licenses granted by it hereunder; 

(b)    as of the Effective Date, (i) it has the corporate power and authority and the legal right to enter
into this Agreement and perform its obligations hereunder; (ii) it has taken all necessary corporate action on its part required to authorize the execution and delivery of the Agreement and the performance of its obligations hereunder; and
(iii) the Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, and binding obligation of such Party that is enforceable against it in accordance with its terms; 

(c)    it is not a party to any agreement that would materially prevent it from granting the rights granted to the
other Party under this Agreement or performing its obligations under the Agreement; and 
 (d)    it shall comply
in all material aspects with all applicable Laws in the course of performing its obligations and exercising its rights under this Agreement. 

9.2    Additional Representations and Warranties of Kazia. Kazia represents, warrants, and covenants (as
applicable) to Simcere that, as of the Effective Date: 

  
 35 

 (a)    Kazia is the sole owner of the Licensed IP (other than
Licensed IP that is in-licensed by Kazia from Genentech under the Genentech Agreement), free and clear of all liens, and Kazia has the right to grant to Simcere the rights and licenses under the Licensed IP as
purported to be granted hereunder; 
 (b)    Kazia has obtained all necessary government approvals required for
the grant of the license and the transfer of the Licensed IP to Simcere, including such approvals required by applicable technology export control laws, and Kazia will do and execute or procure to be done and executed all such further acts, things,
agreements and other documents as may be necessary to give effect to the terms of this Agreement, including to comply with the applicable technology import and export laws and regulations; 

(c)    Kazia and its Affiliates have not granted, and will not grant during the Term, any rights in the Licensed IP
that are inconsistent with the rights granted to Simcere under this Agreement; 
 (d)    to the best of their
knowledge, Kazia and its Affiliates have not infringed or misappropriated any intellectual property of any Third Party during its development and manufacture of the Compound and Product, and have not received any notice from any Third Party
asserting or alleging any such infringement; 
 (e)    to the best of Kazia’s knowledge, after undertaking
the inquiries set out in Exhibit I, the Development, Manufacture and Commercialization (as contemplated by the Parties as of the Effective Date) of the Compound and Product (as such Compound and Product exist as of the Effective Date) can be
carried out under this Agreement without infringing or misappropriating any intellectual property rights of any Third Party; there is no pending or, to the knowledge of Kazia and its Affiliates, alleged or threatened, adverse actions, suits,
proceedings, or claims against Kazia or its Affiliates involving the Licensed IP, Compound or Product; 

(f)    to the best of their knowledge, Kazia and its Affiliates are not aware of any infringement or
misappropriation of any Licensed IP by any Third Party; 
 (g)    Exhibit B includes all Patents
Controlled by Kazia and its Affiliates as of the Effective Date that claim or cover the Compound and Product, all of which have been diligently prosecuted and maintained in accordance with applicable Laws; 

(h)    there is no pending or, to the knowledge of Kazia and its Affiliates, alleged or threatened, re-examination, opposition, interference or litigation, or any written communication alleging that any Licensed Patent is invalid or unenforceable anywhere in the world; 

(i)    Kazia (including its Affiliates and, to the best of its knowledge, its contractors) has complied with all
applicable Laws in connection with the development of the Compound and Product, and has not used any employee, consultant or contractor who has been debarred by any Regulatory Authority, or to its knowledge, is the subject of a debarment proceeding
by any Regulatory Authority; 

  
 36 

 (j)    except for the Genentech Agreement, there is no agreement
between Kazia or its Affiliates and any Third Party pursuant to which Kazia or its Affiliates obtained any right or license to the Compound or Product or any intellectual property rights related to the Compound or Product; 

(k)    Kazia has provided Simcere with a true and complete copy of the Genentech Agreement, and the Genentech
Agreement is in full force and effect; Kazia has the right to grant to Simcere the sublicense under the Genentech Agreement as purported to be granted hereunder; no written notice of default or termination has been received or given under the
Genentech Agreement; and there is no act or omission by Kazia that would provide a right to terminate the Genentech Agreement; 

(l)    during the Term of this Agreement, Kazia shall, at its own cost and expense, use best efforts to maintain
the Genentech Agreement in full force and effect and shall not terminate, amend, waive or otherwise modify (or consent to any of the foregoing) its rights under the Genentech Agreement in any manner that materially diminishes the rights or licenses
granted to Simcere hereunder, without first notifying Simcere and shall obtain Simcere’s consent (not to be unreasonably withheld). If despite of Kazia’s best efforts, the Genentech Agreement is terminated, Kazia shall use best efforts to
assist Simcere to obtain a direct license from Genentech. Where Simcere obtains a direct license from Genentech, the payment provisions of this Agreement will apply as though such license continued to be granted by Kazia, save that Simcere may
deduct from any payment due to Kazia under this Agreement any payment Simcere is obliged to make to Genentech under its license agreement with Genentech. In such circumstances, Kazia shall have the right (limited to Section 5.11) to audit and
confirm any payments due to Genentech under Simcere’s license agreement with Genentech; 
 (m)    in the
event of any notice of breach of the Genentech Agreement by Kazia in a manner that will or is likely to affect Simcere’s rights or obligations under this Agreement, Kazia shall immediately notify Simcere in writing, and if Kazia fails to cure
such breach in a timely manner, Simcere shall have the right, but not the obligation, to cure such breach and to seek reimbursement of or offset any reasonable amount incurred or paid by Simcere in connection with the cure against amount payable to
Kazia hereunder; 
 (n)    in the event of any notice of breach of the Genentech Agreement by Genentech in a
manner that will or is likely to materially affect Simcere’s rights or obligations under this Agreement, Kazia shall immediately notify Simcere in writing and, where it is reasonable for Kazia to do so, take reasonable actions requested by
Simcere to enforce the Genentech Agreement; and 
 (o)    to the best of Kazia’s knowledge, all information
provided by Kazia to Simcere for due diligence purposes in relation to this Agreement is complete and accurate in all material respects. Without limiting the foregoing, to the best of its knowledge, Kazia has disclosed to Simcere and made available
to Simcere for review all material non-clinical and clinical data for the Compound and Product, and all other material information (including relevant correspondence with Regulatory Authorities) relating to
the Compound and Product, in each case that would be material for Simcere to assess the safety and efficacy of the Compound and Product. 

  
 37 

 9.3    Additional Representations and Warranties of Simcere.
Simcere represents, warrants, and covenants (as applicable) to Kazia that, as of the Effective Date and on each day during the Term, in conducting activities contemplated under this Agreement, Simcere will: 

(a)    hold the necessary Regulatory Approvals to perform its obligations under this Agreement; 

(b)    comply with all applicable Laws, including those related to Manufacture, use, labelling, importation and
marketing of Products;. 
 9.4    Disclaimer. TO THE EXTENT PERMITTED BY LAW, EXCEPT AS EXPRESSLY STATED HEREIN,
NO OTHER REPRESENTATIONS OR WARRANTIES WHATSOEVER, INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, IS MADE OR GIVEN BY OR ON BEHALF OF A PARTY. ALL SUCH OTHER REPRESENTATIONS AND WARRANTIES, WHETHER
ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED. Both Parties understand that the Compound and Product are the subject of ongoing research and development and neither Party can assure that any Compound or Product can be
successfully Developed and Commercialized. 
 ARTICLE 10 

INDEMNIFICATION; LIABILITY 

10.1    [***] 

(a)    [***] 

(b)    [***] 

[***] 

(c)    [***] 

(d)    [***] 

10.2    [***] 

(a)    [***] 

(b)    [***] 

  
 38 

 (c)    [***] 

(d)    [***] 

10.3    [***] 

10.4    [***] 

10.5    Limitation of Liability. SUBJECT TO SECTION 10.6, NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY
SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. 

10.6    Personal Injury. Nothing in this Agreement operates to exclude or restrict a Party’s liability
for personal injury. 

  
 39 

 10.7    Insurance. Each Party shall procure and maintain
insurance, including product liability insurance, with respect to its activities hereunder and which is consistent with normal business practices of prudent companies similarly situated at all times during which any Product is being clinically
tested in human subjects or commercially distributed or sold by such Party. Each Party shall provide the other Party with evidence of such insurance upon request and shall provide the other Party with written notice at least sixty (60) days
prior to the cancellation, non-renewal or material changes in such insurance. Such insurance shall not be construed to create a limit of either Party’s liability under this Agreement. 

ARTICLE 11 
 GENERAL
PROVISIONS 
 11.1    Force Majeure. Neither Party shall be held liable to the other Party nor be
deemed to have defaulted under or breached this Agreement for failure or delay in performing any obligation under this Agreement to the extent such failure or delay is caused by or results from causes beyond the reasonable control of the affected
Party, potentially including embargoes, war, acts of war (whether war be declared or not), acts of terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, earthquakes, pandemic, or other acts
of God, or acts, omissions or delays in acting by any Government Authority (each a “Force Majeure Event”). The affected Party shall notify the other Party in writing of a Force Majeure Event, including the circumstances of that
Force Majeure Event, as soon as reasonably practical, and shall promptly undertake and continue diligently all reasonable efforts necessary to cure the Force Majeure Event or to perform its obligations in spite of the ongoing circumstances. If a
Force Majeure Event continues for more than eighteen (18) months and while it continues, the Party other than the affected Party may, at its sole discretion, terminate this Agreement by giving written notice to the affected Party. 

11.2    Assignment. This Agreement may not be assigned or otherwise transferred, nor may any right or
obligation hereunder be assigned or transferred, by either Party without the prior written consent of the other Party. Notwithstanding the foregoing, either Party may, without consent of the other Party, assign this Agreement and its rights and
obligations hereunder in whole or in part to an Affiliate of such Party, or in whole to its successor in interest in connection with the sale of all or substantially all of its business or assets to which this Agreement relates. Any attempted
assignment not in accordance with the foregoing shall be null and void and of no legal effect. Any permitted assignee shall assume all assigned obligations of its assignor under this Agreement. The terms and conditions of this Agreement shall be
binding upon, and shall inure to the benefit of, the Parties and their respected successors and permitted assigns. 

11.3    Severability. If any one or more of the provisions contained in this Agreement is held invalid,
illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely
affects the substantive rights of the Parties. The Parties shall in such an instance use their best efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical,
implement the purposes of this Agreement. 

  
 40 

 11.4    Notices. All notices which are required or
permitted hereunder shall be in writing and sufficient if delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally-recognized overnight courier, sent
by registered or certified mail, postage prepaid, return receipt requested or sent by email, addressed as follows: 
  

							
		 	If to Kazia:	 		  	
			
		 		 	Kazia Therapeutics, Ltd.
		 		 	L24, 300 Barangaroo Avenue
		 		 	Sydney, NSW 2000
		 		 	Australia	  	
		 		 	Attn:           Chief Executive Officer
		 		 	Email:         [***]
				
		 	with a copy to:	 		  	
			
		 		 	K&L Gates
		 		 	L25, 525 Collins Street
		 		 	Melbourne, VIC 3000
		 		 	Australia	  	
		 		 	Attn:         [***]
		 		 	Fax:          +61 3 9205 2055
		 		 	Email:       [***]
				
		 	If to Simcere:	 		  	
			
		 		 	Jiangsu Simcere Pharmaceutical Co, Ltd.
		 		 	No. 699-18 Xuanwu Avenue, Xuanwu District
		 		 	Nanjing City, Jiangsu Province
		 		 	China 210042
		 		 	Attn:         Corporate Counsel
		 		 	Fax:          +86 25 8526 2330
				
		 	with a copy to:	 		  	
			
		 		 	Simcere of America, Inc
		 		 	20 Acorn Park Drive, Suite 200,
		 		 	Cambridge, MA 02140
		 		 	Attn: [***], SVP, BD
		 		 	Telephone: (857)242-4364 x1005
		 		 	E-mail: [***]

  
 41 

							
		 	 and a copy to:
	 		  	
			
		 		 	 Cooley LLP

		 		 	 IFC - Tower 2, Level 35, Unit 3510

		 		 	 8 Century Avenue

		 		 	 Pudong New Area

		 		 	 Shanghai, China 200120

		 		 	 Attn:         [***]

		 		 	 Fax:          +86 21 6030
0700

 or to such other address(es) as the Party to whom notice is to be given may have furnished to the other Party
in writing in accordance herewith. Any such notice shall be deemed to have been given: (a) when delivered if personally delivered or sent by facsimile on a business day (or if delivered or sent on a
non-business day, then on the next business day); (b) on the third (3rd) business day after dispatch if sent by nationally-recognized overnight courier;
(c) on the seventh (7th) business day following the date of mailing, if sent by mail; or (d) if sent by email, two (2) hours after the time the email is sent to the recipient’s
email address, as recorded on the sender’s email system, unless the sender receives within that time period, an automatic notification (other than an out of office message) indicating that the email has not been delivered. 

11.5    Governing Law. This Agreement shall be governed by and construed in accordance with the laws of
Singapore, without reference to any rules of conflict of laws that may require the application of the laws of a different jurisdiction. 

11.6    Dispute Resolution 

(a)    The Parties shall negotiate in good faith and use good faith efforts to settle any dispute, controversy or
claim arising from or related to this Agreement or the breach thereof. Any such dispute, controversy or claim shall be referred to the Executive Officers of the Parties for attempted resolution. In the event the Executive Officers are unable to
resolve such dispute, controversy or claim within thirty (30) days after such matter is referred to them, then, upon the written request of either Party, such dispute, controversy or claim shall be (i) if arising from or related to
Section 5.11(d), referred to an Expert and determined in accordance with Exhibit H, or (ii) if arising from or related to any section of this Agreement other than Section 5.11(d) finally resolved by binding arbitration administered
by Singapore International Arbitration Centre (“SIAC”) pursuant to its arbitration rules. Judgment on the arbitration award may be entered in any court having jurisdiction thereof. 

(b)    If a dispute it to be resolved by arbitration under Section 11.6(a)(ii), the arbitration shall be
conducted by a single arbitrator mutually agreed by the Parties within thirty (30) days after initiation of arbitration. If the Parties are unable or fail to agree upon the arbitrator, the arbitrator shall be appointed by SIAC. The arbitration shall
be held in Singapore, all arbitration proceedings and communications shall be in English and the following terms shall apply: 

(i)    Either Party may apply to the arbitrator for interim injunctive relief until the arbitration award is
rendered or the controversy is otherwise resolved. Either Party also may, without waiving any remedy under this Agreement, seek from any court having jurisdiction any injunctive or provisional relief necessary to protect the rights or property of
that Party pending the arbitration award. The arbitrator shall have no authority to award punitive or any other type of damages not measured by a Party’s compensatory damages. 

  
 42 

 (ii)    The “prevailing” Party, as determined by the
arbitrator, shall be entitled to (A) its share of fees and expenses of the arbitrators, and (B) its reasonable attorneys’ fees and associated costs and expenses. If the arbitrator determines that, given the scope of the arbitration,
neither Party “prevailed”, the arbitrator shall order that the Parties (A) share equally the fees and expenses of the arbitrator’s fees and any administrative fees of arbitration, and (B) bear their own attorney’s fees
and associated costs and expenses. 
 (iii)    Except to the extent necessary to confirm an award or as may be
required by Law, neither a Party nor an arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of both Parties. In no event shall an arbitration be initiated after the date when commencement of
a legal or equitable proceeding based on the dispute, controversy or claim would be barred by the applicable statute of limitations. 

(c)    Notwithstanding the foregoing, in the event of a dispute with respect to the validity, scope, enforceability
or ownership of any Patent or other intellectual property rights, and such dispute is not resolved by the Executive Officers as set forth in Section 11.6(a), such dispute shall not be submitted to an arbitration proceeding and instead, unless
otherwise agreed by the Parties in writing, either Party may initiate litigation in a court of competent jurisdiction in any country in which such rights apply. 

11.7    Entire Agreement; Amendments. This Agreement, together with the Exhibits hereto, contains the entire
understanding of the Parties with respect to the subject matter hereof. Any other express or implied agreements and understandings, negotiations, writings and commitments, either oral or written, with respect to the subject matter hereof are
superseded by the terms of this Agreement. The Exhibits to this Agreement are incorporated herein by reference and shall be deemed a part of this Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument
duly executed by authorized representative(s) of both Parties hereto. 
 11.8    Headings; Language. The
captions to the several Articles, Sections and subsections hereof are not a part of this Agreement, but are merely for convenience to assist in locating and reading the several Articles and Sections hereof. This Agreement was prepared in the English
language, which language shall govern the interpretation of, and any dispute regarding, the terms of this Agreement. 

11.9    Independent Contractors. It is expressly agreed that Kazia and Simcere shall be independent
contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither Kazia nor Simcere shall have the authority to make any statements, representations or commitments of any kind, or to
take any action, which shall be binding on the other Party, without the prior written consent of the other Party. 

11.10    Waiver. The waiver by either Party hereto of any right hereunder, or of any failure of the other
Party to perform, or of any breach by the other Party, shall not be deemed a waiver of any other right hereunder or of any other breach by or failure of such other Party whether of a similar nature or otherwise. 

  
 43 

 11.11    Cumulative Remedies. No remedy referred to in
this Agreement is intended to be exclusive, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under Law. 

11.12    Waiver of Rule of Construction. Each Party has had the opportunity to consult with counsel in
connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply. 

11.13    Business Day Requirements. In the event that any notice or other action or omission is required to
be taken by a Party under this Agreement on a day that is not a business day then such notice or other action or omission shall be deemed to be required to be taken on the next occurring business day. 

11.14    Counterparts. This Agreement may be executed in two or more counterparts by original signature,
facsimile or PDF files, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

(REMAINDER OF PAGE INTENTIONALLY LEFT BLANK) 

  
 44 

 IN WITNESS WHEREOF, the Parties intending to be bound have caused this License Agreement to
be executed by their duly authorized representatives as of the Effective Date. 
 Executed by Simcere Pharmaceutical Co., Ltd.: 

 

	
	  

	Signature of Chief Executive Officer
	
	 /s/ Jinsheng Ren

	Jinsheng Ren
	Name (please print)

 Executed by Kazia Therapeutics, Ltd. AC 063 259 754 in accordance with section 127(1) of the Corporations Act 2001
(Cth): 
  

					
	Signature of director	 		 	Signature of director or company secretary*
			
		 		 	*delete whichever does not apply
			
	Name (please print)	 		 	Name (please print)

 IN WITNESS WHEREOF, the Parties intending to be bound have caused this License Agreement to
be executed by their duly authorized representatives as of the Effective Date. 
 Executed by Simcere Pharmaceutical Co., Ltd.: 

 

	
	  

	Signature of Chief Executive Officer
	
	 Jinsheng Ren

	Name (please print)

 Executed by Kazia Therapeutics, Ltd. ACN 063 259 754 in accordance with section 127(1) of the Corporations
Act 2001 (Cth): 
  

					
		 		 	Signature of director or company secretary*
			
		 		 	*delete whichever does not apply
			
	/s/ James Garner	 		 	/s/ Kate Hill
	James Garner	 		 	Kate Hill
	 Chief Executive Officer
	 		 	 Company Secretary

	Name (please print)	 		 	Name (please print)

 [***] 

 [***] 

Exhibit C:Technology Transfer Plan 
  

	1.	 Project Scope: 

Upon execution of the Agreement the Parties will effect transfer of the Key Items listed below from Kazia to Simcere. Technology transfer for manufacturing
will be elected by Simcere and a detailed plan will be discussed and agreed between the Parties. 
 [***] 

[***] 
  

	4.	 Governance and Support 

JSC will oversee the Technology Transfer. 
 For data and
information that is necessary for regulatory filing and Development of the Compound or Product in the Territory but not under Kazia’s control, Kazia will reasonably assist Simcere to seek to acquire such data and information, at Simcere’s
sole expense. 

 Exhibit D:Endpoints of GBM AGILE 

The primary endpoint of GBM AGILE will be Overall Survival (OS), defined as the time from randomization to death from any cause. Patients still alive at the
time of an analysis will be considered censored at their date of last contact. 
 Paxalisib will be deemed to have met its primary endpoint if the final
probability of HR [Hazard Ratio] < 1.0 is at least 0.98, based on Kaplan-Meier analysis of the Intent-to-Treat dataset. 

The Parties acknowledge that, as of the Effective Date, Kazia and GCAR are in discussion with NMPA regarding the design and conduct of GBM AGILE in China. In
the event that NMPA recommends additional requirements or criteria for GBM AGILE, then “successful completion of GBM AGILE” shall also require that such additional requirements or criteria are met by GBM AGILE. 

 Exhibit E: Pharmacovigilance Terms 

1.    Definitions 
 In this Exhibit
E: 
 “Adverse Event” means an untoward medical occurrence in a patient or clinical investigation subject administered a Product and
which does not necessarily have to have a causal relationship with this treatment. An Adverse Event can therefore by any unfavourable and/or unintended sign (including an abnormal laboratory find, for example), symptom, or disease temporarily
associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse Events may also include pre- or post-treatment complications that occur as a result of protocol mandated procedures, lack of
efficacy, overdose or drug abuse/misuse reports. Pre- existing events that increase in severity or change in nature during or as a consequence of participation in a clinical study with all be considered Adverse Events; 

“FDA” means the U.S. Food and Drug Administration; 

“Investigator Brochure” means a comprehensive document summarizing the body of information about an investigational product (“IP”
or “study drug”) obtained during preclinical and clinical development, compiled in accordance with the principles described by the International Committee for Harmonisation; and 

“SUSAR” means a serious, unexpected or suspected Adverse Reaction. 

2.    Reporting to Regulatory Authorities 

Simcere shall be responsible for all necessary safety data reporting to Regulatory Authorities within the Territory, in accordance with applicable Laws. Kazia
shall be responsible for all necessary safety data reporting to Regulatory Authorities outside the Territory, in accordance with applicable Laws. 
 At
Kazia’s reasonable request, Simcere shall promptly provide a copy of any safety data reported to Regulatory Authorities within the Territory. 

Simcere shall promptly notify Kazia of any questions, directives, or other communications received from a Regulatory Authority in the Territory in relation to
the safety of the Licensed Product. 
 3.    Adverse Events During Development 

3.1    Adverse Event Collection. All Adverse Events occurring during a clinical trial of the Licensed
Product sponsored by Simcere shall be collected in a customary manner, including without limitation: 
 (a)    verbatim
description; 

 (b)    onset and duration; 

(c)    treatment; 

(d)    severity, according to NCI Common Terminology Criteria for Adverse Events; 

(e)    relatedness, per investigator assessment; and 

(f)    outcome, and action taken in response to study drug 

Simcere must report this data to Kazia in aggregate, de-identified form at the conclusion of the clinical trial, or at
any interim analysis of safety data. 
 3.2    SUSARs. Any SUSAR to the Licensed Product must be
reported to Kazia within 72 hours of Simcere becoming aware, even if full information is not available, so that Kazia may satisfy its regulatory obligations to FDA and other Regulatory Authorities. Simcere will reasonably cooperate with Kazia to
investigate any SUSARs, and to resolve any queries from Regulatory Authorities. 
 3.3    Pregnancies.
Simcere shall notify Kazia within 24 hours of becoming aware of any patients who become pregnant while being treated with the Licensed Product, or within 28 days of the last dose of the Licensed Product. Simcere will reasonably cooperate
with Kazia to monitor the course and outcome of such pregnancies, and to resolve any queries from Regulatory Authorities. 

3.4    Clinical Hold. In the event of a Regulatory Authority instituting a ‘clinical hold’
in respect of the Licensed Product, whereby a sponsor is directed to suspend administration of investigational product to trial patients, the Parties will promptly and reasonably collaborate to determine the appropriate course of action in the
Territory. 
 4.    Adverse Events following obtainment of MA 

For all post-market monitoring of the Licensed Product in the Territory, Simcere and Kazia shall reach an agreement before filing of a new drug application in
the Territory. 
 5.    Simcere’s responsibilities to Kazia 

(a)    Simcere shall provide to Kazia, in the form of line listings, such safety information as Kazia may reasonably
request for preparation of Development Safety Update Reports or similar reports to Regulatory Authorities. Kazia shall provide Simcere with at least thirty (30) calendar days’ notice prior to the data lock point, and Simcere shall provide
the requested information no later than fifteen (15) calendar days after the data lock point. Kazia may request such tabulations at no more than a quarterly frequency. 

 (b)    Simcere shall perform customary surveillance for emerging
safety signals. Any material new safety signals shall be promptly shared with Kazia and the Parties shall cooperate to assess their impact and appropriate responses both in and outside the Territory. 

6.    Kazia’s responsibilities to Simcere 

(a)    Kazia shall maintain an
up-to-date Investigator Brochure for the Licensed Product, containing customary summaries of safety information and an updated risk-benefit analysis, and shall provide
that Investigator Brochure to Simcere no less than once per annum for their translation and appropriate distribution. 

(b)    Kazia shall provide to Simcere a copy of the Development Safety Update Report (DSUR) that is prepared on an
annual basis for submission to the FDA for Simcere’s information and reference. 
 (c)    Kazia shall
establish and maintain a global safety database for the Licensed Product and shall perform customary surveillance for emerging safety signals. Any material new safety signals shall be promptly shared with Simcere and the Parties shall cooperate to
assess their impact and appropriate responses in the Territory. 
 (d)    Kazia shall promptly notify Simcere of
any SUSARs occurring in clinical trials of the Licensed Product outside of the Territory, and shall reasonably assist Simcere in reporting such events to IRBs, Regulatory Authorities, investigators, and other relevant parties. 

7.    General obligations 

(a)    Each Party shall have in place customary and appropriate policies, standard operating procedures, processes,
and personnel to ensure that it is able to satisfy its obligations under this Exhibit E and under applicable Laws. 

(b)    All safety information exchanged under this Exhibit E shall be considered Confidential Information of
the Disclosing Party. 
 (c)    English will be used as the common language for all safety information exchanged
between the Parties. 

 Exhibit F: Supply Terms 

1.     Definitions 
 In this
Exhibit F: 
 “Accepted Purchase Order” has the meaning given to it in item 3.2(a) of this Exhibit F; 

“Defective Product” has the meaning given to it in item 5.3(b) of this Exhibit F; 

“Defective Products Notice” has the meaning given to it in item 5.3(b) of this Exhibit F; 

“Delivery Point” means a port in the Territory designated by Simcere; 

“Forecast” has the meaning given to it in item 4 of this Exhibit F; 

“GMP” means then-current applicable standards for the manufacture of pharmaceutical products, including, as applicable, the standards
detailed in the U.S. Current Good Manufacturing Practices, 21 C.F.R. Parts 4, 210, 211, 601, 610 and 820, European Directive 2003/94/EC and Eudralex 4, ICH Q7 ICH guidance Q7 Good Manufacturing Practices, the PIC/S Guide to Good Manufacturing
Practice for Medicinal Products, PE009-8, published by the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme dated 15 January
2009 (as adopted by Therapeutics Goods (Manufacturing Principles) Determination No. 1 of 2013), and corresponding regulations in the Territory; 

“Minimum Lead Time” means the minimum period between the date of submitting a Purchase Order to Kazia and the delivery date for the Compound
or Product, as the case may be, being three (3) months; provided that the initial supply of the Compound and Product shall be provided as soon as possible to enable Simcere to start Development work. 

“Price” means a price set out in Section 4.9(a) of the Agreement; and 

“Purchase Order” has the meaning given to it in item 3.1 of this Exhibit F. 

2.     Obligation to Supply 

Regardless of any other provision of this Agreement, Kazia is not required to supply any Compound or Product to Simcere at any time when: 

(a)    Kazia is not able to obtain or have manufactured Compound or Product; provided that if the Compound or
Product is in short supply, Kazia shall allocate the available Compound and Product equitably between Kazia, Simcere and other third parties to whom Kazia’s has supply obligations, on a pro-rata basis
based on forecasted requirements; 

 (b)    Simcere has not paid for Compound or Product previously
supplied by Kazia for which payment is then due, unless the amount unpaid is the subject of a dispute in good faith and only that portion in dispute is unpaid; or 

(c)    there has been any other material breach of this Agreement by Simcere that has not been duly remedied. 

 

	3.	 Orders 

3.1    Purchase Orders. Simcere must order Compound and Products by completing a purchase order in the form
approved (which approval not to be unreasonably withheld) by Kazia (“Purchase Order”) and submitting it to Kazia by email. All Purchase Orders submitted by Simcere to Kazia must (a) specify the quantity of Compound and/ or
Product required by Simcere, and (b) specify a delivery date that is no earlier than the Minimum Lead Time after the date of the Purchase Order. All Purchase Orders shall be governed exclusively by the terms of this Agreement, and any term or
condition in any purchase order, confirmation, invoice or other document furnished by Simcere or Kazia that is in any way inconsistent with the terms and conditions set forth in this Agreement is hereby expressly rejected. 

3.2    Acceptance of Purchase Orders. 

(a)    Unless Simcere is in breach of any term of this Agreement (including that the Purchase Order fails to take
into account at least the Minimum Lead Time) and subject to item 2(a) of this Exhibit F in case of short supply and item 3.2(b) of this Exhibit F for Purchase Order that differs materially from Forecast, Kazia will use best endeavours
to accept Purchase Orders which are within the Forecasts. On acceptance by Kazia, the Purchase Order becomes an Accepted Purchase Order. 

(b)    Kazia may reject a Purchase Order in whole or in part if the amount of Compound or Product ordered is
materially different (i.e. greater than twenty percent (20%) difference) to the quantity of the Compound or Product set out for that particular quarter in the applicable Forecast. 

3.3    Unfilled Purchase Order.    If Kazia is, or expects to be, unable to
satisfy a Purchase Order placed by Simcere under item 3.1 of this Exhibit F, whether before or after Kazia has accepted that Purchase Order under item 3.2 of this Exhibit F (a) Kazia must immediately notify Simcere of that fact,
and (b) Simcere may cancel all or part of the relevant Purchase Order. 
 3.4    Cancellation or
suspension of Accepted Purchase Orders. Subject to item 3.3 of this Exhibit F, an Accepted Purchase Order cannot be cancelled or suspended by either Party without the other Party’s prior written agreement and, in the case of
cancelation or deferral by Simcere, then only on terms that Simcere will fully reimburse Kazia for any out-of-pocket cost (including manufacturing cost) incurred by
Kazia as a result of that cancellation or deferral. 

	4.	 Forecasts 

Simcere must provide to Kazia each calendar quarter during the Term unless and until Simcere itself commences Manufacturing or having Manufactured Compound or
Product (as the case may be) in accordance with Section 4.9(b) of the Agreement, a rolling yearly forecast (broken down to quarter level) of Simcere’s anticipated volume requirements for the Compound and Product
(“Forecast”). The Forecast represents Simcere’s estimate of requirements and is not binding. 
  

	5.	 Delivery of Finished Products 

5.1    Delivery. Kazia will use reasonable endeavours to deliver the Compound and Products the subject of an
Accepted Purchase Order to the Delivery Point at the date specified therein. Kazia will not be liable for any loss of any kind whatsoever caused directly or indirectly by any failure to deliver or any delay in delivery that is outside Kazia’s
control. 
 5.2    Title and risk. Title to the Compound and Product will pass to Simcere from Kazia on
payment in full by Simcere to Kazia in relation to the Compound or Product, as the case may be. Risk in the Compound and Product will pass to Simcere from Kazia on delivery of the Compound or Product, as the case may be, to the Delivery Point. 

 

	5.3	 Defective Products 

(a)    Simcere will use reasonable efforts to conduct a visual inspection of the Compound and Product on delivery.

 (b)    If Simcere believes that any Compound or Products were, at the time of delivery, damaged or defective
(“Defective Products”), within thirty (30) business days of delivery of the Compound or Products (or ten (10) business days after the discovery of the defect for non-obvious defects
not reasonably susceptible to discovery upon receipt), Simcere may issue a written notice to Kazia rejecting the Defective Products (“Defective Products Notice”). 

(c)    Following receipt by Kazia of a Defective Products Notice, Kazia may at its own cost (i) request access
to Simcere’s premises and inspect the Defective Products, and/or (ii) instruct Simcere to either return the Defective Products to Kazia (or a designated third party) or to dispose of the Defective Products and Simcere must comply with such
request. 
 (d)    If the cause of the Compound or Products being Defective Products was not to any extent caused
by Simcere, Kazia must pay the cost of the return or disposal of the Defective Products undertaken in accordance with item 5.3(c)(ii) of this Exhibit F and, at Simcere’s option, either refund to Simcere any payments made by Simcere in
respect of any Defective Products or replace the Defective Products. 

 (e)    If the cause of the Compound or Products being Defective
Products was partly or solely caused by Simcere, Simcere must pay a portion of (i) the cost of the return or disposal of the Defective Products undertaken in accordance with item 5.3(c)(ii) of this Exhibit F, and (ii) the invoice
relating to the Defective Products; which portion represents the extent to which Simcere’s action or inaction caused the Compound or Products to be Defective Products. 

(f)    If the Parties do not agree whether a Product is Defective Product or the cause thereof, the Parties shall
engage a mutually agreed independent third party laboratory to examine the Product in question.    The conclusion of such laboratory shall be final and binding upon the Parties, and the Party in error shall bear the cost of such
laboratory examination. 
  

	6.	 Price, Invoicing and Payment 

Simcere must pay to Kazia the Price for all Compound and Product that is delivered to Simcere in accordance with an Accepted Purchase Order. On, or within
fifteen (15) days from the delivery of the Compound or Products to the Delivery Point, Kazia must provide an invoice to Simcere for the Price of the Compound or Products. Simcere must pay Kazia the amount invoiced within thirty (30) days
after the later of the date on which Simcere receives the invoice and the Compound and/or Products (including customs clearance documents). 

7.    Manufacture Cost Audit. Simcere shall have the right (similar to Section 5.11) to audit and confirm the Manufacturing
Cost of the Product supplied by Kazia 
 8.    Regulatory/Quality Audit. Simcere shall have the right (similar to
Section 4.13) to audit the regulatory, quality and compliance systems, procedures and practices of Kazia (and its contractor manufacturers, subject to Kazia’s audits rights under any agreement with its contractor manufacturer) relating to
the Manufacture and supply of the Product. 

 [***] 

 [***] 

 [***] 

 [***] 

 Exhibit H:    Expert Determination 

 

	1.	 Delivering a Dispute Notice 

(a)    If Simcere and Kazia have been unable to resolve any dispute arising between them in relation to any
underpayment or overpayment reported by an Auditor under Section 5.11(d) (a “Financial Dispute”), then Simcere or Kazia may refer the Financial Dispute to an Expert for determination in accordance with this this Exhibit
H. 
 (b)    For the purposes of this Exhibit H, the Expert is a person: 

(i)    having appropriate qualifications and experience relevant to determining the Financial Dispute; 

(ii)    who is agreed by the Parties or, failing agreement within five (5) business days, is nominated at the
request of any Party by the Chinese Institute of Certified Public Accountants (“CICPA”) in accordance with CICPA’s rules and procedures (Rules); and 

(iii)    who does not act, or whose firm does not act, generally for any Party. 

 

	2.	 Determination by Expert 

The Expert: 

(a)    must conduct its determination in accordance with the Rules, which Rules are taken to be incorporated into
this Agreement; 
 (b)    will act as an expert and not as an arbitrator; 

(c)    may determine the time, place and procedures (which will be as informal as is consistent with the proper
conduct of the matter) for the determination by the Expert, having regard to the nature of the Financial Dispute and the provisions of this Agreement; 

(d)    may communicate privately with the Parties or with their lawyers; 

(e)    may or may not allow the appearance of lawyers on behalf of the Parties; 

(f)    may accept written submissions from a Party in relation to the Financial Dispute, provided a copy of the
submission is also given to all other Parties; 
 (g)    may co-opt other
expert assistance; 

 (h)    must have regard to the fairness and reasonableness of any
matters pertaining to the Royalty Dispute; and 
 (i)    must deal with any matter as expeditiously as possible
and by no later than twenty (20) Business Days after referral to the Expert. 
  

	3.	 Obligations of Parties 

If an Expert is required to resolve a Financial Dispute: 

(a)    the Expert’s determination will, except in the case of manifest error, be final and binding on the Parties;

 (b)    the Parties must attend the sessions with the Expert and make a determined and genuine effort to resolve
the Financial Dispute as soon as reasonably possible; 
 (c)    without limiting item 3(b) of this Exhibit
H, the Parties must use their best endeavours to make available to the Expert all information relevant to the Financial Dispute and which the Expert reasonably requires in order to resolve the Financial Dispute; 

(d)    everything that occurs before the Expert must be in confidence and in closed session; 

(e)    all discussions must be without prejudice; 

(f)    each Party must pay its own costs of complying with this Exhibit H and the costs of the Expert and any
other costs of complying with this Exhibit H must be shared half as to Simcere and half as to Kazia; and 

(g)    the Parties must continue performing their obligations under this Agreement while the Financial Dispute is
being resolved. 
  

	4.	 Other Proceedings 

A Party may not commence court proceedings in respect of a Financial Dispute unless it has complied with the terms of the Agreement, and if applicable until
the procedures in this Exhibit H have been followed in full, except where: 
 (a)    the Party seeks injunctive
relief in relation to a Financial Dispute from an appropriate court where failure to obtain such relief would cause irreparable damage to the Party concerned; or 

(b)    following those procedures would mean that a limitation period for a cause of action relevant to the issues
in dispute will expire. 

 Exhibit I:    Inquires made by Kazia 

At the time of Kazia’s license agreement with Genentech (October 2016):- 
  

	 	•	 	 Review of prior art documents cited in International Search Report 

	 	•	 	 Review of prior art documents cited in US prosecution 

	 	•	 	 Review of prior art documents citied in European application 

	 	•	 	 Review of patent agency correspondence in key territories 

	 	•	 	 Consultation with inventor (Dr Alan Olivero)EX-4.20

 Exhibit 4.20 

CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT WAS OMITTED BY MEANS OF MARKING SUCH INFORMATION WITH BRACKETS (“[***]”) BECAUSE
THE IDENTIFIED CONFIDENTIAL INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

LICENSE AGREEMENT 
 BY
AND BETWEEN 
 EVOTEC 

and 
 KAZIA 

This LICENSE AGREEMENT (this “Agreement”) is entered into by and between Kazia Therapeutics Limited (ACN 063 259 754), a
company existing under the laws of Australia, having a place of business at Three International Towers, L24, 300 Barangaroo Avenue, Sydney, NSW 2000, Australia (“Kazia”), and Evotec (France) SAS, a company existing under the laws of
France, having a place of business at 195 Route d’Espagne, 31036 Toulouse, France (“Evotec”). Each of Evotec and Kazia is sometimes referred to individually herein as a “Party” and collectively as the
“Parties”. 
 RECITALS 

WHEREAS, Evotec and/or its Affiliates have developed and/or in-licensed under a license agreement
between Evotec and Sanofi dated 30th July 2015 (“Sanofi License”) certain technology, patent rights and proprietary materials related to
EVT-801, a pre-clinical-stage, small molecule, orally available inhibitor of VEGFR3 for treating, preventing or delaying onset or progression of diseases in humans or as
biomarkers or stratification makers; and 
 WHEREAS, Kazia desires to obtain from Evotec, and Evotec is willing to grant to Kazia exclusive
rights to, and associated intellectual property in such molecule. 
 NOW, THEREFORE, in consideration of the mutual covenants contained
herein, and for other good and valuable consideration, the Parties hereto, intending to be legally bound, hereby agree as follows: 
  

	1.    DEFINITIONS	 

Whenever used in this Agreement with an initial capital letter, the terms defined in this Article 1 shall have the meanings specified herein
and therein. 
 1.1    “Adverse Event” means any untoward medical occurrence in a Clinical Trial
subject or patient who is administered a Product, whether or not considered related to such Product, including any undesirable sign (including abnormal laboratory findings of clinical concern), symptom or disease associated with the use of such
Product. 
 1.2    “Affiliate” means, with respect to any Party, any other Person that, directly or
indirectly, controls, or is controlled by, or is under common control with, such Party. For purposes of this definition, “control” (including, with correlative meaning, the terms “controlled by” and “under the common
control”) means (a) ownership of more than fifty percent (50%) of the shares of stock entitled to vote for the election of directors in the case of a corporation, or more than fifty percent (50%) of the equity interests in the case of any
other type of legal entity, or, with respect to either of the foregoing, such lesser maximum percentage permitted in those jurisdictions where majority ownership by foreign entities is prohibited, (b) status as a general partner in any
partnership, or (c) any other arrangement whereby a Person controls or has the right to control the board of directors of a corporation or equivalent governing body of an entity other than a corporation. 

 1.3    “Annual Net Sales” means, with respect to any
Calendar Year, the aggregate amount of the Net Sales of Product sold in the Territory in such Calendar Year. 

1.4    “Applicable Laws” means any national, federal, state or local laws, treaties, statutes,
ordinances, rules and regulations, including any rules, regulations, guidance, guidelines or requirements of any Regulatory Authority having the binding effect of law, or of any national securities exchange or securities listing organization on
which a Party’s or its Affiliates’ stock is publicly traded, or other government authority (other than a Regulatory Authority), legislative body or commission that are in effect from time to time during the Term and applicable to a
particular activity under this Agreement. 
 1.5    “Business Day” means any day other than a Saturday,
Sunday or public holiday in Germany and Australia. 
 1.6    “Calendar Quarter” means the period
beginning on the Effective Date and ending on the last day of the calendar quarter in which the Effective Date falls, and thereafter each successive period of three (3) consecutive calendar months ending on March 31, June 30,
September 30 and December 31; provided that the final Calendar Quarter shall end on the last day of the Term. 

1.7    “Calendar Year” means the period beginning on the Effective Date and ending on December 31 of the
calendar year in which the Effective Date falls, and thereafter each successive period of twelve (12) months commencing on January 1 and ending on December 31; provided that the final Calendar Year shall end on the last day of the Term.

 1.8    “Challenge” means any challenge to the validity or enforceability of any of the Licensed
Patent Rights, including without limitation by (a) filing a declaratory judgment action, any claim, demand, action or cause of action for declaratory relief, damages or any other remedy or for an enjoinment, injunction or any other equitable
remedy in which any of the Licensed Patent Rights is alleged to be invalid, not infringed or unenforceable, (b) citing prior art pursuant to 35 U.S.C. §301 or third party submission pursuant to 35 U.S.C. §122, filing third party
observations in any of the Licensed Patent Rights, or (c) filing any interference, derivation proceeding, reexamination, inter partes review, opposition, cancellation, nullity or similar proceedings against or based on any of the
Licensed Patent Rights in any country. 
 1.9    “Clinical Trial” means, collectively, any Phase 1
Clinical Trial, Phase 2 Clinical Trial or Phase 3 Clinical Trial, as applicable, conducted by or on behalf of a Party. 

1.10    “Combination Product” means a single Product that includes, in combination with a Licensed
Product, one or more therapeutically-active ingredients other than the Licensed Product that are sold in a single package or as a unit at a single price either as a fixed dosage form or as separate dosage forms. 

1.11    “Commercialization” or “Commercialize” means any and all activities directed to
the offering for sale and sale of a Product after Marketing Authorization has been received with respect to that Product, including (a) activities directed to marketing, promoting, detailing, distributing, importing, selling and offering to
sell that Product, (b) conducting approved investigator-initiated Clinical Trials and/or any other Clinical Trials with respect to that Product with respect to which Marketing Authorization has been received or for a use that is subject of an
investigator-initiated Clinical Trial, (c) interacting with Regulatory Authorities regarding the above, (d) seeking pricing approvals and reimbursement approvals (as applicable) for that Product in the Territory, and (e) undertaking
health economics studies and other activities designed in order to achieve favorable pricing approvals and reimbursement approvals for that Product in the Territory. When used as a verb, “to Commercialize” and
“Commercializing” means to engage in Commercialization and “Commercialized” has a corresponding meaning. 

1.12    “Commercially Reasonable Efforts” means, with respect to the Research, Development, Manufacture
or Commercialization of any Licensed Product, as applicable, the efforts and resources that are consistent with those used by a Party in the research, development, manufacture or commercialization of compounds and products of comparable market
potential as such Licensed Product, taking into account all relevant factors including, as applicable, the stage of development, efficacy and safety relative to competitive products in the marketplace, actual or anticipated Regulatory Authority
approved labeling, the nature and extent of market exclusivity (including patent coverage and regulatory exclusivity), the cost and likelihood of obtaining Marketing Authorization, and actual or projected profitability. For purposes of clarity,
Commercially Reasonable Efforts is determined on a market-by-market basis for each Licensed Product or particular Product, and it is anticipated that the level of effort
may be different for different markets and may change over time, reflecting changes in the status of each Licensed Product or Product and the market(s) involved. 

  
 2 

 1.13    “Confidential Information” means (a) the
terms of this Agreement and its subject matter, (b) all Licensed Technology, and (c) all information, Technology and Proprietary Materials belong to or relating to a Party, whether oral, graphic, electronic, written or in any other form, that
is or should reasonably be regarded as confidential to the Party to whom it belongs or relates and that is disclosed or provided by or on behalf of a Disclosing Party to a Receiving Party. 

1.14    “Control” or “Controlled” means (a) with respect to Technology or Patent
Rights, the possession by a Party of the right to grant a license, sublicense, access or other right to such Technology or Patent Rights as provided herein, and (b) with respect to Proprietary Materials, the possession by a Party of the right
to supply, or grant access or another right to, such Proprietary Materials to the other Party as provided herein. 

1.15    “Cover” or “Covered” or “Covering” means, with respect to any
Patent Rights, Licensed Product or Product, that the use, import, manufacture or sale of such Licensed Product or Product in a particular country by an unlicensed Third Party would infringe a Valid Claim within such Patent Rights. 

1.16    “CTA” means (a) a Clinical Trial application or any successor application or procedure
required to initiate clinical testing of a Product in humans in the Territory in accordance with Applicable Laws, and (b) all supplements and amendments to any of the foregoing. 

1.17    “Development” or “Develop” means, with respect to a Licensed Product or Product,
(a) all non-clinical and clinical drug development activities that are undertaken after the Initiation of the first GLP-toxicology study for such Licensed Product in order to file and maintain a
Regulatory Filing or obtain Marketing Authorization for such Licensed Product or Product in the Territory up to the date of receipt of Marketing Authorization with respect to that Licensed Product or Product, including toxicology and pharmacology
testing, the conduct of chemistry manufacturing and controls, test method development and stability testing, process development (including the manufacture of validation and engineering batches), formulation development, delivery system development,
quality assurance and quality control development, statistical analysis and report writing; the conduct of Clinical Trials; preparing and filing and all regulatory affairs related to the foregoing, and (b) the conduct of manufacturing
development activities. When used as a verb, “Developing” means to engage in Development and “Developed” has a corresponding meaning. 

1.18    “Disclosing Party” means a Party to whom information belongs or relates. 

1.19    “Distributor” means any Person that purchases any Product from Kazia or any of Kazia’s
Affiliates or Sublicensees for the purpose of reselling that Product to end users in the Territory (including any wholesalers, pharmacists or hospitals). 

1.20    “DMF” means a Drug Master File maintained with a Regulatory Authority in any country within the
Territory. 
 1.21    “Effective Date” means the date of last signature under this Agreement. 

1.22    “EMA” means the European Medicines Agency or any successor agency or authority thereto. 

  
 3 

 1.23    “FDA” means the United States Food and Drug
Administration, or any successor agency or authority thereto. 
 1.24    “FDCA” means the United States
Federal Food, Drug, and Cosmetic Act, as amended. 
 1.25    “Field” means all therapeutic,
prophylactic and diagnostic uses in humans. 
 1.26    “First Commercial Sale” means, with respect to
any Product in any country in the Territory, the first sale, transfer or disposition for value of that Product in that country after Marketing Authorization for the Product has been received in that country; provided that the following shall not
constitute a First Commercial Sale: (a) any sale by Kazia to an Affiliate, Sublicensee or Distributor (unless the Affiliate, Sublicensee or Distributor is the last entity in the distribution chain of the Product), (b) any use of a Product in
Clinical Trials, pre-clinical studies or other Research or Development activities, or (c) the disposal or transfer of Products for a bona fide charitable purpose, including compassionate use and/or
“named patient sales”. 
 1.27    “Force Majeure” means any occurrence beyond the reasonable
control of a Party that (a) prevents or substantially interferes with the performance by such Party of any of its obligations hereunder, and (b) occurs by reason of any act of God, flood, fire, explosion, earthquake, strike, lockout, labor
dispute, casualty or accident, or war, revolution, civil commotion, epidemic, pandemic, act of terrorism, blockage or embargo, or any injunction, law, order, proclamation, regulation, ordinance, demand or requirement of any government or of any
subdivision, authority or representative of any such government. 
 1.28    “GLP” means the
then-current Good Laboratory Practice Standards promulgated or endorsed by the FDA or in the case of any other country in the Territory, comparable regulatory standards promulgated or endorsed by that country, including those procedures expressed in
or contemplated by any Regulatory Filings. 
 1.29    “GMP” means the then-current Good Manufacturing
Practices that apply to the Manufacture (including clinical or commercial supply ) of each Licensed Product, including where applicable the United States regulations set forth under Title 21 of the United States Code of Federal Regulations, parts
210 and 211, as may be amended from time-to-time, as well as all applicable guidance published from
time-to-time by the FDA and the ICH Guidelines ICHQ7A Good Manufacturing Practice Guidance for the principles and guidelines of Good Manufacturing Practices for
Medicinal Products as defined with EC Directive 2003/94/EC and associated EC Guide to Good Manufacturing Practice. 

1.30    “GCP” means the then-current good clinical practice applicable to the clinical Development of any
Licensed Product or Product under Applicable Laws, including as applicable the ICH guidelines and U.S. Good Clinical Practice. 

1.31    “Hatch-Waxman Act” means the Drug Price Competition and Patent Term Restoration Act of 1984, as
amended. 
 1.32    “ICH” means the International Council for Harmonisation of Technical Requirements
for Pharmaceuticals for Human Use. 
 1.33    “Improvement” means any improvement, enhancement,
modification, adaptation, extension, development, mutation, application of and all other technical advances made by or on behalf of a Person, whether or not protected by statute. 

1.34    “IND” means (a) an investigational new drug application as defined in the FDCA and
regulations promulgated thereunder or any successor application or procedure required to initiate clinical testing of a Licensed Product or Product in humans in the United States; (b) a foreign equivalent of an investigational new drug
application that is required in any other country or region in the Territory before beginning clinical testing of a Licensed Product or Product in humans in such country or region; and (c) all supplements and amendments to any of the foregoing.

  
 4 

 1.35    “Indirect Taxes” means VAT, sales taxes,
consumption taxes and other similar taxes required by law to be disclosed on an invoice. 

1.36    “Initiation” means (a) with respect to a study, the commencement of such study, or
(b) with respect to a Clinical Trial, the date on which the first subject or patient is dosed in such Clinical Trial. 

1.37    “Knowledge” means, with respect to a Party, the actual knowledge of the officers of such Party.

 1.38    “Licensed Patent Rights” means the Patent Rights listed on Exhibit A attached hereto.

 1.39    “Licensed Product” means EVT-801 a pre-clinical-stage, small molecule, orally available inhibitor of VEGFR3 as set out in Exhibit C. 

1.40    “Licensed Technology” means (a) Technology Controlled or
in-licensed by Evotec or its Affiliates at the Effective Date which is reasonably required by Kazia for the Research, Development, Manufacture or Commercialization of the Licensed Product or Products as listed
on Exhibit A, and (b) pursuant to Section 9.4, any Improvements thereof. 

1.41    “MAA” means any application for Regulatory Approval submitted to the EMA pursuant to the
centralized approval procedure to obtain European Commission approval for the marketing of a Product in the European Union, or any successor application or procedure required to sell a Product in the European Union. 

1.42    “Manufacture” or “Manufacturing” or “Manufactured” means all
activities related to the production of any clinical or commercial quantities of Licensed Product or Product, including, the manufacture, receipt, inspection, storage and handling of materials, and the manufacture, processing, purification,
packaging, labeling, warehousing, quality control testing (including in-process release and stability testing), shipping and release of each such Licensed Product or Product. 

1.43    “Marketing Authorization” means, with respect to any Product, the Regulatory Approval required by
Applicable Laws to Commercialize such Product for use in a country or region in the Territory. For purposes of clarity (a) “Marketing Authorization” in the United States means final approval of an NDA or biological license application
permitting marketing of such Product in interstate commerce in the United States, and (b) “Marketing Authorization” in the European Union means marketing authorization for such Product granted either by a Regulatory Authority in any
European Country or by the EMA pursuant to Council Directive 2001/83/EC, as amended, or Council Regulation 2309/93/EEC, as amended. 

1.44    “NDA” means a New Drug Application, as defined in the FDCA and regulations promulgated
thereunder, or any successor application or procedure required to sell a Licensed Product or Product in the United States. 

1.45    “Net Sales” means the gross invoiced amount on sales of the Products by or on behalf of Kazia and
its Affiliates and Sublicensees to Third Parties after deduction of the following amounts, to the extent taken (a) normal and customary trade, quantity or prompt settlement discounts (including chargebacks and allowances) actually allowed,
(b) amounts repaid or credited by reason of rejection, returns or recalls of goods, rebates or bona fide price reductions determined by Kazia or its Affiliates in good faith, (c) rebates and similar payments made with respect to sales paid
for by any Regulatory Authority such as, by way of illustration and not in limitation of the Parties’ rights hereunder, Federal or state Medicaid, Medicare or similar state program in the United States or equivalent governmental program in any
other country; (d) excise taxes, Indirect Taxes, customs duties, customs levies and import fees imposed on the sale, importation, use or distribution of the Products; for clarity, the portion of any annual fee on prescription drug manufacturers
imposed by the United States Patient Protection and Affordable Care Act, Pub. L. No. 111-148 (as amended) or other similar governmental fee based on revenues from pharmaceutical products that may be
allocated by Kazia, its Affiliates or its Sublicensees to sales of the Products shall not be considered for the purpose of this definition of Net Sales; (e) reasonable charges for insurance, freight, transportation costs directly related to the
delivery of the Product; (f) any other similar and customary deductions that are consistent with international financial reporting standards, or other applicable accounting standards. Net Sales shall be calculated using Kazia’s internal
audited systems used to report such sales as adjusted for any of items (a) to (f) above not taken into account in such systems. Deductions pursuant to subsection (d) above are taken in the Calendar Quarter in which such sales are no longer
recorded as a receivable. 

  
 5 

 Net Sales for a Combination Product shall be calculated by multiplying the actual Net Sales of such
Combination Product in any country by the fraction A/(A+B), where A is the average gross invoice price in such country of a Product, containing the same amount of Licensed Product as the sole active ingredient as the Combination Product in question
(a “Comparable Product”), if sold separately, and B is the average gross invoice price in the given country of the ready for sale form of a product containing the same amount of the other therapeutically active ingredient(s) in the
Combination Product that are not Licensed Products (the “Other Ingredients”), if sold separately. If, on a country-by-country basis, the Other
Ingredients are not sold separately in a country, Net Sales in such country for the purpose of determining royalties of the Combination Product shall be calculated by multiplying actual Net Sales of such Combination Product in such country by the
fraction A/C where A is the average gross invoice price in such country of a Comparable Product, if sold separately, and C is the average gross invoice price of the Combination Product in such country. If, on a country-by-country basis, a Comparable Product is not sold separately, Net Sales in such country for the purpose of determining royalties of the Combination Product shall be calculated by multiplying actual
Net Sales of such Combination Product by the fraction (C-B)/C, where B is the average gross invoice price in such country of the Other Ingredients and C is the average gross invoice price in such country of
the Combination Product. For the purpose of the above, the average gross invoice price for a Comparable Product and for each Other Ingredient shall be for a quantity comparable to that used in the Combination Product in question and of the same
class, purity and potency. If, on a country-by-country basis, neither a Comparable Product nor the Other Ingredients are sold separately in a country, Net Sales in such
country for the purposes of determining royalties of such Combination Product shall be determined based on the ratio of the cost of the Licensed Product in the Combination Product to the sum of the cost of the Licensed Product in the Combination
Product and the cost of the Other Ingredients in the Combination Product. 
 1.46    “Patent Costs”
means the reasonable external costs and expenses incurred by Evotec(including reasonable attorneys’ fees) in preparing, filing, prosecuting or maintaining any Licensed Patents Rights in accordance with this Agreement. The Parties acknowledge
that such costs may include reasonable pass through costs incurred by Sanofi in it preparing, filing, prosecuting or maintaining any Licensed Patents. 

1.47    “Patent Rights” means the rights and interests in and to issued patents and pending patent
applications (which, for purposes of this Agreement, include certificates of invention, applications for certificates of invention and priority rights) in any country or region, including all provisional applications, substitutions, continuations, continuations-in-part, divisions, renewals, all letters patent granted thereon, and all reissues, re-examinations, utility models,
supplementary protection certificates, and extensions thereof, and all foreign counterparts of any of the foregoing. 

1.48    “Person” means an individual, sole proprietorship, partnership, limited partnership, limited
liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including a government or political subdivision, department or
agency of a government. 
 1.49    “Phase 1 Clinical Trial” means a human clinical trial for a Product
in any country that would satisfy the requirements of 21 CFR 312.21(a), or its successor regulation, or the equivalent in any foreign country. 

  
 6 

 1.50    “Phase 2 Clinical Trial” means a human clinical
trial conducted in any country that would satisfy the requirements of 21 CFR 312.21(b) or its successor regulation, or the equivalent in any foreign country and is intended to explore the safe and effective dose range for the proposed therapeutic
indication of Product and other characteristics of safety and efficacy, for any Product in a patient population. 

1.51    “Phase 3 Clinical Trial” means a clinical trial in any country in an extended human patient
population designed to obtain data determining efficacy and safety of any Product to support Regulatory Approvals in a therapeutic indication, as more fully defined in 21 CFR 312.21(c), or its successor regulation, or the equivalent in any foreign
country. 
 1.52    “Product” means any pharmaceutical or medicinal item, substance, formulation or
dosage that comprises a Licensed Product as the active pharmaceutical ingredient. “Product” includes Combination Products. 

1.53    “Proprietary Materials” means any tangible chemical, biological or physical materials that are
Controlled by one Party and (a) are furnished by or on behalf of such Party to the other Party in connection with this Agreement, whether or not specifically designated as proprietary by the Party transferring that material, or (b) are
otherwise conceived or reduced to practice by or on behalf of such Party in connection with the Research, Development, Manufacture or Commercialization of Products. 

1.54    ”Receiving Party” means a Party to whom information is disclosed or who possesses or otherwise
acquires information belonging or relating to a Disclosing Party. 
 1.55    “Regulatory Approval”
means, with respect to any country or region in the Territory, any approval, product and establishment license, registration or authorization of any Regulatory Authority required for the Manufacture, use, storage, importation, exportation, transport
or distribution of a Licensed Product or Product for use in such country or region. 
 1.56    “Regulatory
Authority” means any national, international, regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity with authority over the distribution, importation, exportation, Manufacture,
production, use, storage, transport, clinical testing, pricing or sale of a Product in the Territory, including the FDA and the EMA. 

1.57    “Regulatory Documentation” means any Regulatory Filings, submission, communications,
correspondence, registrations and other filings made to, received from or otherwise conducted with a Regulatory Authority. 

1.58    “Regulatory Filing” means, collectively (a) any IND, CTA, MAA, establishment license
application, DMF, application for designation as an “Orphan Product” under the Orphan Drug Act, for “Fast Track” status under Section 506 of the FDCA (21 U.S.C. § 356) or for a Special Protocol Assessment under
Section 505(b)(4)(B) and (C) of the FDCA (21 U.S.C. § 355(b)(4)(B)) and all other similar filings (including counterparts of any of the foregoing in any country or region in the Territory), (b) all supplements and amendments to any of
the foregoing; and (c) all data and other information contained in, and correspondence relating to, any of the foregoing. 

1.59    “Research” means, with respect to each Licensed Product, all research and non-clinical drug development activities that are undertaken with respect to such Licensed Product prior to Initiation of the first GLP-toxicology study conducted for such
Licensed Product. 
 1.60    “Royalty Term” means, with respect to each Product in each country of the
Territory, the period beginning on the date of First Commercial Sale of such Product in such country [***] 

  
 7 

 1.61    “Second Indication” means a claim the subject
of a Regulatory Approval received for a Product that is subsequent to the initial Regulatory Approval received for that Product, which claim is for a disease, disorder or medical condition which the Product can be used to diagnose, treat or prevent
that is separate and distinct from the disease, disorder or medical condition listed in the initial Regulatory Approval for the Product. 

1.62    “Sublicensee” means a Person, other than an Affiliate of Kazia, who is granted a sublicense in
accordance with the provisions of this Agreement. For clarity, any Person to which a Sublicensee grants a further sublicense shall also be a Sublicensee. 

1.63    “Tax” means any form of tax or taxation, levy, duty, charge, contribution, or withholding of
whatever nature (including any related fine, penalty, surcharge or interest) imposed by, or payable to, a Tax authority. 

1.64    “Technology” means, collectively, inventions, discoveries, improvements, trade secrets and
proprietary methods, whether or not patentable, including: (a) methods of Manufacture or use of, and structural and functional information pertaining to, chemical compounds; and (b) compositions of matter, data, formulations, processes,
techniques, know-how and results (including any negative results). 

1.65    “Territory” means any country or territory in the world. 

1.66    “Third Party” means a Person other than Kazia and Evotec and their respective Affiliates. 

1.67    “Valid Claim” means any claim of a pending patent application to the extent such claim continues
to be prosecuted in good faith or an issued unexpired patent that (a) has not been finally cancelled, withdrawn, abandoned or rejected by any administrative agency or other body of competent jurisdiction, (b) has not been permanently
revoked, held invalid, or declared unpatentable or unenforceable in a decision of a court or other body of competent jurisdiction that is unappealable or unappealed within the time allowed for appeal, (c) has not been rendered unenforceable
through terminal disclaimer or otherwise, and (d) is not lost through an interference proceeding that is unappealable or unappealed within the time allowed for appeal. 

1.68    Additional Definitions. In addition, each of the following definitions have the respective meanings set
forth in the section of this Agreement indicated below: 
  

			
	 Definition
	 	Section
	 Agreement
	 	Preamble
	 Claims
	 	13.1.
	 Comparable Product
	 	1.45
	 Diligence Failure Notice
	 	5.4
	 Disclosing Party
	 	1.18
	 Evotec
	 	Preamble
	 Evotec Diligence Failure
	 	5.5
	 Evotec Indemnitees
	 	13.1
	 Generic Entry
	 	6.3.3
	 Generic Product
	 	6.3.3
	 Indemnified Party
	 	13.3
	 Indemnifying Party
	 	13.3
	 Infringement
	 	10.2.1(a)(i)
	 Infringement Notice
	 	10.2.1(a)(i)
	 Infringement Response
	 	10.2.1(a)(ii)
	 Kazia
	 	Preamble
	 Kazia Diligence Failure
	 	5.4
	 Kazia Indemnitees
	 	13.2

  
 8 

			
	 Definition
	  	Section
	 Losses
	  	13.1
	 Other Ingredients
	  	1.45
	 Patent Coordinator
	  	9.3
	 Party/Parties
	  	Preamble
	 Payments
	  	6.3.8
	 Receiving Party
	  	1.54
	 Recovery
	  	10.2.1(d)
	 Sanofi License
	  	Recitals
	 Supply Agreement
	  	3.3
	 Term
	  	11.1
	 Third Party License
	  	6.3.2
	 Upfront Payment
	  	6.1

 1.69    List of Exhibits. 

Exhibit A                    Licensed Patent Rights
and Licensed Technology (As of the Effective Date) 
 Exhibit
B                    List of Countries for Patent Filing 

Exhibit C                    Structure of EVT-801 
 Exhibit
D                    Quote from Third Party provider for delivery of Licensed Product 

 

	2.    RESEARCH	 AND DEVELOPMENT 

2.1    Objectives. The objective of conducting the Research and Development activities with respect to the
Licensed Product under this Agreement is to progress Licensed Products and Commercialize Products. 
 2.2    Kazia
Responsibilities. During Term, Kazia shall use Commercially Reasonable Efforts to conduct Research and Development activities, at its own cost and expense, in order to Commercialize Products. [***]. 

2.3    Evotec Responsibilities. Within sixty (60) days of the Effective Date, Evotec must provide to
Kazia all Licensed Technology that exists on the Effective Date as set out at Exhibit A, including by (a) providing to Kazia all tangible Licensed Technology and, to the extent possible, copies of documents describing the
intangible Licensed Technology, and (b) otherwise providing Kazia with access to intangible Licensed Technology. Upon Kazia’s reasonable request, for a period of one hundred and twenty (120) days of the Effective Date, Evotec shall
also provide Kazia with reasonable technical assistance in connection with the Licensed Technology provided under this Section 2.3, including reasonable access to Evotec’s available technical personnel involved in the Research and
Development of the Licensed Product and Products at no additional cost to Kazia. 
 2.4    Compliance.
Kazia shall perform Research and Development activities for which it is responsible under this Agreement in compliance with all Applicable Laws. In conducting Research and Development activities, Kazia shall comply, as applicable, with GLPs, GMPs or
GCPs (or, if and as appropriate under the circumstances, ICH guidance or other applicable comparable regulation or guidance of any Regulatory Authority in any country or region in the Territory). 

2.5    Records; Reports. During the Term, Kazia shall maintain complete and accurate records of its Research
and Development activities conducted in relation to the Licensed Product and any Products. Such records shall be kept in sufficient detail and in a manner that reflects all work done and results achieved. Kazia shall inform Evotec in writing of the
progress of its Research and Development activities not less than once each Calendar Year by 31 October. 

  
 9 

	3.    MANUFACTURING	 RIGHT 

3.1    Kazia Manufacturing Rights. Kazia shall have the sole right and responsibility, at its sole cost and
expense, to Manufacture and supply and/or obtain from Third Parties such quantities of each Licensed Product and Product as may be required by Kazia, including for all Clinical Trials. 

3.2    Assignment of Licensed Product. Evotec herewith assigns to Kazia and Kazia herewith accepts such
assignment of Evotec’s inventory of Licensed Products existing as of the Effective Date. 
 3.3    Supply
Arrangement. Kazia and Evotec will separately and in good faith discuss a potential supply agreement in which Evotec shall continue to manufacture Licensed Product on Kazia’s behalf on commercial terms (“Supply
Agreement”). If the Parties enter into a Supply Agreement, Kazia shall consider Evotec as a preferred supplier for any Manufacturing of the Licensed Product and/or supply services of the Licensed Product that are outsourced by Kazia. 

 

	4.    REGULATORY	 ACTIVITIES 

4.1    Responsibility for Regulatory Filings. Kazia shall have the exclusive right and responsibility for
(a) preparing, filing and maintaining all Regulatory Filings for each Product in its own name, (b) to the extent required by Applicable Laws, reporting to Regulatory Authorities any Adverse Events related to a Product that it is reasonably
aware of, and (c) otherwise communicating and interacting with Regulatory Authorities with respect to Products prior and subsequent to Regulatory Approval. 

4.2    Reports. Kazia shall, at its own cost and expense: (a) maintain records of its Regulatory
Filings for each Product; and (b) inform Evotec on the progress of its Regulatory Filings not less than once each Calendar Year by 31 October. 

4.3    Existing Documentation. Within sixty (60) days of the Effective Date, Evotec shall, at its own
cost and expense, assign and provide to Kazia all of the Regulatory Documentation and any available Regulatory Approvals with respect to the Licensed Product Controlled by Evotec, if any, as of the Effective Date. 

 

	5.    COMMERCIALIZATION	 OF PRODUCTS 

5.1    Responsibility. Kazia shall have the exclusive right and responsibility for Commercialization of
Products in the Territory, at its sole cost and expense. 
 5.2    Reports. Kazia shall inform Evotec on
the progress of its Commercialization plans not less than once each Calendar Year by 31 October. 

5.3    Commercialization Diligence. Kazia shall use Commercially Reasonable Efforts during the Term to
(a) Commercialize Products in the Territory and (b) commit such resources (including employees, consultants, contractors, facilities, equipment and materials) as it deems reasonably necessary to Commercialize such Products in the
Territory. 
 5.4    Failure by Kazia to Satisfy Diligence Obligations. Evotec shall have the right, in
its sole discretion, to provide Kazia with written notice if it reasonably believes Kazia has failed to satisfy its diligence obligations under Section 5.3 of this Agreement with respect to any Product in any country or countries in the
Territory (a “Kazia Diligence Failure”). Such written notice (a “Diligence Failure Notice”) shall set forth in reasonable detail the nature of the alleged failure and shall request written justification, in the form
of detailed reasons that would support the proposition that Kazia has satisfied such diligence obligations. The Parties shall meet within thirty (30) days after such notice to discuss in good faith Evotec’s concerns and Kazia’s plans
for Development and Commercialization with respect to the applicable Product in the applicable country(ies). If, after such good faith discussions (a) Kazia remains reasonably found by Evotec in material breach of its obligations under
Section 5.3 of this Agreement with respect to such Product in such country, and (b) Kazia does not take all reasonable steps designated to rectify such breach within ninety (90) days after meeting with Evotec pursuant to this
Section 5.4 (or if such failure cannot be rectified within such ninety (90)-day period, if Kazia does not commence actions to rectify such breach within such period and thereafter diligently pursue such
actions), then Evotec shall have the right, in its discretion, on a Product-by-Product basis as to the Product with respect to which such Kazia Diligence Failure
occurred to (i) terminate any or all of the licenses and rights granted under Section 8.1.1 hereof with respect to the Product that is the subject of the Diligence Failure Notice, or (ii) convert the licenses and rights granted under
any or all of Section 8.1.1 from exclusive licenses to non- exclusive licenses only as such licenses and rights apply to such Product, which termination or conversion, as the case may be, shall be at the discretion of Evotec and be effective
immediately upon issuance by Evotec of written notice to Kazia specifying the remedy that Evotec is electing to exercise under this Section 5.4. 

  
 10 

 5.5    Failure by Evotec to Satisfy Diligence Obligations.
Evotec must notify Kazia immediately in writing upon receiving a written notice from Sanofi regarding any alleged failure by Evotec to satisfy its diligence obligations under the Sanofi License (“Evotec Diligence Failure”). If such Evotec
Diligence Failure can reasonably be attributed to any action or inaction of Kazia resulting in a Kazia Diligence Failure, the terms of Section 5.4 shall apply provided, however, that in such case the time periods set out in Section 5.4
shall be adjusted to reflect the time periods applicable to the rectification or otherwise of the Evotec Diligence Failure under the Sanofi License. 
  

	6.    PAYMENTS	 

6.1    Upfront Payment. In consideration of the rights granted by Evotec to Kazia under this Agreement, Kazia
shall pay Evotec a non-refundable fee of 1,000,000.00 (One million) Euros after execution of this Agreement and within thirty (30) Business Days after receipt of a valid tax invoice from Evotec. Such fee
will be unconditional and as such shall not be subject to any offset, credit, reduction or repayment for any reason whatsoever, whether provided for in this Agreement or not. 

In addition, Kazia will reimburse Evotec (at cost up to [***]) for the purchase of certain Licensed Product that are being purchased by Evotec
from a third party provider similar in all material aspects as per the quotes set out in Exhibit D hereto. 

6.2    Milestone Payments. 

6.2.1    Development and Regulatory Milestones. Subject to Section 6.3.4, Kazia shall make the
following one-time, non-refundable, non-creditable payments to Evotec within thirty (30) Business Days after receipt of a
valid tax invoice from Evotec issued following the first achievement of the corresponding milestone event by Kazia or its Affiliates or Sublicensees: 
  

			
	Milestone Event	  	Milestone Payment
	 [***]
	  	
		  	[***]
	
	Milestone
Event                                       
                             Milestone Payment
		
	For the avoidance of doubt, the Parties agree that all payments under this Section 6.2.1 are payable only once, unless expressly noted.	  	
		
	6.2.2    Sales Milestones. In addition to the milestone payments contemplated by Section 6.2.1, Kazia shall make the following one-time, non-refundable, non-creditable payments to Evotec within
thirty (30) Business Days after receipt of a valid tax invoice from Evotec issued following the first achievement of the corresponding milestone event by Kazia or its Affiliates or Sublicensees:	  	

  
 11 

			
		
		  	 Milestone Event

[***]

 For the avoidance of doubt, the Parties agree that all payments under this Section 6.2.2 are payable only once. 

6.2.3    Notice of Milestones. 

(a)    Notice of Milestone Events. Kazia shall provide Evotec with prompt written notice upon the occurrence of
each milestone event set forth in this Section 6.2. If Evotec believes any such milestone event has occurred and has not received a written notice of same from Kazia, it shall so notify Kazia in writing and shall provide to Kazia documentation
or other information that supports its belief. Any dispute under this Section 6.2.3(a) that relates to whether or not a milestone event has occurred shall be resolved in accordance with Section 14.3. 

6.3    Payment of Royalties; Royalty Rates; Accounting and Records. 

6.3.1    Payment of Royalties. Kazia shall pay Evotec a royalty amount on Annual Net Sales in each Calendar
Year of the Term, on a Product-by-Product basis, commencing with the First Commercial Sale of such Product in any country in the Territory and ending upon the last day
of the last Royalty Term for such Product, at the following rates: 

  
 12 

					
	 Annual Net Sales within first 24 months from First
	  		 	Royalty Rate (%)
	 Commercial Sale
	  		 	
	 All amounts
	  	[***]	 	

  

					
	 Annual Net Sales Increment following 24 months
	  		 	Royalty Rate (%)
	 from First Commercial Sale

[***]
	  	[***]	 	
	 [***]
	  	[***]	 	
	 [***]
	  	[***]	 	
	 [***]
	  	[***]	 	

 6.3.2    Royalty Adjustment for Third Party Intellectual Property. If Kazia
or its Affiliates or their Sublicensees, as applicable, determines, in its reasonable judgment, that it is necessary to obtain a license from any Third Party (a “Third Party License”) under any Valid Claim in order to avoid
potential infringement or misappropriation of such Valid Claim by the importation, sale, manufacture or use of a Licensed Product, then the royalty payment that would otherwise be due in any Calendar Quarter pursuant to Section 6.3.1 shall be
reduced, on a Calendar Quarter-by-Calendar Quarter basis, by fifty percent (50%) of any royalty amount payable by Kazia or its Affiliates or their Sublicensees in such
Calendar Quarter to such Third Party in consideration for such Third Party License, in the event such Third Party License is obtained by Kazia or its Affiliate or their Sublicensees. Notwithstanding the foregoing, the royalty payment that would
otherwise be due to Evotec pursuant to Section 6.3.1 with respect to any particular Calendar Quarter shall not be reduced by more than fifty percent (50%) by operation of this Section 6.3.2. 

6.3.3    Royalty Adjustment in Certain Circumstances. On a Product-by-Product and country-by-country basis, if in any Calendar Quarter during the Royalty Term following introduction of a
Generic Product in a country (“Generic Entry”) there is no Valid Claim within the Licensed Rights in such country then the applicable royalty payable to Evotec under Section 6.3.1 shall be reduced by fifty percent (50%). For
the purposes of this Section 6.3.3, “Generic Product” means, with respect to a Product being sold by Kazia and its Affiliates or their Sublicensees or subcontractors, as applicable, any pharmaceutical product containing the
same Licensed Product as that contained in such Product (and the same other active ingredient(s), as applicable, in the case of a Combination Product) which is marketed by an entity other than Kazia and its Affiliates or their Sublicensees or
subcontractors, to the extent such Sublicensees or subcontractors are acting in their capacity as sublicensees or subcontractors of Kazia or its Affiliates, in the Field. 

6.3.4    Sublicensing Revenues. If Kazia sublicenses Commercialization rights to any Sublicensee, Kazia shall pay
to Evotec the greater of, at Evotec’s sole discretion, (i) the milestone and royalty payments pursuant to Sections 6.2 and 6.3, or (ii) in lieu of the then outstanding milestone and royalty payments under Sections 6.2 and 6.3, a
percentage of any and all payments received by Kazia or its Affiliates from each such Sublicensee in consideration for such sublicense, on a Product-by-Product basis, as
follows: 
 (a)    [***] of any upfront payment received by Kazia from each Sublicensee for a Sublicense granted prior to
Initiation of Phase 2 Clinical Trial; and (b) [***] of any upfront payment received by Kazia from each Sublicensee for a Sublicense granted after Initiation of Phase 2 Clinical Trial; and 

  
 13 

	 	(c)    [***] of	 the Development and Regulatory Milestones received by Kazia from each Sublicensee; and 

 

	 	(d)    [***] of	 the Sales Milestones received by Kazia from each Sublicensee; and 

 

	 	(e)	 [***] of any Royalties received by Kazia from each Sublicensee. 

6.3.5    Payment Dates and Reports. Royalty payments shall be made by Kazia with respect to each Product
within thirty (30) Business Days after the receipt of a valid tax invoice from Evotec issued following the end of each Calendar Quarter in which a sale of such Product occurs, commencing with the Calendar Quarter in which the First Commercial
Sale of such Product occurs. Within 20 Business Days after the end of each Calendar Quarter, Kazia shall provide a report showing (a) the Net Sales of each Product by type of Product and country in the Territory, (b) the total amount of
deductions from gross sales to determine Net Sales, (c) the applicable royalty rates for Product in each country in the Territory after applying any deductions set forth above; and (d) a calculation of the amount of royalty due to Evotec,
taking into account any royalty adjustments under Sections 6.3.2, 6.3.3 and 6.3.4. 
 6.3.6    Records; Audit
Rights. Kazia shall, and shall procure that its Affiliates and Sublicensees will, keep and maintain for three (3) years from the date of each payment of royalties hereunder complete and accurate records of gross amounts invoiced and Net
Sales by Kazia and its Affiliates and Sublicensees of each Product, in sufficient detail to allow royalties to be determined accurately. Evotec shall have the right for a period of three (3) years after receiving any royalty payment under this
Section 6.3 to appoint at its expense an independent certified public accountant reasonably acceptable to Kazia to audit the relevant records of Kazia and its Affiliates and Sublicensees to verify that the amount of such payment was correctly
determined. Kazia shall make, and shall procure that its Affiliates and Sublicensees make, its records available for audit by such independent certified public accountant during regular business hours at such place or places where such records are
customarily kept, upon thirty (30) days written notice from Evotec. Such audit right shall not be exercised by Evotec more than once in any Calendar Year or more than once with respect to sales of a particular Product in a particular period.
All records made available for audit shall be deemed to be Confidential Information of Kazia. In the event that an underpayment by Kazia hereunder is identified as a result of the audit, Kazia shall promptly (but in any event no later than thirty
(30) days after Kazia’s receipt of any undisputed audit report so concluding) make payment to Evotec of any shortfall.    In the event that an overpayment by Kazia hereunder is identified as a result of the audit, then
Kazia may take credit for such overpayment against any future payments due to Evotec (if no future payment is due, then Evotec shall promptly refund such amount to Kazia). Evotec shall bear the full cost of any audit unless such audit discloses an
underreporting by Kazia of five percent (5%) or greater of the aggregate amount of royalties payable in any Calendar Year, in which case Kazia shall reimburse Evotec for all reasonable costs incurred by Evotec in connection with such audit. 

6.3.7    Overdue Payments. All payments not made by Kazia to Evotec when due under this Agreement, shall
bear interest at a rate equal to 5 percent (5%) per year from the due date until paid in full or, if less, the maximum interest rate permitted by Applicable Laws. Any such overdue payment shall, when made, be accompanied by, and credited first
to, all interest so accrued. 
 6.3.8    Tax. The royalties, milestones and other amounts payable by one
Party to the other Party pursuant to this Agreement (“Payments”) shall not be reduced on account of any Taxes unless required by Applicable Law. Each Party alone shall be responsible for paying any and all Taxes (other than
withholding taxes required by Applicable Law to be paid by Kazia) levied on account of, or measured in whole or in part by reference to, the income of such Party. 

6.3.9    Payments; Indirect Taxes. All Payments are exclusive of Indirect Taxes. If any Indirect Taxes are
chargeable in respect of any Payments, the paying Party shall pay such Indirect Taxes at the applicable rate in respect of such Payments following receipt, where applicable, of an Indirect Taxes invoice in the appropriate form issued by the
receiving Party in respect of those Payments. The Parties shall issue invoices for all amounts payable under this Agreement consistent with Indirect Tax requirements and irrespective of whether the sums may be netted for settlement
purposes.    If such amounts of Indirect Taxes are refunded by the applicable Regulatory Authority or other fiscal authority subsequent to payment, the Party receiving such refund shall transfer such amount to the paying Party
within thirty (30) days of receipt. The Parties agree to reasonably cooperate to provide any information required by the Party pursuing a refund of Indirect Taxes paid. 

  
 14 

 6.3.10    Withholding Tax. If Applicable Laws require
withholding of income or other taxes imposed upon any payments made by Kazia to Evotec under this Agreement, Kazia shall (i) make such withholding payments as may be required, (ii) subtract such withholding payments from such payments,
(iii) submit appropriate proof of payment of the withholding taxes to Evotec within a reasonable period of time, and (iv) promptly provide Evotec with all official receipts with respect thereto. Kazia shall render Evotec reasonable
assistance in order to allow Evotec to obtain the benefit of any present or future treaty against double taxation which may apply to such payments. 

6.3.11    Foreign Currency Exchange.    All payments to be made by Kazia to Evotec under
this Agreement shall be made in Euros and shall be paid by bank wire transfer in immediately available funds to such bank account as may be designated in writing by Evotec from time to time. If, in any Calendar Quarter, Net Sales are made in any
currency other than Euros, such Net Sales shall be converted into Euros as follows: (A/B), where A = foreign Net Sales in such Calendar Quarter expressed in such foreign currency; and B = the applicable foreign exchange conversion rate, expressed in
local currency of the foreign country per Euro (in accordance with the rates of exchange for the relevant month for converting such other currency into Euros used by Kazia’s internal accounting systems, which are independently audited on an
annual basis). 
  

	7.    TREATMENT	 OF CONFIDENTIAL INFORMATION; PUBLICITY 

7.1     Confidentiality. 

7.1.1    Confidentiality Obligations. Evotec and Kazia each recognize that the other Party’s
Confidential Information and Proprietary Materials constitute highly valuable assets of such other Party. Evotec and Kazia each agrees that subject to Sections 7.1.2 and 7.1.3, during the Term and for an additional five (5) years after
termination or expiration of this Agreement it shall (a) not disclose, and shall cause its Affiliates and Sublicensees not to disclose, any Confidential Information of the other Party, (b) not use, and shall cause its Affiliates and
Sublicensees not to use, any Confidential Information of the other Party, except as expressly permitted in this Agreement, and (c) take all reasonable steps to ensure that any person to whom it discloses Confidential Information under
Section 7.1.3 complies at all times with the terms of this Section 7 as if that Person were a Receiving Party. 

7.1.2    Exceptions. The obligations of confidentiality under Section 7.1.1 do not apply to any
Confidential Information that (a) as of the date of disclosure, is known to the Receiving Party or its Affiliates as demonstrated by contemporaneous credible written documentation, other than by virtue of a prior confidential disclosure to such
Receiving Party, (b) as of the date of disclosure is in the public domain, or it subsequently enters the public domain through no fault of the Receiving Party, (c) it is obtained by the Receiving Party from a Third Party having a lawful
right to make such disclosure free from any obligation of confidentiality to the Disclosing Party, (d) it is independently developed by or for the Receiving Party without reference to or use of any Confidential Information of the Disclosing
Party as demonstrated by contemporaneous credible written documentation, or (e) is required to be disclosed as a result of Applicable Law, in which case only that information which must be disclosed in order to comply with Applicable Law should
be disclosed and, where possible, the confidential nature of the disclosed information must be highlighted to the recipient of the disclosed information. Notwithstanding the foregoing, the obligations of confidentially under Section 7.1.1 shall
apply to any scientific, technical, manufacturing or financial information of a Party that is disclosed at any meeting of the Parties or disclosed through an audit report. For the avoidance of doubt, any combination of Confidential Information shall
not be considered in the public domain or in the possession of the Receiving Party merely because individual elements of such Confidential Information are in the public domain or in the possession of the Receiving Party unless the combination and
its principles are in the public domain or in the possession of the Receiving Party. 

  
 15 

 7.1.3    Limited Disclosure. Evotec and Kazia each agrees
that disclosure of its Confidential Information may be made by a Receiving Party to any employee or consultant of such other Party or its Affiliates or any Third Party subcontractor engaged by a Party to enable such other Party to exercise its
rights or to carry out its responsibilities under this Agreement; provided, that, any such disclosure shall only be made to Persons who are bound by written obligations of confidentiality consistent with those in this Article 7. In addition, Evotec
and Kazia each agrees that a Receiving Party may disclose a Disclosing Party’s Confidential Information (a) on a need-to-know basis to the Receiving
Party’s legal and financial advisors, (b) as reasonably necessary in connection with an actual or potential (i) permitted sublicense of such Receiving Party’s rights hereunder, (ii) debt or equity financing of such Receiving
Party or (iii) merger, acquisition, consolidation, share exchange or other similar transaction involving such Receiving Party and any Third Party, (c) to any Third Party that is engaged by the Receiving Party to perform services in
connection with the Research or Development of Products or the Commercialization of Products as necessary to enable such Third Party to perform such services, and (d) for any other purpose with the other Party’s consent, which consent
shall not be unreasonably withheld. Furthermore, Evotec and Kazia each agrees that a copy of this agreement is provided to Sanofi within ten (10) days from the Effective Date. Each Party further agrees that a Receiving Party may disclose the
Disclosing Party’s Confidential Information or provide the Disclosing Party’s Proprietary Materials (A) as reasonably necessary or useful to file, prosecute or maintain Patent Rights, or to file, prosecute or defend litigation related
to Patent Rights, in accordance with this Agreement; (B) as reasonably necessary or useful to obtain government regulatory approval to Develop, Manufacture, transport, or Commercialize a Product; or (C) as required by Applicable Laws;
provided that in the case of any disclosure under (C), the Receiving Party shall (1) if practicable, provide the Disclosing Party with reasonable advance notice of and an opportunity to comment on any such required disclosure and (2) if
requested by the Disclosing Party, cooperate in all reasonable respects with the Disclosing Party’s efforts to obtain confidential treatment or a protective order with respect to any such disclosure, at the Receiving Party’s expense. The
Receiving Party is liable for any breach of this Article 7 by any Person to whom it has disclosed the Disclosing Party’s Confidential Information to as if that Person were the Receiving Party in relation to the Confidential Information
disclosed. 
 7.1.4    Employees and Consultants. Evotec and Kazia each hereby represents that all of its
employees and consultants, and all of the employees and consultants of its Affiliates, who have access to Confidential Information or Proprietary Materials of the other Party are or shall, prior to having such access, be bound by written obligations
to maintain such Confidential Information or Proprietary Materials in confidence. Each Party agrees to use, and to cause its Affiliates to use, reasonable efforts to enforce such obligations and to prohibit its employees and consultants from using
such information except as expressly permitted hereunder. Each Party shall be liable to the other for any disclosure or misuse by its employees of Confidential Information or Proprietary Materials of the other Party. 

7.2    Publicity. Each Party shall be permitted to publicly announce material developments with respect to
any Licensed Product or Product, including the occurrence of any milestone event and the amount of any milestone payment under Section 6.2 and any other event with respect to a Licensed Product or Product that such Party reasonably believes is
material; provided that, subject to compliance with the requirements of Applicable Laws: (i) the disclosing Party shall provide the other Party with a draft of any proposed publication at least thirty (30) days prior to the intended
publication; and (ii) if any such disclosure is reasonably likely to affect the ability of the Parties to publish or present data with respect to a Licensed Product or Product or otherwise names the other Party, the disclosing Party shall
obtain the other Party’s prior written consent to the content to such release, which consent shall not be unreasonably withheld, delayed or conditioned. 

7.3    Publications and Presentations. Except to the extent required by Applicable Laws, the Parties shall
not publish any scientific or medical publications or give other forms of similar public disclosure, such as abstracts or presentations, relating to the Licensed Product or a Product other than with the other Party’s approval (not to be
unreasonably withheld). If either Party, its employees or consultants wish to make such a publication or presentation, that Party shall deliver to the other Party a copy of the proposed written publication or an outline of an oral disclosure at
least thirty (30) days prior to submission for publication or presentation. Without derogating from its general approval right, the reviewing Party shall have the right to require a delay of up to ninety (90) days in publication or
presentation in order to enable patent applications protecting each Party’s rights in such information to be filed and each Party shall have the right to prohibit disclosure of any of its Confidential Information in any such proposed
publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with
customary standards. 

  
 16 

 7.4    Use of Names. Except as expressly stated in this
Agreement, Kazia shall not, and shall ensure that its Affiliates and Sublicensees shall not use or register the name of Evotec and/or Sanofi (alone or as part of another name) for any purpose except with the prior written approval of, and in
accordance with restrictions required by, Evotec and/or Sanofi. This restriction shall not apply to any information required by Applicable Laws to be disclosed to any Regulatory Authority. 

 

	8.	 LICENSE GRANTS; EXCLUSIVITY 

8.1    Licenses. 

8.1.1    Exclusive License Grants. Subject to the terms and conditions of this Agreement, during the Term of
this Agreement, Evotec hereby grants to Kazia an exclusive license or sub-license under the Licensed Technology and the Licensed Patent Rights, including the right to grant sublicenses as provided in Section 8.2, to Research, Develop,
Manufacture and Commercialize Licensed Products and Products in the Field in the Territory. Kazia hereby agrees and covenants that Kazia shall not, and will procure that its Affiliates and Sublicensees shall not, use the Licensed Technology and the
Licensed Patents rights outside the scope of the license granted to Kazia under this Section 8.1.1. For purposes of clarity, the licenses granted to Kazia under this Section 8.1.1 shall be subject to the retained rights of Evotec and
Sanofi solely to conduct Research (but not Development or Commercialization) with respect to Licensed Products and Products in the Field in the Territory. 

8.2    Right to Sublicense. 

8.2.1    Development and Manufacturing Activities. Kazia shall have the right to grant sublicenses under the
licenses granted to it under Section 8.1.1 to any of its Affiliates and to any Third Party engaged by it to conduct Research, Development and Manufacturing activities subject to the same restrictions, limitations and obligations imposed upon
Kazia in this Agreement. 
 8.2.2    Commercialization of Products. Kazia shall have the right to grant
sublicenses under the licenses granted to it under Section 8.1.1 to any of its Affiliates and to any Third Party; provided that (a) it shall be a condition of any such sublicense that Kazia shall remain responsible to Evotec for the
compliance of all terms of this Agreement applicable to the Commercialization of Products in the Territory by such Third Party, (b) Kazia shall provide written notice to Evotec of any such proposed sublicense agreement at least thirty
(30) days prior to such execution and provide copies to Evotec of each such sublicense agreement within ten (10) days of its execution, and (c) Kazia shall not be relieved of its obligations pursuant to this Agreement as a result of
such sublicense agreement. 
 8.3    No Other Rights. Kazia shall have no rights to use or otherwise
exploit Licensed Technology or Licensed Patent Rights, except as expressly set forth in this Agreement. 

8.4    Exclusivity. As from the Effective Date, and subject to the exclusive licenses granted under
Section 8.1.1, Evotec shall not, independently of this Agreement, either itself or through an Affiliate or Sublicensee, initiate any Development or Commercialization activities, whether for its own account or for the benefit of any Third Party,
during the Term with respect to any Licensed Product or Product or, for a period of two (2) years following the Effective Date, with respect to any product for which the primary mechanism of action relies on small molecule inhibition of
vascular endothelial growth factor receptor 3 (“VEGFR3”). 

  
 17 

 Notwithstanding anything to the contrary contained herein, Evotec shall be free to 

 

	(i)	 conduct screens on VEGFR3(s) hereunder if, (a) requested by a Third Party or Evotec Affiliate and
(b) solely in connection with screening to determine whether a certain compound has off-target activity. By way of example, if target A is VEGFR3, and target B is a separate target, then Evotec would have
the right to screen compounds that a Third Party is evaluating for use in connection with Target B in a counter-screen containing VEGFR3 solely in order to attempt to determine whether such compounds have
off-target activity against VEGFR3; 

  

	(ii)	 conduct screens and profiling of compounds on VEGFR3 hereunder if, (a) requested by a Third Party and
(b) such certain compounds are provided by the Third Party; 

  

	(iii)	 determine biophysical properties (Kd, Ki, kon, koff, DH, DS) as part of compound screening and profiling
campaigns; 

  

	(iv)	 determine target protein-ligand complex structures by X-Ray
crystallography and related methods if such ligands/compounds are provided by the Third Party; 

  

	(v)	 conduct fee for service protein, cells, probes and other reagent production, without using any gene constructs
that are Kazia’s property; 

  

	(vi)	 conduct biomarker discovery, development and testing services on VEGFR3 and/or related biological pathway for a
Third Party client of Evotec to characterize drug mechanism of action and efficacy, diagnose disease state, and stratify patients; and 

  

	(vii)	 conduct any development activities including IND enabling studies, CMC, formulation and API manufacture on
candidate molecules as identified by a Third Party where the target might be known but is not required to perform the scope of work. 

  

	9.    INTELLECTUAL	 PROPERTY RIGHTS 

9.1    Evotec Intellectual Property Rights. As between the Parties, Evotec shall have exclusive ownership of
all right, title and interest, on a worldwide basis in and to any and all Licensed Patent Rights and Licensed Technology. 

9.2    Kazia Intellectual Property Rights. As between the Parties, Kazia shall have sole and exclusive
ownership of all right, title and interest on a worldwide basis in and to any and all Patent Rights and Technology owned by Kazia. 

9.3    Patent Coordinators.    Each Party shall appoint a patent coordinator reasonably
acceptable to the other Party (each, a “Patent Coordinator”) to serve as such Party’s primary liaison with the other Party on matters relating to patent filing, prosecution, maintenance and enforcement of Patent Rights under
this Agreement. Each Party may replace its Patent Coordinator at any time by notice in writing to the other Party. Such notice becomes effective upon written acknowledgment of receipt by the other Party. The initial Patent Coordinators shall be:

 For Kazia:     Dr James Garner [***] 

For Evotec: [***] 

9.4    Improvements. Each Party must notify the other Party of any Improvements which it or its
personnel, Affiliates, Sublicensees or subcontractors discovers or develops with respect to any of the Licensed Patent Rights or Licensed Technology within sixty (60) days of discovery or development. The Parties agree that (a) all rights,
title and interest in Improvements to the Licensed Patent Rights or Licensed Technology developed or discovered by or on behalf of a Party, vest in (as between the Parties) Evotec, and (b) upon discovery or development of any Improvement to the
(i) Licensed Patent Rights, the Improvement will become part of the Licensed Patent Rights, and (ii) Licensed Technology, the Improvement will become part of the Licensed Technology. For the avoidance of doubt, any Improvements in and to
any Patent Rights and Technology owned by Kazia will vest in Kazia. 

  
 18 

	10.	 MANAGEMENT OF PATENT RIGHTS 

 

	 	10.1	 Patent Filing, Prosecution and Maintenance. 

10.1.1    Evotec Prosecution Rights. As between the Parties, Evotec, acting through patent counsel or agents
of its choice, shall be responsible for the prosecution and maintenance of the Licensed Patent Rights. At Evotec’s reasonable request, Kazia shall cooperate with and assist Evotec in all reasonable respects, in connection with the preparation,
filing, prosecution (including, at Kazia’s option, reviewing and commenting on draft responses to office actions from patent offices in the Territory) and maintenance of the Licensed Patent Rights. From the Effective Date, Evotec (via Sanofi,
as the case may be) shall use Commercially Reasonable Efforts to prosecute and maintain composition-of-matter claims within the Licensed Patent Rights set forth on
Exhibit A in the countries set forth on Exhibit B attached hereto. Evotec shall be free, at is sole discretion and at any time upon ninety (90) days prior written notice to Kazia, to abandon any Licensed Patent Rights, provided that Evotec
shall not abandon any of the Licensed Patent Rights set forth on Exhibit A in the countries set forth on Exhibit B that Cover a Licensed Product being Researched, Developed or Commercialized by Kazia hereunder after the Effective Date. Any Licensed
Patent Rights set forth on Exhibit A in other countries than those countries set forth on Exhibit B that Cover a Licensed Product being Researched, Developed or Commercialized by Kazia hereunder may only be abandoned by Evotec with Kazia’s
prior written consent, which consent shall not be unreasonably withheld, in which case Kazia shall have the right (but no obligation) to continue to prosecute and maintain such Licensed Patent Rights, in Evotec’s and/or Sanofi’s name and
at Kazia’s cost and expense, acting through patent counsel or agents of its choice. 
 10.1.2    Kazia
Prosecution Option. Evotec must promptly notify Kazia in writing of any decision it makes to abandon any Licensed Patent Rights. In such event, upon Kazia’s request, Evotec shall use best endeavours to transfer the right to file,
prosecute and maintain such Licensed Patent Rights to Kazia and Kazia shall have the right to continue filing, prosecution and / or maintenance of such Licensed Patents Rights at Kazia’s own expense. 

10.1.3    Patent Costs. Prior to incurring any Patent Costs, Evotec must obtain Kazia’s prior written
consent, which consent shall not be unreasonably withheld or delayed. If Kazia consents to any Patent Costs being incurred, such Patent Costs shall be borne by Kazia. If Kazia does not consent to Patent Costs being incurred, Kazia will not be
responsible for such Patent Costs, in which case (i) Evotec may continue to prosecute and maintain the applicable Licensed Patent Rights solely at its cost and expense or (ii) Evotec may elect to cease such prosecution and maintenance, in
which case Kazia shall have the right (but no obligation) to continue to prosecute and maintain such Licensed Patent Rights, in Evotec’s and/or Sanofi’s name and at Kazia’s sole cost and expense, acting through patent counsel or
agents of its choice. 
 10.1.4    Kazia Prosecution Rights. Kazia, at its sole expense and acting through
patent counsel or agents of its choice, shall be responsible for the preparation, filing, prosecution and maintenance of all Patent Rights owned by Kazia. At Kazia’s request and cost, Evotec shall cooperate with and assist Kazia in all
reasonable respects, in connection with Kazia’s preparation, filing, prosecution and maintenance of such Patent Rights. 

10.1.5    National Registration of Exclusive License. Kazia shall at is sole discretion be responsible for,
and shall support all costs relating to, the filing of the exclusive licenses granted hereunder with any national patent register in the Territory as is required by Applicable Law. 

 

	 	10.2	 Enforcement and Defense. 

[***] 

  
 19 

 10.3    Patent Term Extension. The Parties shall cooperate
with each other in obtaining patent term extensions or supplemental protection certificates or their equivalents in any country in the Territory where applicable to Licensed Patent Rights. Such cooperation shall include diligently and timely
conferring and coordinating with respect to such matters to ensure compliance with applicable filing deadlines, and agreeing on procedures to be followed by the Parties to ensure such compliance. In the event that elections with respect to obtaining
such patent term extension are to be made with respect to a Product, Kazia shall have the right to make the election with respect to Licensed Patent Rights. All costs and expenses reasonably incurred by either Party in connection with obtaining and
maintaining such patent term extension shall be paid by Kazia. 
  

	11.	 TERM AND TERMINATION 

11.1    Term. This Agreement shall commence on the Effective Date and shall continue in full force and
effect, unless otherwise terminated pursuant to Section 11.2, until the expiration of all payment obligations under this Agreement with respect to Products in all countries in the Territory (the “Term”). Upon the expiration of
this Agreement as set forth in this Section 11.1, the license rights granted under Section 8.1.1 and 8.2 shall be converted to perpetual and fully paid-up
non-exclusive licenses. 
 11.2    Termination. This Agreement may
be terminated by either Party as follows: 
 11.2.1    Unilateral Right to Terminate Agreement. 

(a)    Kazia Right to Terminate Agreement. Kazia may terminate this Agreement effective immediately at any time
after the third (3rd) anniversary of the Effective Date. 

(b)    Evotec Rights to Terminate. Except to the extent the following is unenforceable under the law of a
particular jurisdiction where a patent application within the Licensed Patent Rights is pending or a patent within the Licensed Patent Rights is issued, Evotec may terminate this Agreement immediately upon written notice to Kazia in the event that
(i) Kazia or any of its Affiliates, Sublicensees or Distributors Challenges any Licensed Patent Rights or assists a Third Party in initiating a Challenge of any Licensed Patent Rights; or (ii) the Sanofi License terminates. 

  
 20 

 11.2.2    Termination for Breach. If a Party materially
breaches any of its obligations under the Agreement, the non-breaching Party may provide the breaching Party with a written notice specifying the nature of the breach, and stating its intention to terminate
this Agreement if such breach is not cured. If the material breach is not cured within ninety (90) days after the receipt of such notice, the non- breaching Party shall be entitled, without prejudice to any of its other rights under this
Agreement, and in addition to any other remedies available to it by law or in equity, to terminate this Agreement by providing written notice to the other Party. 

11.2.3    Termination for Insolvency. To the extent permitted by Applicable Law, if either Party makes an
assignment for the benefit of creditors, appoints or suffers appointment of a receiver or trustee over all or substantially all of its property, files a petition under any bankruptcy or insolvency act or has any such petition filed against it which
is not discharged within sixty (60) days of the filing thereof, the other Party may terminate this Agreement effective immediately upon written notice to such Party. 

11.3    Consequences of Termination of Agreement. If this Agreement is terminated pursuant to
Section 11.2, the following provisions shall apply, as applicable. 
 11.3.1    Termination by Evotec under
11.2.1(b), 11.2.2 or 11.2.3 or by Kazia under Section 11.2.1(a): 
 (a)    If this Agreement is terminated
by Kazia pursuant to Section 11.2.1(a) or by Evotec pursuant to Section 11.2.1(b), 11.2.2 or 11.2.3, all licenses and rights granted pursuant to this Agreement shall immediately terminate. 

(b)    If this Agreement is terminated by Kazia pursuant to Section 11.2.1(a) or by Evotec pursuant to
Section 11.2.1(b)(i), 11.2.2 or 11.2.3, Kazia shall and hereby does grant to Evotec an option to obtain (i) an exclusive license to all Patent Rights and (ii) an non-exclusive license to all
Technology; in each case (i) and (ii) owned or Controlled by Kazia and required to research, develop, have developed, make, have made, use, distribute for sale, sell, offer for sale, import and have imported Licensed Products and Products for
use in the Field (“Termination License”). If Evotec - at its sole discretion - exercises the option to obtain the Termination License, the Termination License will be royalty bearing, with the royalty payment for the Termination
License calculated at the following rates: 
 (i)    If Evotec - at its sole discretion - exercises the option to
obtain the Termination License and Kazia has not completed the Phase 1 Clinical Trial for the relevant Licensed Products or Products that is subject to the Termination License, the Termination License shall be royalty- free. 

(ii)    If Evotec - at its sole discretion - exercises the option to obtain the Termination License and Kazia has
completed the Phase 1 Clinical Trial but not the Phase 2 Clinical Trial for the relevant Licensed Products or Products that is subject to the Termination License, the Termination License shall be subject to royalty payment for the Termination
License calculated at the following rates. 
  

					
	 Annual Net Sales of Licensed Products or Products
	  	Royalty Rate (%)	 
	 [***][***][***][***]
	  			
	[***][***][***][***]	  			

  
 21 

 (iii)    If Evotec - at its sole discretion - exercises the option to
obtain the Termination License and Kazia has completed the Phase 2 Clinical Trial for the relevant Licensed Products or Products that is subject to the Termination License, the Termination License shall be subject to royalty payment for the
Termination License calculated at the following rates. 
  

					
	 Annual Net Sales of Licensed Products or Products
	  	Royalty Rate (%)	 
	 [***]
	  	 	[	***] 
	 [***]
	  	 	[	***] 
	 [***]
	  	 	[	***] 
	 [***]
	  	 	[	***] 

 The royalty term for such reverse royalties per these Sections 12.3.1 (b) (ii) and (iii) shall be, with respect to each
Product in each country of the Territory, the period beginning on the date of First Commercial Sale of such Product in such country [***]. 

(c)    If this Agreement is terminated by Kazia pursuant to Section 11.2.1(a) or by Evotec pursuant to
Section 11.2.1(b)(i), 11.2.2 or 11.2.3, upon Evotec’s request Kazia shall, where permitted under Applicable Laws, use Commercially Reasonable Efforts to transfer to Evotec all Regulatory Approvals held by Kazia with respect to such
Products within thirty (30) Business Days after the effective date of the termination. All transfers described in this Section 11.3.1(c) shall be at Kazia’s expense in cases of termination by Evotec pursuant to
Section 11.2.1(b)(i), 11.2.2 or 11.2.3; and at Evotec’s expense in cases of termination by Kazia pursuant to Section 11.2.1(a). 

(d)    If this Agreement is terminated by Kazia pursuant to Section 11.2.1(a) or by Evotec pursuant to
Section 11.2.1(b), 11.2.2 or 11.2.3, each Party shall promptly cease use of and return all Confidential Information and Proprietary Materials of the other Party that are not subject to a continuing license hereunder; provided that each Party
may retain one copy of the Confidential Information of the other Party in its archives solely for the purpose of establishing the contents thereof and ensuring compliance with its obligations hereunder. 

(e)    If the notice of the termination by Kazia under 11.2.1(a) is given at a time when any Clinical Trials have been
initiated but not yet completed, then the Parties shall work together in good faith during the termination notice period to ensure that Kazia’s involvement in and responsibilities for such activities shall be discontinued and ceased as
efficiently and promptly as possible (by way of transitioning such involvement and responsibilities to Evotec or by other means agreed to by the Parties), subject to Applicable Laws, including GCP. 

(f)    If this Agreement is terminated by Kazia pursuant to Section 11.2.1(a) or by Evotec pursuant to
Section 11.2.1(b), 11.2.2 or 11.2.3, all sublicense agreements between Kazia and its Affiliates or Sublicensees, shall terminate as of the effective date of the termination, unless Evotec provides written consent, which it shall not
unreasonably withhold, delay or condition, to the assignment of any such sublicense agreement, or license agreement, as the case may be, to Evotec (to the extent assignable). 

(g)    If this Agreement is terminated by Kazia pursuant to Section 11.2.1(a) or by Evotec pursuant to
Section 11.2.1(b), 11.2.2 or 11.2.3, any continuing reporting obligations of Kazia shall be verified exclusively through a Third Party to be mutually agreed, and Evotec shall not have direct access anymore to Kazia’s Confidential
Information. 

  
 22 

 11.3.2    Termination by Kazia. If this Agreement is
terminated by Kazia pursuant to Section 11.2.2 or 11.2.3: 
 (a)    Subject to the Sanofi License remaining in
force, all licenses and rights granted by Evotec to Kazia pursuant to this Agreement, including, all licenses granted to Kazia under Section 8.1.1, survive the termination in each case subject to Kazia’s continued payment of all milestone,
royalty and other payments under and in accordance with this Agreement with respect thereto; provided that, in case this Agreement is terminated by Kazia pursuant to Section 11.2.2, Kazia shall have the right to reduce any such payment by half;

 (b)    All licenses and rights granted by Kazia to Evotec pursuant to this Agreement terminate; and 

(c)    Each Party shall promptly cease use of and return all Confidential Information and Proprietary Materials of the
other Party that are not subject to a continuing license hereunder; provided that each Party may retain one copy of the Confidential Information of the other Party in its archives solely for the purpose of establishing the contents thereof and
ensuring compliance with its obligations hereunder. 
 11.4    Surviving Provisions. Termination or
expiration of this Agreement for any reason shall be without prejudice to: (a) the survival of rights specifically stated in this Agreement to survive, including as set forth in Section 11.3; (b) the rights and obligations of the Parties
provided in the following Sections: Section 6.3.6 (for a period of three (3) years, as provided therein); Article 7 (for a period of five (5) years, as provided in Section 7.1.1); this Section 11.4; and Article 1, Article
13, and Article 14 (including all other Sections or Articles referenced in any such Section or Article), all of which shall survive such termination except as provided in this Article 11; and (c) any other rights or remedies provided at law or
equity which either Party may otherwise have. 
  

	12.	 REPRESENTATIONS, WARRANTIES AND COVENANTS 

12.1    Mutual Representations and Warranties. Evotec and Kazia each represents and warrants to the other,
as of the Effective Date, as follows: 
 12.1.1    Organization. It is a corporation duly organized,
validly existing and in good standing under the laws of the jurisdiction of its organization, and has all requisite power and authority, corporate or otherwise, to execute, deliver and perform this Agreement. 

12.1.2    Authorization. The execution and delivery of this Agreement and the performance by it of the
transactions contemplated hereby have been duly authorized by all necessary corporate action and shall not violate (a) such Party’s certificate of incorporation or bylaws, (b) any agreement, instrument or contractual obligation to
which such Party is bound in any material respect, (c) any requirement of any Applicable Laws, or (d) any order, writ, judgment, injunction, decree, determination or award of any court or governmental agency presently in effect applicable
to such Party. 
 12.1.3    Binding Agreement. This Agreement is a legal, valid and binding obligation of
such Party, enforceable against it in accordance with its terms and conditions. 
 12.1.4    No Inconsistent
Obligation. It is not under any contractual obligation to any Person that conflicts with or is inconsistent in any respect with the terms of this Agreement or that would materially impede the diligent and complete fulfillment of its
obligations hereunder. 
 12.2    Additional Representations of Evotec. Evotec further represents and
warrants to Kazia as follows: 

  
 23 

 12.2.1    Licensed Patent Rights. Except as expressly
disclosed in Exhibit A, as at the Effective Date, the Licensed Patent Rights set forth on Exhibit A (i) are Controlled by Evotec, (ii) represent the complete and accurate (in all material respects) list of all Licensed Patent Rights
Controlled by Evotec that relate to the Licensed Product; and (iii) to Evotec ́s Knowledge have been filed in accordance with the requirements of the applicable patent office, prosecuted with Commercially Reasonable Efforts and are not
lapsed or abandoned. To Evotec’s Knowledge, it has the ability to grant to Kazia the rights and licenses granted to Kazia under the Licensed Patents. Kazia hereby acknowledges that the certain Licensed Patent Rights is either owned by Sanofi or
jointly owned by Evotec and Sanofi. 
 12.2.2    No Claims. As at the Effective Date, there are no claims,
judgment or settlements against Evotec pending, or to Evotec’s Knowledge, threatened in writing (including email), that invalidate or seek to invalidate the Licensed Patent Rights. 

12.2.3    No Infringement or Misappropriation. To Evotec’s Knowledge, as at the Effective Date, Evotec
and its Affiliates have not infringed or misappropriated any intellectual property of any Third Party during its Research, Development, Manufacture or Commercialization of the Licensed Product or any Products. Evotec and its Affiliates have not
received any notice from any Third Party asserting or alleging any such infringement. 
 12.2.4    Compliance with
Applicable Laws. To Evotec’s Knowledge, as at the Effective Date, Evotec and its Affiliates have complied with all Applicable Laws in connection with the Research, Development, and Manufacture of the Licensed Product. 

12.2.5    Information. The information provided to Kazia by or on behalf of Evotec in relation to the
Licensed Product, Licensed Patent Rights or the Licensed Technology is complete, true and accurate and all the information that Kazia could reasonably require in order to understand and appreciate the composition and status of these items. 

12.2.6    No Conflicting Rights. Except for the Sanofi License, as at the Effective Date and on each day
during the Term, there is no agreement between Evotec or its Affiliates and any Third Party pursuant to which Evotec or its Affiliates obtained any right or license to the Licensed Product or Product or any intellectual property rights related to
the Licensed Product or Product. Evotec has not granted any right, license or interest under the Licensed Patent Rights or the Licensed Technology that is inconsistent with the licenses granted to Kazia under this Agreement. 

12.2.7    Licensed Technology. The Licensed Technology set forth in Exhibit A represents the complete and
accurate (in all material respects) list of all Technology Controlled or in-licensed by Evotec or its Affiliates at the Effective Date which is reasonably required by Kazia for Research, Development,
Manufacture or Commercialization of the Licensed Product or Products. Evotec has the ability to grant to Kazia the rights and sub-licenses granted to Kazia under the Licensed Technology. Kazia hereby
acknowledges that the certain Licensed Technology is either owned by Sanofi or jointly owned by Evotec and Sanofi. 

12.2.8    Sanofi License. As at the Effective Date, no written notice of default or termination has been
received or given under the Sanofi License and there is no act or omission by Evotec that would give rise to a right to terminate the Sanofi License. During the Term, Evotec will, at its own cost and expense, use best efforts to maintain the Sanofi
License in full force and effect.    In the event of any breach of the Sanofi License by Evotec, Evotec shall immediately notify Kazia in writing. If Evotec fails to cure such breach in a timely manner, Kazia shall have the right
(but not the obligation) to support Evotec to cure such breach and to offset any reasonable amount incurred or paid by Kazia in connection with the cure against the amount payable to Evotec under this Agreement. Evotec shall not terminate the Sanofi
License without first obtaining Kazia’s prior written consent, which consent shall not be unreasonably withheld. If, despite Evotec’s best efforts, the Sanofi License is terminated, Evotec shall use best efforts to assist Kazia to obtain a
direct license from Sanofi. 

  
 24 

 12.2.9    [***]. 

12.3    Additional Representations of Kazia.    Kazia further represents and warrants to
Evotec as of the Effective Date, as follows: 
 12.3.1    No Debarment. Neither Kazia nor any of its
Affiliates has been debarred or is subject to debarment pursuant to Section 306 (or comparable law or regulation) of the USFDA. During the Term, Kazia and its Affiliates shall use Commercially Reasonable Efforts to avoid using in any capacity,
in connection with the Research or Development of any Licensed Product or Product, or the Manufacture or Commercialization of any Product, any Person who to Kazia’s Knowledge has been debarred pursuant to Section 306 (or comparable law or
regulation) of the USFDA, or who, to Kazia’s Knowledge, is the subject of a conviction described in such section. Kazia agrees to inform Evotec in writing if it or any Person who is performing services hereunder is debarred or is the subject of
a conviction described in Section 306 (or comparable law or regulation), or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to Kazia’s knowledge, is threatened, relating to the debarment or
conviction of Kazia or any Person used in any capacity by Kazia or any of its Affiliates in connection with the Research or Development of any Licensed Product or Product, or the Manufacture or Commercialization of any Product. 

12.4    Warranty Disclaimer. TO THE EXTENT PERMITTED BY LAW, EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS
AGREEMENT, NEITHER PARTY MAKES ANY WARRANTY WITH RESPECT TO ANY KNOW-HOW, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND EACH PARTY HEREBY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED,
INCLUDING, WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. WITHOUT LIMITING THE FOREGOING AND EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, EVOTEC MAKES NO REPRESENTATIONS OR
WARRANTIES OF ANY KIND WITH RESPECT TO (A) OWNERSHIP OF INTELLECTUAL PROPERTY RELATED TO COMPOUNDS, OR PRODUCTS, OR (B) NONINFRINGEMENT OR MISAPPROPRIATION OF ANY THIRD PARTY INTELLECTUAL PROPERTY RIGHTS. 

13.    INDEMNIFICATION; INSURANCE 

13.1    [***] 

13.2    [***] 

13.3    [***] 

13.4    Insurance. Not later than thirty (30) days before the date on which Kazia or any Affiliate,
Sublicensee or Distributor of Kazia shall, on a commercial basis, Commercialize or Manufacture any Products, and at all times thereafter until the expiration of (a) all applicable statutes of limitation pertaining to any such Commercialization
or Manufacture of any Products or (b) where the applicable statute of limitation is unknown, five (5) years following the expiration or termination of this Agreement, Kazia shall, at its expense, with respect to Products, obtain and
maintain in full force and effect, comprehensive general liability insurance, with a minimum coverage of [***] per occurrence and [***] annual aggregate. Such commercial general liability insurance shall provide: (a) product liability coverage
and (b) broad form contractual liability coverage for Kazia’s indemnification obligations under this Agreement. Kazia shall provide Evotec with written notice at least fifteen (15) days prior to the cancellation, non-renewal or material change in such insurance and shall obtain replacement insurance providing comparable coverage within such fifteen (15) day period. 

13.5    [***] 

  
 25 

 13.6    Personal Injury. Nothing in this Agreement
operates to exclude or restrict a Party’s liability for (a) its gross negligence, intentional misconduct or fraud, or (b) for personal injury or death. 

14.    MISCELLANEOUS 

14.1    Notices. All notices and communications shall be in writing and delivered by email to the email
address below or personally or by internationally-recognized express courier providing evidence of delivery or mailed via certified mail, return receipt requested, addressed as follows, or to such other address as may be designated from time to
time: 
  

			
	If to Evotec:	 	Evotec (France) SAS
		 	195 route d’Espagne
		 	31036 Toulouse Cedex
		 	France
		 	Attention: General Counsel
		 	[***]
		
	If to Kazia:	 	Kazia Therapeutics Limited
		 	L24, 300 Barangaroo Avenue
		 	Sydney, NSW 2000
		 	Australia
		 	Attn: Chief Executive Officer
		 	[***]
		
	With a copy to:	 	K&L Gates
		 	L25, 525 Collins Street
		 	Melbourne, VIC 3000
		 	Australia
		 	[***]

 Except as otherwise expressly provided in this Agreement or mutually agreed by the Parties in writing,
any notice, communication or document (excluding payment) required to be given or made shall be deemed given or made and effective upon actual receipt or, if earlier, (a) three (3) Business Days after deposit with an internationally-recognized
express courier with charges prepaid, (b) seven (7) Business Days after mailed by certified, registered or regular mail, postage prepaid, or (c) if sent by email, two (2) hours after the time the email is sent to the recipient’s
email address, as recorded on the sender’s email system, unless the sender receives within that time period, an automatic notification (other than an out of office message) indicating that the email has not been delivered, in each case
addressed to a Party at its address stated above or to such other address as such Party may designate by written notice given in accordance with this Section 14.1. 

14.2    Governing Law.    This Agreement shall be governed by and construed in
accordance with the laws of New York State, United States of America, without regard to the application of principles of conflicts of law. 

14.3    Dispute Resolution. 

14.3.1    Referral of Disputes. In the event of any dispute between the Parties arising out of or in
connection with this Agreement (“Dispute”), either Party may, provide a written notice (“Dispute Notice”) to the other which sets out the nature of the Dispute and the relief or remedy that the Party seeks. 

  
 26 

 14.3.2    Negotiation by Parties’ Senior
Executives. During the period thirty (30) days after delivery of the Dispute Notice, or any longer period agreed in writing by the Parties (“Initial Period”), the senior executives of each Party must use their
reasonable endeavours and act in good faith to resolve the Dispute by discussion and negotiation. 

14.3.3    Referral to Arbitration. If the Dispute is not resolved within the Initial Period, then the
Dispute must be resolved by arbitration administered by the American Arbitration Association in accordance with the Commercial Arbitration Rules which are operating at the time the Dispute is referred to arbitration. Judgment on the award rendered
by the arbitrator(s) may be entered in any court having jurisdiction thereof. 
 14.3.4    Conduct of
Arbitration. The arbitration shall be conducted by a single arbitrator mutually agreed by the Parties within thirty (30) days after initiation of arbitration. If the Parties are unable or fail to agree upon the arbitrator, the
arbitrator shall be appointed by the American Arbitration Association. The seat of arbitration must be New York State and the language of arbitration must be English. 

14.3.5    Other Proceedings. Subject to Section 14.3.7, no Party may commence any judicial proceedings
in relation to the Dispute unless those proceedings are commenced for the purpose of enforcing this Section 14.3 or to seek interlocutory relief during the Initial Period. 

14.3.6    Costs. The “prevailing” Party, as determined by the arbitrator, shall be entitled to its
share of reasonable attorney fees associated with the arbitration.    If the arbitrator determines that, given the scope of the arbitration, neither Party “prevailed”, the arbitrator shall order that the Parties
(a) share equally the arbitrators’ fees and any administrative fees of arbitration, and (b) bear their own attorneys’ fees and associated costs and expenses. 

14.3.7    Intellectual Property Disputes. Notwithstanding anything to the contrary, any and all issues
regarding the scope, inventorship, construction, validity, enforceability or ownership of any Patent Rights hereunder shall be determined in a court of competent jurisdiction under the local patent laws of the jurisdictions having issued the Patent
Rights in question. 
 14.3.8    Jurisdiction. Subject to this Section 14.3, the Parties submit to
the exclusive jurisdiction of the courts of New York State, United States of America, in respect of any dispute, controversy or claim arising out of or relating to this Agreement, including the existence, negotiation, validity, formation,
interpretation, breach, performance or application of this Agreement. 
 14.4    Binding Effect. This
Agreement shall be binding upon and inure to the benefit of the Parties and their respective legal representatives, successors and permitted assigns. 

14.5    Headings. Section and subsection headings are inserted for convenience of reference only and do not
form a part of this Agreement. 
 14.6    Counterparts. This Agreement may be executed simultaneously in
two or more counterparts, each of which shall be deemed an original and both of which, together, shall constitute a single agreement. 

14.7    Amendment; Waiver. This Agreement may be amended, modified, superseded or canceled, and any of the
terms of this Agreement may be waived, only by a written instrument executed by each Party or, in the case of waiver, by the Party or Parties waiving compliance. The delay or failure of either Party at any time or times to require performance of any
provisions shall in no manner affect the rights at a later time to enforce the same. No waiver by either Party of any condition or of the breach of any term contained in this Agreement, whether by conduct, or otherwise, in any one or more instances,
shall be deemed to be, or considered as, a further or continuing waiver of any such condition or of the breach of such term or any other term of this Agreement. 

  
 27 

 14.8    No Partnership. Nothing in this Agreement shall be
construed (a) to create or imply a general partnership between the Parties, (b) to make either Party the agent of the other for any purpose, (c) to alter, amend, supersede or vitiate any other arrangements between the Parties with
respect to any subject matters not covered hereunder, (d) to give either Party the right to bind the other, (e) to create any duties or obligations between the Parties except as expressly set forth herein, or (f) to grant any direct
or implied licenses or any other right other than as expressly set forth herein. 
 14.9    Assignment and
Successors. Neither this Agreement nor any obligation of a Party hereunder may be assigned by either Party without the consent of the other which shall not be unreasonably withheld, except that each Party may assign this Agreement and the
rights, obligations and interests of such Party, (a) in whole or in part, to any of its Affiliates, or (b) in whole, but not in part, to any purchaser of all of its assets or all of its assets to which this Agreement relates or shares
representing a majority of its common stock voting rights or to any successor corporation resulting from any merger, consolidation, share exchange or other similar transaction. 

14.10    Force Majeure. Neither Kazia nor Evotec shall be liable for failure of or delay in performing
obligations set forth in this Agreement, and neither shall be deemed in breach of its obligations, if such failure or delay is due to a Force Majeure. In event of such Force Majeure, the Party affected shall use reasonable efforts to cure or
overcome the same and resume performance of its obligations hereunder. 
 14.11    Interpretation. The
Parties hereto acknowledge and agree that: (a) each Party and its counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision; (b) the rule of construction to the effect that any
ambiguities are resolved against the drafting Party shall not be employed in the interpretation of this Agreement; and (c) the terms and provisions of this Agreement shall be construed fairly as to each Party and not in a favor of or against
either Party, regardless of which Party was generally responsible for the preparation of this Agreement. In addition, unless a context otherwise requires, wherever used, the singular shall include the plural, the plural the singular, the use of any
gender shall be applicable to all genders, the word “or” is used in the inclusive sense (and/or) and the word “including” is used without limitation and means “including without limitation”. 

14.12    Integration; Severability. This Agreement (including the Exhibits attached hereto) sets forth the
entire agreement with respect to the subject matter hereof and thereof and supersedes all other agreements and understandings between the Parties with respect to such subject matter. If any provision of this Agreement is or becomes invalid or is
ruled invalid by any court of competent jurisdiction or is deemed unenforceable, it is the intention of the Parties that the remainder of the Agreement shall not be affected. In the event of any conflict or inconsistency between the text of this
Agreement and the attached Exhibits, the text of this Agreement shall control. 
 14.13    Further
Assurances. Each of Evotec and Kazia agrees to duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such additional
assignments, agreements, documents and instruments, as the other Party may at any time and from time to time reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes of, or to better assure
and confirm unto such other Party its rights and remedies under, this Agreement. 
 [Signature page follows] 

  
 28 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly
authorized representatives. 
 Executed by Evotec (France) SAS: 
  

					
	 /s/ Craig Johnstone
	  		 	 /s/ Christian Dargel

	Signature of director	  		 	 Signature of director or company secretary*

		  		 	 *delete whichever does not apply

			
	 Craig Johnstone
	  		 	 Christian Dargel

	Name (please print)	  		 	Name (please print)

 Executed by Kazia Therapeutics, Ltd. ACN 063 259 754 in accordance with section 127(1) of the Corporations
Act 2001 (Cth): 
  

					
	 /s/ James Garner
	  		 	 /s/ Kate Hill

	Signature of director	  		 	 Signature of director or company secretary*

		  		 	 *delete whichever does not apply

			
	 James Garner
	  		 	 Kate Hill            Company
Secretary

	Name (please print)	  		 	Name (please print)

  
 29 

 [***] 
  

	
	  

[***]
  

 [***] 

 [***] 

 [***] 

 [***] 

 [***] 

							
	 	  	[***]
	  	[***]
	
[***]
	  	[***]	  	[***]
	
[***]
	  	[***]	  	 

 [***] 

							
	 	  	[***]
	  	[***]
	
[***]
	  	[***]	  	[***]
	
[***]
	  	[***]

 [***] 

							
	 	  	[***]
	  	[***]
	
[***]
	  	[***]	  	[***]
	
[***]
	  	[***]

 [***] 

							
	 	  	[***]
	  	[***]
	
[***]
	  	[***]	  	[***]
	
[***]
	  	[***]

 [***] 

							
	 	  	[***]
	  	[***]
	
[***]
	  	[***]	  	[***]
	
[***]
	  	[***]

 [***] 

 [***] 

							
	 	  	[***]
	  	[***]
	
[***]
	  	[***]	  	[***]
	
[***]
	  	[***]

 [***] 

 [***] 

							
	 	  	[***]
	  	[***]
	
[***]
	  	[***]	  	[***]
	
[***]
	  	[***]

 [***] 

							
	 	  	[***]
	  	[***]
	
[***]
	  	[***]	  	[***]
	
[***]
	  	[***]

 [***] 

							
	 	  	[***]
	  	[***]
	
[***]
	  	[***]	  	[***]
	
[***]
	  	[***]

 [***] 

							
	 	  	[***]
	  	[***]
	
[***]
	  	[***]	  	[***]
	
[***]
	  	[***]

 [***] 

							
	 	  	[***]
	  	[***]
	
[***]
	  	[***]	  	[***]
	
[***]
	  	[***]

 [***] 

							
	 	  	[***]
	  	[***]
	
[***]
	  	[***]	  	[***]
	
[***]
	  	[***]

 [***] 

[***] 

 [***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]